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Chapter 1
Cancer
Cancer was first described in 400 BC by the Greek physician and “father of Medi-
cine” Hippocrates. He found masses all over the body with a finger- like structure, 
which he called ‘carcinos’, referring to the Greek word for crab. It is thought that the 
typical structure of the lesions reminded him of the shape of this animal. Later, the 
Roman physician Celcus (28-50 BC) translated the Greek term into the Latin word 
for crab; cancer. 
Nowadays, cancer is the generic term for a group of over a hundred diseases, af-
fecting any part of our body. Although there are many different kinds of cancer, 
they all have one thing in common, which is that cells acquire abnormal properties 
and lose their intrinsic proliferation inhibition. In normal cells, cell proliferation is a 
very well-orchestrated process, with cell growth and cell death occurring in a tightly 
balanced manner. Cancer cells tend to escape from regulation and instead of dying 
off, they continue to divide more rapidly resulting in increasing numbers of abnor-
mal cells which all together form a mass of cells; a tumor. Furthermore, tumors can 
grow outside the usual boundaries to which the tissues they are derived from are 
limited, and invade adjacent parts of the body. Moreover, tumor cells can travel 
to other parts of the body where they can seed, grow and form new tumors that 
crowd out normal tissue. This usually occurs when cancer cells get into the body’s 
bloodstream or lymph vessels, which facilitate their migration to other locations. 
The process of cancer spreading, i.e. metastasis, is the major cause of cancer mor-
tality.
Cancer is emerging as one of the leading causes of morbidity and mortality world-
wide, with approximately 14 million newly diagnosed patients and 8.2 million can-
cer related deaths in 2012 [1]. Amongst men the most common sites for tumori-
genesis are lung, prostate, colorectum, stomach, and liver cancer, while in women 
breast, colorectum, lung, cervix, and stomach cancer are most prevalent [2]. This 
thesis will focus mainly on colorectal cancer, however in chapter 3 we will also dis-
cuss prostate cancer. 
Colorectal cancer
Colorectal cancer (CRC) is one of the most common types of cancer, and includes 
tumors in the large intestine, rectum, and appendix. Worldwide, approximately 1.2 
million people are diagnosed with CRC each year, accounting for almost 10% of all 
cancer cases [3]. There are environmental and genetic factors that contribute to 
the development of CRC [4]. Although inherited susceptibility results in the most 
striking increase in risk, the majority of CRCs are sporadic rather than familial [5]. 
Familial adenomatous polyposis (FAP) is a relatively common form of familial colon 
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cancer syndrome, but accounts for less than 1 percent of the total CRC cases. Envi-
ronmental factors that are involved in the pathogenesis of CRC include low physical 
activity, obesity, smoking, and diet [6]. 
CRC is typically starts with the growth of a non-cancerous polyp, which in time pro-
gresses from precursor lesions (adenoma) to a malignant cancer. Removal of ad-
enomas could reduce the risk of developing full blown cancer [7] and as a result 
screening strategies in order to identify such lesions before they turn malignant 
have made their appearance in the clinic [8].
Typical symptoms associated with CRC include fecal blood loss or melena, abdomi-
nal pain, and/or a change in bowel habits. Most patients however, present with an 
otherwise unexplained iron deficiency anemia due to the fecal occult blood loss, 
and do not have any specific complaints [9]. When detected in a non-metastatic 
state, patients can be treated curatively by removal of the primary cancer lesion 
[10]. Unfortunately, around 20 percent of the patients are diagnosed after spread-
ing of the cancer has already occurred, therefore removal of the primary tumor will 
not be sufficient to cure these patients [3]. 
Figure 1. Schematic overview of cancer development. Normal epithelial cells gain mutations which 
results in the formation of hyperplasia and eventually invasive carcinoma. Carcinoma cells migrate 
away from the primary tumor via the blood stream to form a secondary tumor or metastasis. (figure 
adapted from CSH perspectives.)
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Several therapeutic options have been developed to treat patients with metas-
tasized CRC. Chemotherapy was the first additional kind of therapy, and is still in 
use in the clinic today [11]. These chemical substances are cytotoxic, interfering 
in processes that govern DNA synthesis and selectively attacking rapidly dividing 
cells. Since this is one of the hallmarks of cancer cells, these therapies have been 
quite successful. However, chemotherapy also targets cells that under normal cir-
cumstances divide quickly, resulting in several side-effects, such as hair loss and 
decreased production of blood cells [12]. Even though the two traditional cancer 
treatments, chemotherapy and radiation, were not specifically designed to target 
tumor cells alone, the enhanced sensitivity to either DNA damage or cell cycle ar-
rest due to the inherent replication stress in cancer cells has been exploited, seek-
ing an optimal dose and schedule to kill tumor cells while minimizing the damage 
to normal cells. However, the ideal anticancer strategy would be the one that selec-
tively kills tumor cells while sparing normal cells. This is the goal of ‘targeted cancer 
therapies’, which made their appearance in the clinic over the last decades [13,14]. 
These ‘targeted therapies’ are designed to block specific molecules that play a role 
in the signaling pathways involved in the growth, spreading, or progression of can-
cer cells. The limitation of these therapies is however, that cancer cells can become 
resistant to them [15]. The tumors will find a new pathway to achieve tumor growth 
that does not depend on the target of the therapy. Therefore these types of target-
ed therapies will probably work best in combination.
CRC as heterogeneous disease
All carcinomas found in the large intestine are referred to as ‘colorectal cancer’, 
suggesting that they are all similar. However, this is actually an overall term for a 
large heterogeneous group of diseases which all differ in terms of molecular mecha-
nism, regional distribution, pathology of the lesions, therapy response, and natural 
history [16]. There are at least three major molecular mechanisms that give rise 
to colorectal cancer. The predominant chromosomal instability (CIN) pathway [17], 
the CpG island methylator phenotype (CIMP) pathway [18], and the microsatellite 
instability (MSI) pathway which is characterized by a (germline) mutation in DNA 
mismatch repair (MMR) genes [19]. Regardless of the underlying pathway, for a 
cancer to develop, multiple and sequential genetic alterations must occur. These 
alterations occur in tumor suppressor genes and oncogenes. In their normal state, 
tumor suppressor genes inhibit cell proliferation. This growth inhibition is lost when 
both alleles are inactivated by mutation and/or epigenetic changes, such as pro-
moter methylation. Tumor suppressor genes broadly conform to Knudson’s classic 
two-hit hypothesis, where inactivation of both alleles is required for tumor suppres-
sor genes to lose their normal function [20]. In contrast, oncogenes act by promot-
ing cell proliferation. Mutation of these genes leads to abnormal overexpression or 
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increased activity of the protein, leading to increased cell proliferation [21]. Each 
genetic perturbation provides the cell with a relative proliferative advantage, to-
gether resulting in uncontrolled cancer growth.
Chromosomal instability (CIN) pathway
Up to 85% of the CRC cases develop via the “classical” CIN-pathway. This pathway 
is associated with a loss of function mutation in the APC (Adenomatous Polyposis 
Coli) tumor suppressor gene [17,22]. This is the most critical gene in CRC develop-
ment. Somatic mutations in both alleles are present in 80 percent of sporadic CRCs, 
and a single germline mutation in this gene is responsible for the hereditary polypo-
sis syndrome FAP [23] – a second hit in the remaining APC allele (loss of heterozy-
gosity, LOH) is required for these patients to develop CRC. The APC gene encodes a 
312 kDa multidomain protein that participates in several cellular processes, includ-
ing cell cycle regulation, apoptosis, cell adhesion and cell migration [24–26]. The 
most important role of APC however, is its tumor suppressing function through its 
capacity to regulate intracellular β-catenin (CTNNB1) levels [27–29]. As part of the 
canonical Wnt signaling pathway, the APC protein binds to β-catenin and, together 
with glycogen synthase kinase 3β (GSK3β) and axin/conductin, promotes β-catenin 
degradation, thereby preventing its signaling activity to the nucleus. When APC is 
mutated, its ability to downregulate β-catenin expression is lost, resulting in an ac-
cumulates of cytoplasmic β-catenin, which subsequently translocates to the nucle-
us where it forms a complex with T-cell factor (TCF) and lymphoid enhancer factor 
(LEF), activating transcription of Wnt target genes involved in proliferation and ap-
optosis [30,31]. Usually a loss of function mutation in APC is the first “hit” in the 
adenoma-to-carcinoma sequence of the CIN-pathway, resulting in an early “tumor” 
lesion called aberrant crypt foci [32]. 
In the transition from an early to intermediate lesion, APC mutations are followed 
by activating mutations in the oncogenes KRAS and BRAF in approximately 50% and 
10% of cases, respectively [33,34]. The proteins encoded by both these genes are 
involved in the transduction of cell division signals as part of the RAS/RAF/ERK path-
way [35]. In response to extracellular engagement by growth factors, cytokines or 
hormones of their respective cell surface receptors, Ras is activated, resulting in ac-
tivation of the mitogen-activated protein kinase cascade. Herein, Ras activates the 
protein kinase activity of RAF kinase, which in turn phosphorylates and activates 
the kinase MEK, which subsequently activates the ERK kinase, resulting in ERK-de-
pendent gene transcription. Mutations in KRAS and BRAF constitutively activate this 
pathway resulting in increased proliferation [35].
The next step in the adenoma-to-carcinoma sequence is loss of the SMAD pro-
teins, SMAD2 and SMAD4. They are located at 18q21.1 and allelic loss at this site is 
found in up to 60% of CRCs [36]. SMADs are essential regulators of the transform-
14
Chapter 1
ing growth factor (TGF)-β signaling pathway, which is important in regulation of 
cell growth, cell differentiation, apoptosis, and cellular homeostasis [37]. Loss of 
SMAD4 protein function appears to be directly correlated to metastatic potential 
of CRC [38]. 
Finally, impairment of tumor suppressor gene TP53 through allelic loss of 17p chro-
mosomal arm, is often the latest event in the traditional CIN-pathway resulting 
in the transition from adenoma to adenocarcinoma [36]. TP53 mutations or LOH 
increase relative to the increasing histological stage of the lesion. Only 4–26% of 
the adenomas have impaired function of the TP53 protein product p53, while it is 
observed in 50% of adenomas with invasive foci, and 50–75% of CRCs respectively 
[34]. The normal function of p53 is to slow down the cell cycle, providing ample 
time for DNA repair. However, when the sustained DNA damage is too great to re-
pair, p53 induces pro-apoptotic genes, sending the cell into programmed cell death 
[39]. Thus, loss of p53 function allows tumor cells to rapidly divide, while acquiring 
new mutations. 
The CIN pathway and the corresponding adenoma-to-carcinoma sequence has pro-
vided the basis for the molecular classification of CRC, however it is now clear that 
this is not the only pathway by which CRC can develop.
Microsatellite instability (MSI) pathway
Microsatellites are short repeat nucleotide sequences that are prone to errors dur-
ing replication due to their repetitive nature. Usually, when errors in these repeats 
occur during DNA replication, the DNA mismatch repair (MMR) system recognizes 
these errors and repairs the mismatches. Microsatellite instability refers to a dis-
crepancy in the number of repeats found in the microsatellite regions of tumor 
versus germline DNA. Therefore this ‘instability of microsatellites’ is a reflection of 
the inability of the MMR-genes to correct these errors in the microsatellite areas 
[40,41]. The affected cell thus acquires thousands of mutations, and while micro-
satellite loss in itself is not causative of cancer, when they occur inn cancer-relat-
ed genes, such DNA replication errors may result in unbridled cell proliferation. In 
around 15% of sporadic CRCs somatic mutations or hypermethylation-based silenc-
ing of MMR genes occurs [42]. Several members of the MMR gene family have been 
identified such as MSH2, MLH1, MSH6, PMS2, MLH3, MSH3, and PMS1. The pure 
form of MSI-H tumors are due to an inherited autosomal dominant syndrome with 
a germline defect in one of the mismatch repair (MMR) proteins, called hereditary 
nonpolyposis CRC (HNPCC) or Lynch syndrome [43]. However, sporadic mutations 
in these genes also occur, resulting in tumors with a similar phenotype as the inher-
ited form [44]. 
15
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Figure 2. Schematic representation of the progression from normal epithelium to colorectal cancer 
for the three main CRC pathways; CIN, MSI, and CIMP. Progression from normal epithelium through 
adenoma to colorectal carcinoma is characterized by accumulated abnormalities of particular genes. 
In the CIN-pathway, the loss of one normal copy of the tumor suppressor gatekeeper gene APC is the 
first event. Mutations of the oncogene K-RAS seem to occur next. Additional mutations or losses of 
heterozygosity of SMAD2/4 and inactivation of the tumor suppressor gene p53. MSI-high tumors are 
characterized by a mutation in one of the mismatch repair (MMR) genes, resulting in DNA replication 
errors. CIMP-positive tumors are associated with BRAF-mutations, and are characterized by a hyper-
methylation of CpG-islands. This is phenotypically associated with sessile serrated adenomas. (Adapt-
ed from R. Justin Davies, Richard Miller & Nicholas Coleman, Nature Reviews Cancer 2005)
16
Chapter 1
The CpG Island Methylator Phenotype (CIMP) Pathway
The CpG Island Methylator Phenotype pathway is the second most common path-
way for sporadic CRCs and accounts for approximately 15% of sporadic cases 
[45,46]. The CIMP pathway is characterized by a widespread hypermethylation of 
promoter CpG islands, which results in so called epigenetic gene-silencing of target 
genes (46). Via this hypermethylation, the expression of tumor suppressor genes 
such as MLH1 can be decreased, leading to the development of CIMP-positive CRCs. 
This CIMP-positive status is based on the hypermethylation analysis of a panel of 
CIMP-genes, however, there is no universal consensus on which panel is the golden 
standard for this diagnosis. Clinically, CIMP-positive CRCs are characterized by prox-
imal location, female gender, and older age. The phenotype is dependent on the 
genes that are silenced, especially if there is a concomitant presence or absence 
of microsatellite instability due to methylation-induced transcriptional silencing of 
MLH1 [48]. Classically, CIMP-positive CRCs that are also MSI-H, have similar clini-
cal characteristics to the MSI-H, such as the relative good prognosis. However, in 
the absence of MSI-H, the CIMP-positive phenotype tumors are characterized by a 
worse prognosis and more advanced pathology. However the most important dif-
ference concerns the precursor lesion - CIMP-positive cancer arises from sessile 
serrated adenomas, while CRCs developing via the CIN and MSI pathway, originate 
from adenomatous polyps [49,50].
Kinases and phosphatases in cancer signaling pathways
What all the pathways described above have in common, is that due to mutations 
or epigenetic alterations, cellular homeostasis is disturbed, resulting in uncon-
trolled cell growth. Every cell in the body has a tightly regulated system that dictates 
when it needs to divide, grow, mature and eventually die off. This system is based 
on a network of signaling pathways, cooperating in maintaining a normal cellular 
homeostasis. Regulation of these signaling pathways is heavily dependent on a bal-
anced equilibrium between two seemingly opposing enzymes; kinases and phos-
phatases. While kinases add phosphate groups to their substrates, phosphatases 
remove these groups by hydrolyzing the phosphoester bonds by which they are 
attached to the substrate [51]. Protein phosphorylation typically occurs on either 
serine, threonine or tyrosine residues, with an estimated relative distribution with-
in the human proteome of 79.3%, 16.9% and 3.8% respectively [52], with approxi-
mately 17.000 proteins that possess at least one of these residues [53]. The human 
genome encodes 518 protein kinases of which the majority is known or predicted to 
phosphorylate serine and/or threonine residues [54,55]. In contrast, there are only 
approximately 200 phosphatases encoded in the human genome, targeting either 
phosphorylated proteins or lipids. Based on structure, phosphatases are subdivid-
ed into six distinct functional and structural superfamilies: protein tyrosine phos-
phatases (PTPs, 108 members), metal-dependent protein phosphatases (PPMs, 13 
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members), phosphoprotein protein phosphatases (PPPs, 15 members), lipid phos-
phatases (LPs, 37 members), haloacid dehalogenases (HADs, 21 members) and nu-
cleoside-diphosphate-linked moiety X (NUDT,five members) [56]. This thesis will 
focus on several phosphatases, mostly concerning the protein tyrosine (PTP) family, 
and the lipid phosphatase family.
Phosphorylation is an efficient means to control cell response to internal and ex-
ternal cues: it is rapid, sometimes taking as little as a few seconds, it does not re-
quire new proteins to be synthesized or degraded and can be easily reverted. It is 
well-established that aberrant activation of kinases due to mutations or upregula-
tion often occurs in cancer [57]. As a result of these alterations, cancer cells tend 
to be characterized by a shift the balance between the kinases and phosphatases, 
leading to uncontrolled cell growth and increased capability to invade surrounding 
tissue. Therefore, these crucial signal transduction molecules represent attractive 
targets for cancer therapy. Much of the research in past years has focused on the 
potential role of kinases in cancer development, since it is generally assumed that 
phosphorylation of substrates by kinases results in activation of signaling and that 
this class of enzymes may therefor present as a valuable target for treatment. As 
such, kinase inhibitors have been developed with some promising success [58]. 
Phosphatases however, have received far less attention. The current dogma states 
that phosphatases act as tumor suppressors by damping growth factor-induced sig-
naling pathways.
Furthermore, due to their highly conserved structure and close similarity, phos-
phatases have the reputation to be ‘undruggable’. It was deemed to be too challeng-
ing to develop inhibitors targeting one phosphatase, without effecting their closely 
related counterparts with distinct functions. It is now becoming apparent that both 
these arguments do not hold true anymore. More and more phosphatases have 
been shown possess oncogenic potential, increasing their potential interest as ther-
apeutic targets [59,60]. Moreover, due to increasing knowledge of the crystal struc-
ture of phosphatases, drug development is now able to targeting these enzymes 
more specifically. Interestingly, this is not only true for the phosphatases acting as 
oncogenes - tumor suppressor phosphatases can now be targeted as cancer treat-
ment by reactivation of the dysregulated phosphatase [61].
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Scope of this thesis
As stated above, the role of phosphatases in cancer is an underlit research field, 
mostly based on the dogma that phosphatases function as tumor suppressor genes. 
However, in our opinion dephosphorylation events by phosphatases can also en-
hance signaling in cancer. The current research was therefore focused on eluci-
dating the role of several phosphatases in cancer, concentrating on phosphatases 
which have the potential to act as oncogenes rather than tumor suppressor genes, 
and which can have clinical implications as biomarker of future treatment target. 
More specifically, we investigated the role of the Low Molecular Weight protein 
tyrosine phosphatase (LMWPTP) in colorectal and prostate cancer, and studied the 
role of the protein tyrosine phosphatase 1B (PTP1B) and lipid phosphatase SH2 do-
main containing inositol 5-phosphatase 2 (SHIP2) in colorectal cancer.
Outline of this thesis
In order to highlight the hiatus in the current literature regarding phosphatases in 
cancer, this thesis starts with a review of the existing literature concerning the role 
of protein tyrosine phosphatases in colorectal cancer (Chapter 2), where it becomes 
clear that the current knowledge on phosphatases in cancer is mainly based on pre-
liminary data, with relatively few studies concentrating on the possible oncogenic 
role of these enzymes. However, it also becomes apparent that phosphatases can 
indeed act as activators of cellular signaling, providing further rationale for onco-
genic properties of these enzymes.
One of the phosphatases for which an oncogenic role has been proposed is the low 
molecular weight protein tyrosine phosphatase (LMWPTP). We investigated the role 
of this protein in the setting of prostate cancer (Chapter 3) and colorectal cancer 
(Chapter 4). We show that this enzyme acts as an oncogene in both these cancer 
types, by increasing the metastatic potential of cancer cells. Therefore LMWPTP has 
possible implications as biomarker and future treatment target in these diseases. 
Another phosphatase implicated in tumorigenesis is PTP1B. This enzyme is the first 
phosphatase ever to be identified, and mostly described as the “prototypical” PTP. 
Interestingly, it has been shown that PTP1B can act as tumor suppressor in certain 
cell types, while it acts as an oncogene in others. We therefore studied its role in 
colorectal cancer (Chapter 5), showing that PTP1B indeed acts as an oncogene in 
colorectal cancer as well. PTP1B expression, and more importantly, enzymatic activ-
ity are increased in CRC, thereby enhancing the oncogenic potential of this tumor. 
Interestingly, PTP1B inhibitors are slowly finding their way into the clinic for breast 
cancer. Our study now provides a rationale the use of these inhibitors in CRC.
In chapter 6 we step away from the tyrosine phosphatases, and study the lipid phos-
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phatase SHIP2. This enzyme acts as part of the PI3K-PKB-mTOR pathway by dephos-
phorylating phospholipids at the cell membrane. Since its function resembles the 
well-known tumor suppressor gene PTEN, it was long suggested SHIP2 must also 
function in a tumor suppressive way. However, our data shows that this enzyme 
acts as an oncogene in colorectal cancer, thereby suggesting that the use of SHIP2 
inhibitors in a clinical setting might be warranted. 
Since we identified several phosphatases as therapeutic targets, we reviewed the 
current status of drug targeting in the phosphatase field based on the recent Euro-
phosphatase conference in chapter 7. This 5-day conference deals with all aspects 
of phosphatase research. We highlighted the latest findings on this class of enzymes 
in the oncological field, with special attention to phosphatases as treatment tar-
gets in cancer. It is becoming ever more clear that phosphatases can no longer be 
ignored in this sense. Targeting of oncogenic as well as tumor suppressor phos-
phatases by small molecules is now becoming available.
In chapter 8 we dig deeper into one of the most important signaling pathway in 
colorectal cancer; the β-catenin pathway. Mutations in the tumor suppressor APC 
are the first step of the cancer process in the majority of the CRCs, resulting in in-
creased β-catenin signaling. However, different mutations in APC result in different 
levels of β -catenin signaling dosage. We believe these different APC mutations do 
not occur entirely in a random manner, but rather in such a way that the cells reach 
an optimal level of enhanced β-catenin signaling, described as the ‘just-right’ sign-
aling model. In this chapter we provide direct evidence for this theory, by showing 
that reducing the β-catenin levels leads to a shift from an intestinal to a mammary 
tumor phenotype in an APC-driven cancer model in mice. 
The novel insights obtained in this thesis will be summarized and discussed in chap-
ter 9, moving the role of phosphatases in cancer out of the shadow of the kinases, 
and into the big league of the cancer field.
20
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Abstract
Colorectal cancer is one of the most common oncogenic diseases in the Western 
world. Several cancer associated cellular pathways have been identified, in which 
protein phosphorylation and dephosphorylation, especially on tyrosine residues, 
is one of most abundant regulatory mechanisms. The balance between these pro-
cesses is under tight control by protein tyrosine kinases (PTKs) and protein tyrosine 
phosphatases (PTPs). Aberrant activity of oncogenic PTKs is present in a large por-
tion of human cancers. Because of the counteracting role of PTPs on phosphoryla-
tion-based activation of signal pathways, it has long been thought that PTPs must 
act as tumor suppressors. This dogma is now being challenged, with recent evi-
dence showing that dephosphorylation events induced by some PTPs may actually 
stimulate tumor formation. As such, PTPs might form a novel attractive target for 
anticancer therapy. In this review, we summarize the action of different PTPs, the 
consequences of their altered expression in colorectal cancer, and their potential as 
target for treatment of this deadly disease.
Graphical abstract. Three major CRC related signaling pathways, and their modulation by the PTPs 
are reviewed.
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Introduction
Colorectal cancer (CRC) is a common form of cancer and a lethal disease. Approx-
imately 945,000 new cases of colorectal cancer were diagnosed worldwide in the 
year 2000. In almost half of the cases this proves to be fatal [1]. Although CRC mor-
tality has been progressively declining since 1990, it still remains the second most 
common cause of cancer death in the US and Europe [2-3]. There are environmental 
and genetic factors that contribute to the development of CRC. Although inherited 
susceptibility results in the most striking increases in risk, the majority of CRCs are 
sporadic rather than familial. Familial adenomatous polyposis (FAP) is a relatively 
common form of familial colon cancer syndrome, but accounts for less than 1 per-
cent of the total CRC cases [4]. 
Many different genes and signaling pathways are involved in the development 
of colorectal cancer. These signaling pathways are involved in the control of cell 
proliferation, adhesion and migration and are under control of a delicate balance 
between protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs) 
[5]. Disturbance of this balance has been shown to play a role in the pathogen-
esis of numerous inherited or acquired human diseases such as cancer, immune 
deficiencies and inflammation [6]. Regulation of protein tyrosine phosphorylation 
contributes to many important physiological processes including cell growth, differ-
entiation, and migration as well as glucose metabolism, synaptic transmission, and 
the immune response [5]. As such, the importance of protein kinases in health and 
disease has been extensively investigated and reviewed. These studies are boosted 
by the wide ranging efforts made to develop the large panel of kinase inhibitors 
currently available, of which some show clinical promise. In contrast, the equally 
important phosphatases have received much less attention. However, because of 
their role in human disease, it is also vitally important to gain more understanding 
in the function of PTPs in these processes.
The PTP gene superfamily is a large group of highly specific enzymes and comprises 
a total of 107 PTP genes in the human genome [7] (Table 1). They are composed of 
four main families based on their amino acid sequence in the phosphatase catalytic 
domains (Table 1). By far the largest family is the Class I cysteine based PTPs. These 
can be further divided into the classical PTPs, including the receptor PTPs (RPTPs) 
and nonreceptor PTPs (NRPTPs), and the dual specificity phosphatases (DUSPs), 
which can dephosphorylate serine and threonine in addition to tyrosine residues. 
Class II cysteine based PTPs is the smallest class of PTPs; presently only the low mo-
lecular weight phosphatases (LMWPTPs) are known to belong to this group. Class III 
cysteine based PTPs are tyrosine/threonine specific phosphatases. In humans this 
class contains three CDC25 phosphatase genes. Lastly, the four enzymes included in 
the Class IV aspartate based PTPs are shown to have Tyr/Ser phosphatase activity 
[7]. Several genomic modifications in genes encoding PTPs have been observed, 
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and emerging evidence suggests that these alterations play a role in various hu-
man cancers. Wang and colleagues performed a systematic screen for mutations 
in genes encoding PTPs in different human cancers. They identified 83 somatic mu-
tations in six PTPs (PTPRF, PTPRG, PTPRT, PTPN3, PTPN13, PTPN14) affecting 26% 
of the colorectal cancers. With a frequency of 17%, PTPRT was most frequently 
mutated [8]. Interestingly, in their mutational screen on cancers with high level of 
microsatellite instability, Korff et al. described frameshift mutations in five different 
PTP genes (PTPRA, PTPRS, PTPN5, PTPN23, PTPN21, as well as the PTPN13 found in 
the screen by Wang et al.) affecting 32% of the colorectal cancers [9]. In this review 
we will summarize the structure and role of different PTPs in the development of 
colorectal cancer.
PTP Family Members (N) Substrate specificity
Class I cys-based PTPs Receptor PTPs (21) PTyr
Non-receptor PTPs (17) PTyr
MAPKs (11) PTyr, PThr
Atypical DUSPs (19) PTyr, PThr, mRNA
Slingshots (3) PSer
PRLs (3) PTyr
CDC14 (4) PSer, PThr
PTENs (5) D3-phosphoinositides
Myotubularins (16) PI(3)P
Class II cys-based PTPs LMWPTP (1) PTyr
Class III cys-based PTPs CDC25 (3) PTyr, PThr
Class IV asp-based PTPs EyA (4) PTyr, PSer
Table 1. Classification and substrate specificity of the 107 PTPs
The table shows an overview of the PTP family, which is subdivided in 4 classes. PTP: protein tyros-
ine phosphatase; MKP: mitogen-activated protein kinases phosphatase; DUSP: dual-specificity phos-
phatase; PRL: phosphatase of regenerating the liver; CDC: cell division cycle; PTEN: phosphatase and 
tensin homolog; LMWPTP: low molecular weight protein tyrosine phosphatase; Eya: Eyes absent ho-
molog. Based on Alonso et al. [7].
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PI3K-PKB-mTOR pathway
 
The phosphatidyl inositol 3-OH kinase (PI3K) - protein kinase B (PKB/Akt) - mam-
malian target of rapamycin (mTOR) pathway is an important signal transduction 
axis and regulates survival, growth and proliferation in different human cells. The 
PI3K family are lipid kinases capable of phosphorylating the hydroxyl group at the 3’ 
position of the inositol ring. After activation by various cytokines and growth factor 
receptors, this enzyme catalyzes the formation of phosphatidylinositol (3,4,5) tris-
phosphate (PtdIns(3,4,5)P3) by phosphorylation of PtdIns(4,5)P2. PtdIns(3,4,5)P3 is 
a critical second messenger for the membrane recruitment of several proteins, and 
binds to PKB through its pleckstrin homology (PH) domain. PKB plays a major role 
in cell survival by phosphorylating mTOR, GSK3 and forkhead transcription factors 
(reviewed in [10]). The PI3K pathway is regulated by the lipid phosphatases PTEN, 
SHIP1 and SHIP2, which will be discussed further in this review. 
PTEN
Characteristics of PTEN
The tumor suppressor gene, phosphatase and tensin homolog (PTEN), originally 
described as MMAC (mutated in multiple advanced cancers), is located on chromo-
some 10q23.3 [11-12]. Mutations in PTEN are the second most common genetic al-
terations in human cancer, behind p53 mutations. Germline mutations in this gene 
lead to the development of rare autosomal dominant inherited disorders called 
Cowden disease, Lhermitte-Duclos disease, and Bannayan-Zonana syndrome [13-
15]. These syndromes are characterized by numerous tumor-like growths, called 
hamartomas, and give an increased risk of developing certain forms of cancer, in-
cluding CRC. The PTEN protein is a DUSP, which acts on both proteins and lipids, 
with a greater affinity for the latter. As a lipid phosphatase, it acts as a negative reg-
ulator of the PI3K/PKB/mTOR pathway by converting PtdIns(3,4,5)P3 to PtdIns(4,5)
P2 at the plasma membrane. It has been shown that inactivation of PTEN results 
in constitutive activation of the PI3K/PKB pathway and increases cell proliferation, 
cell survival, migration and metastasis [16], all well-known characteristics of tumor 
cells. 
Role of PTEN in colorectal cancer 
As part of the PI3K/PKB/mTOR pathway, PTEN alterations are found in many dif-
ferent human neoplasms, including colorectal cancer. Langlois and colleagues ob-
served that PTEN protein expression as determined by Western blot analysis is 
reduced by 40% in approximately 60% of the CRC samples [17]. This is in accord-
ance with immunohistochemical reports from Li et al. and Jiang et al. who found 
PTEN expression in colorectal carcinoma to be statistically lower than the adjacent 
non-cancerous mucosa [18-19]. In vitro studies have shown that knocking down 
PTEN in colorectal cancer cell lines by using an siRNA approach, increases PKB phos-
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phorylation, confirming that the PI3K-pathway is activated in PTEN-deficient cells. 
In these cells, migration and invasion capacity was also increased, thereby result-
ing in a higher oncogenic potential. In addition, PTEN knockdown was associated 
with a change in E-cadherin expression, showing that loss of PTEN induces cellu-
lar changes consistent with epithelial to mesenchymal transition (EMT), a common 
phenomenon in tumorigenesis [20]. These data lead to the conclusion that loss of 
PTEN expression is involved in pathogenesis, invasion and metastasis of colorec-
tal carcinomas and that PTEN expression may be a good marker for prognosis of 
colorectal carcinoma. 
SHIP2
Characteristics of SHIP2
Like PTEN, the SH2-domain-containing 5 inositol phosphatases, SHIP1 and SHIP2 
are lipid phosphatases, although not characterized as PTP. Nevertheless, because 
of their potential role in CRC, we will discus this class of phosphatases here. SHIP1 
and SHIP2 share 38% amino acid homology but whereas SHIP2 is ubiquitously ex-
pressed with high expression in adult heart, skeletal muscle and placenta [21], 
SHIP1 is predominantly found in cells of the haematopoietic lineage [22]. SHIP2 
(INPPL1) is a 155-kDa protein containing a SH2-domain in the amino (N) terminus, 
a catalytic 5-phosphatase domain in the central region, potential phosphotyrosine 
binding (PTB) consensus sequences (NPXY), a proline-rich domain (PRD) and sterile 
alpha-motif (SAM) domain in the carboxy (C)-terminus [21, 23]. Just like PTEN, the 
lipid phosphatases SHIP1 and SHIP2 have long been thought to act as tumor sup-
pressors by counteracting the PI3K survival signaling pathway. SHIP dephosphoryl-
ates the PI3K product PtdIns(3,4,5)P3 at the 5D position of the inositol ring, thereby 
generating PtdIns(3,4)P2. However, recent evidence suggests PtdIns(3,4)P2 has a 
higher affinity for PKB than PtdIns(3,4,5)P3. Although PtdIns(3,4,5)P3 is required 
for PKB phosphorylation, PtdIns(3,4)P2 may actually be necessary for full activation 
of PKB [24]. These findings indicate that both PtdIns may be required to achieve a 
malignant state, which has been referred to as the “two PIP hypothesis” [25]. 
Role of SHIP2 in colorectal cancer 
Work performed by the group of N.K. Prasad showed upregulation of SHIP2 in 
breast cancer. 45% percent of the tumor specimens showed high SHIP2 levels, while 
only 15% of adjacent normal cells expressed high SHIP2 levels. Patients with higher 
SHIP2 levels in invasive carcinomas had significantly reduced disease-free and over-
all survival periods [26-27]. The observation that SHIP2 could play a role in breast 
cancer was further confirmed by the observation that novel pan-SHIP1/2 inhibitors 
inhibited cell growth of different breast cancer cell lines. In this study, SHIP inhi-
bition resulted in decreased phosphorylation of PKB on both Threonine 308 and 
Serine 473 residues, and reduced cell viability of SHIP2 expressing breast cancer 
cells. Intriguingly, this process could be rescued by adding exogenous PtdIns(3,4)P2, 
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confirming the importance of PtdnIns(3,4)P2 in cell survival [28]. In the same light, 
Zhou et al. recently found elevated SHIP2 expression in laryngeal squamous cell car-
cinoma [29]. Reducing SHIP2 expression by siRNA resulted in a decreased epidermal 
growth factor (EGF) receptor-induced PKB phosphorylation in breast cancer cells. 
Considering the fact that increased phosphorylation of PKB and mTOR has been 
observed in a large number of colorectal cancer biopsies, and is attributed to some 
extent to increased EGF receptor signaling, it seems that SHIP2 could play a role 
in colorectal carcinomas. Indeed, silencing of SHIP2 was shown to increase EGFR 
degradation in some cells [30]. A report by Lincová et al. demonstrated that reduc-
tion of SHIP2 expression sensitizes colon cancer cells to the antiproliferative effect 
of the cytostatic indomethacin, although they attributed this effect to an increase 
in PKB activation [31]. Together, these data suggest that SHIP2 may be a target for 
decreasing CRC cell viability. 
PRL-3
Characteristics of PRL-3
Phosphathase of regenerating the liver-3 (PRL-3, also known as PTP type IVA and 
encoded by PTP4A3) is part of a subfamily of PTPs which also contain PRL-1 and PRL-
2. PRLs have a core PTP domain with the C(X)5R active site motif and are the only 
PTPs known to carry the membrane-targeting CAAX motif at their COOH-terminus 
[7, 32-33]. Among normal adult human tissues, PRL-3 mRNA is expressed primarily 
in skeletal muscle and heart, with lower expression levels in lung, pancreas, spleen, 
and testis. The exact function of PRL-3 in these tissues is currently unknown [34-36]. 
Role of PRL-3 in colorectal cancer
Using global gene expression profiling of colorectal cancer (CRC) samples, it was 
recently found that in metastatic colorectal carcinomas, PRL-3 expression levels 
were increased in comparison to normal epithelium and non-metastatic tumors, 
suggesting a role for PRL-3 in tumor survival and metastasis. PRL-3 expression has 
also been associated with poor prognosis in CRC [37]. Several proteins have been 
identified as possible PRL-3 target proteins. Forte et al. found evidence that indi-
cates Ezrin pThr567 as a direct substrate of PRL-3 in the HCT116 colon cancer cell 
line. The identification of Ezrin as a target of PRL-3 action is of interest because of 
the role of the ERM family members (Ezrin-Radixin-Moesin) in several cellular pro-
cesses involved in tumorigenesis, such as cell survival, proliferation, invasiveness 
and migration. Ezrin inactivation by PRL3 may enhance downstream activation of 
targets such as the Src kinase and Rho family of cytoskeletal proteins [38]. Other 
investigations led to the conclusion that PRL-3 is a direct target of TGF-beta signal-
ing in colon cancer cells. The loss of TGF-beta signaling leads to the upregulation of 
PRL-3 and activation of the PI3K/PKB pathway [39]. Wang et al. found that PI3K/PKB 
activation as a result of PRL-3 activity can promote EMT. On further examination, 
they demonstrated that PTEN protein expression is downregulated by PRL-3. Con-
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sequently, PI3K and PKB are activated, whereas GSK-3b is inhibited, which leads to 
the upregulation of mesenchymal markers and downregulation of epithelial mark-
ers [40]. Fiordalisi et al. have provided evidence that RhoA and RhoC family GTPases 
can also act downstream of PRL-1 and PRL-3 PTPs to promote motility, invasion, and 
possibly metastasis, although in this study the direct substrate of PRL activity was 
not identified [41].  
PRL-3 is structurally similar to the lipid phosphatase PTEN, and carries a C-terminal 
CAAX box, which is not only featured in known lipid phosphatases but also localizes 
PRL-3 to the cellular compartments rich in phosphoinositides (PIPs). For this reason 
McParland et al. have speculated on a potential novel role for PRL-3 and provided 
the first evidence that PRL-3 may possess phosphatidylinositol 5-phosphatase ac-
tivity [39]. This would suggest that, like PTEN, PRL-3 may act as tumorsuppressor. 
Nevertheless, as described above, other studies imply that PRL-3 and PTEN counter-
act each other both on protein level and in terms of PKB activation. Hence, whereas 
PTEN activity in cancer is most often decreased, PRL-3 expression is increased in 
CRC and can therefore possibly act as target for treatment.
JAK-STAT-signaling
The Janus kinase/signal transducers and activators of transcription (JAK/STAT) path-
way is an important signaling mechanism triggered by a large number of cytokines 
and growth factors, such as interleukin-6 (IL-6), and is involved in cell proliferation, 
differentiation, cell migration and apoptosis, as well as drug resistance. Cytokine 
receptor engagement activates receptor-associated JAKs, which in turn mediate 
phosphorylation of specific receptor tyrosine residues. This allows the recruitment 
of STATs, present in the in the cytoplasm. Activation of STATs occurs through their ty-
rosine phosphorylation, which permits STATs to dimerize, translocate to the nucleus 
and bind to specific regulatory DNA sequences to activate or repress transcription 
of target genes (reviewed in [42]). Enhanced STAT3 pathway activation is a charac-
teristic of CRC and is associated with poor prognosis [43]. 
LMWPTP
Characteristics of LMWPTP
The family of low molecular weight protein tyrosine phosphatases (LMWPTP), rep-
resented by a single gene called ACP1, are a group of 18-kDa cytosolic enzymes that 
are widely expressed in different tissues [44]. LMWPTP is involved in cell growth 
regulation, in most instances as a negative regulator of growth factor-induced cell 
proliferation, but in some cases it may have an opposite role. Modulation of the ac-
tivity of LMWPTP is based on its phosphorylation/dephosphorylation as well as re-
versible oxidation of its cysteine residues. LMWPTP contains two tyrosines, Tyr131 
and Tyr132, which are preferential sites for phosphorylation by protein tyrosine 
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kinases such as Src [45-46]. Whereas Tyr131 phosphorylation causes a dramatic 
increase in enzymatic activity, phosphorylation of Tyr132 serves as a scaffold for the 
SH2 domain of growth factor receptor-bound protein 2 (Grb2), which may activate 
the Ras-ERK pathway (see below), but has no affect on its phosphatase activity [45]. 
In the presence of reactive oxygen species (ROS), oxidation of the cysteine residue 
in the catalytic site leads to oxidative inactivation of the enzyme. The ensuing pre-
vention of LMWPTP auto-dephosphorylation causes an increase of Tyr132 phos-
phorylation, and may induce a prosurvival response.[47-48].
LMWPTP interacts with several, cancer relevant proteins, including platelet derived 
growth factor receptor (PDGFR) [49], Ephrin A2 receptor (Eph A2) [50], β-Catenin 
[51] and the JAK-STAT pathway. Oxidized LMWPTP is unable to dephosphorylate 
and inactivate JAK2 and STAT5, which contributes to its tumorigenicity [52]. On the 
other hand, LMWPTP oncogenic potential may also be associated with the recep-
tor tyrosine kinase EphA2, which negatively regulates tumor cell growth, survival, 
migration, and invasion. Kikawa et al. showed that LMWPTP is a critical negative 
regulator of EphA2 tyrosine phosphorylation [50]. 
Figure 1. Schematic overview of the role of PTPs in colorectal cancer. Three main signaling path-
ways commonly over-activated in cancer are the PI3K–PKB–mTOR, the JAK–STAT and the Ras–Raf–
MEK–ERK pathways (described in detail in the main body of the text). These pathways are generally 
activated through engagement of growth factors to receptor tyrosine kinases (RTK). Indicated in 
black are the phosphatases reviewed, and their interaction with these three important pathways.
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Role of LMWPTP in colorectal cancer
When comparing the expression levels of LMWPTP mRNA in different human car-
cinomas (breast, colon, and lung) to their paired adjacent non-affected tissues, 
Malentacchi et al. found increased expression of LMWPTP mRNA in breast and co-
lon cancers, but not in lung cancers [53]. This difference was most predominant in 
patient groups expressing negative predictive markers, such as G2–G4 patients, pa-
tients with lymph node involvement or advanced Dukes’ stage, and in patients with 
a lower differentiation grade. Patients whose cancer LMWPTP mRNA expression is 
higher than that in paired non-affected tissue, have a significantly reduced survival 
probability in comparison to subjects who do not show an increase in LMWPTP 
mRNA in their tumours. The elevated mRNA also corresponded with an increase in 
LMWPTP protein, which was increased 2- to 20-fold in tumour samples compared 
to normal tissue. In the same light, Marzocchini et al. found a significant increase in 
LMWPTP expression in rat adenocarcinomas induced by DMH, especially proximal 
tumors, although the observed 2-fold increase did not reach statistical significance 
[54]. These results suggest that overexpression of LMWPTP is a phenomenon asso-
ciated with the onset of malignancy.
There are three common ACP1 alleles; A, B, and C, which give rise to six pheno-
types. Subsequent alternative splicing of the ACP1 mRNA results in two isoforms of 
the LMWPTP protein, a slow migrating form (S) and a fast migrating form (F) [55]. 
The different genotypes of LMWPTP show different enzymatic activities and other 
molecular properties. Whereas the S-forms seems to be associated with enhanced 
LMWPTP catalytic activity, the F-variants appear to play a role in cell adhesion, mi-
gration and extracellular matrix degradation by metalloproteinases. In colorectal 
cancer, the LMWPTP genotype is shifted from ACP1 S-forms to ACP1 F-forms, which 
may contribute to tumor invasiveness and metastasis potential [56]. 
Giving the possible oncogenic and metastatic roles in colorectal cancer, and the re-
cent development of LMWPTP-inhibitors [57], it is tempting to speculate that there 
might be a future role for these inhibitors in a therapeutic setting. 
PP2A
Characteristics of PP2A
Serine/threonine-specific protein phosphatase 2A (PP2A) is a major serine/tyrosine 
phosphatase protein involved in several cellular processes. Based on the finding 
that okadaic acid, a strong inhibitor of PP2A, is a potent tumor promoter, it was 
originally thought that PP2A acts as tumor supressor [58]. This dogma is now chal-
lenged by the finding that PP2A is essential for cell survival, and inhibition of PP2A 
with novel inhibitors may actually attenuate cancer cell growth [59]. PP2A is a pro-
tein composed of three regulatory subunits, A, B and C. The core enzyme consists of 
the 65-kDa scaffolding subunit (A), a 36-kDa catalytic subunit (C), and one of several 
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regulatory B subunits that can bind to the core enzyme. Each subunit has multiple 
isoforms which are all encoded by different genes, creating many forms of the PP2A 
holoenzyme, differing in expression patterns and specificity [60-61]. These different 
holoenzymes play a role in many fundamental cellular processes, such as signal 
transduction, DNA repair, transcription, translation, and growth control.
Role of PP2A in colorectal cancer
Because of a high frequency of loss of heterozygosity (LOH) in the region of chro-
mosome 11q23 in colorectal cancers, Wang et al. systematically surveyed this spe-
cific region for candidate tumor suppressor genes. They found alterations in the 
PPP2R1B gene in colon and lung cancer [62]. This gene encodes the B isoform of 
the structural/regulatory A subunit PP2A-Ab which is necessary for interaction with 
the catalytic C-unit or regulatory B-unit. Similarly, others confirmed the presence 
of mutations in the Ab subunit, resulting in defective binding to the B and/or C unit 
[63-64]. These point mutations, deletions, frameshifts, and splicing abnormalities 
found in the PPP2R1B gene occur in 15% of the primary colon tumors suggesting a 
role for PP2A inactivation in colorectal cancer. One of the targets of PP2A is STAT6, 
whose dephosphorylation at certain serine residues results in its inactivation. En-
hanced activation of this growth promoting signal transducer in colorectal cancer 
cells was attributed to the decreased expression of its positive regulators PPP2CA 
and PPP2CB [65].
PTPRT
Charcteristics of PTPRT
Protein tyrosine phosphatase receptor T (also designed as PTPρ) is a frequently mu-
tated PTP in several human neoplasms, such as lung, gastric, skin and colorectal can-
cers [8]. Together with PTPRM, PTPRK and PTPRU, it belongs to the receptor type 
IIB PTP family. They share the same domain architecture, with an extracellular do-
main, a juxtamembrane region and two tandem intracellular catalytic domains (D1 
and D2). The large extracellular domain contains a MAM (meprin-A5 antigen-PTP) 
domain, Ig-like domain and fibronectin type III-repeats [66]. The precise role of this 
PTP in signaling pathways has not been identified clearly yet. 
Role of PTPRT in colorectal cancer
In the mutational screen performed by Wang et al. described earlier, PTPRT was 
found to be the most frequently mutated PTP in colorectal carcinomas. A large 
fraction of these mutations include nonsense and frameshift mutations, suggesting 
inactivating mutations. Many of the missense mutations in the catalytic domains 
(both D1 and D2) of PTPRT lead to diminished phosphatase activity. In addition, 
overexpression of PTPRT inhibits CRC cell growth, suggesting a tumor suppressive 
role for this PTP [8]. Recently, both paxillin and STAT3 were identified as substrates 
of PTPRT. Paxillin is a signal transduction adaptor protein which plays a role in 
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cell-cell adhesion. PTPRT dephosphorylates paxillin specifically at Y88 in CRC cells, 
which plays an important role in CRC tumorigenesis and CRC cell migration through 
established signaling pathways such as AKT, p130CAS and SHP2 [67]. STAT3 dephos-
phorylation by PTPRT negatively regulates its translocation to the nucleus and tran-
scriptional activation of target genes, such as SOCS3 and Bcl-XL [68]. Hence, inacti-
vation of PTPRT in colorectal cancer may contribute to the survival signals induced 
by STAT3 signaling in these cells. 
PTP1B
Characteristics of PTP1B
PTP1B (or PTPN1) is the first mammalian PTP identified and is widely expressed 
[69]. The gene is located on human chromosome 20q13.1-q13.2 and has a molecu-
lar weight of approximately 50 kDa [70]. PTP1B is prototypic for the PTP superfam-
ily, with an N-terminal catalytic (PTP) domain, followed by two proline-rich motifs, 
and localizes to the ER through a hydrophobic domain in its C-terminus [71]. PTP1B 
is involved in the regulation of a variety of cellular events through different molec-
ular pathways, such as the epidermal growth factor receptor (EGFR) [72], plate-
let-derived growth factor receptor (PDGFR) [73], insulin receptor (IR) [74], insulin 
growth factor I receptor (IGF-IR) [75], p210 Bcr-Abl [76], Janus kinase 2 (JAK2), and 
TYK2 [77]. Given the central role PTP1B plays in the negative regulation of oncogen-
ic signaling, by the dephosphorylating PTKs such as p210 Bcr-Abl, PTP1B inhibition 
is generally thought to act as a carcinogenic [76]. In contrast, PTP1B has also been 
identified as one of the major phosphatases that activate Src in breast cancer cells 
[78], thus suggesting a dual role for PTP1B in carcinogenesis [79]. 
Role of PTP1B in colorectal cancer
By evaluating distinct genomic DNA alterations for a large number of candidate on-
cogenes and tumor suppressor genes in 22 colorectal cancer samples, Lassmann 
et al. identified DNA amplifications of PTP1B in 22% of the cases, with the highest 
percentage in CIN-positive tumors [80]. Like earlier reports in breast cancer, Zhu 
et al. found PTP1B to be the major tyrosine phosphatase capable of specifically 
dephosphorylating Src at its negative regulatory site Y530 in six of seven human 
epithelial colon cancer cell lines. In addition, phosphatase activities were greatly 
elevated in these colon cancer cell lines compared to a normal colon epithelial cell 
line, thus resulting in enhanced Src activity in these tumor cells [81]. Enhanced Src 
activity is associated with the majority of CRC, and directs downstream activation of 
the PI3K-PKB, JAK-STAT, but also Ras-ERK pathways [82-83]. Interestingly, increased 
Src activity is based on increased expression/activity modulation rather then on Src 
mutations, since these are very rare, suggesting a role for PTPs in this process. Mod-
ulation of this important kinase through PTPs may therefore find clinical relevance. 
Giving the oncogenic role for PTP1B in this respect, PTP1B-inhibitors might be a 
useful therapeutic target for these malignancies. 
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RAS-RAF-ERK pathway
The Ras/Raf/MEK/ERK cascade is an important signaling system that controls fun-
damental cellular processes such as proliferation, differentiation, survival and apop-
tosis. Ras acts as a molecular switch by cycling between an active, GTP bound state, 
and an inactive, GDP bound state. A wide array of stimuli can recruit nucleotide 
exchange factors, such as the well characterized sons of sevenless (SOS), to the 
cell membrane where it binds to the adaptor protein growth-factor-receptor-bound 
protein 2 (Grb2). Once at the cell membrane, SOS promotes the exchange of GDP 
for GTP, thereby converting Ras into its active conformation. Activated Ras will re-
sult in a cascade of mitogen-activated protein kinase (MAPK) activation. The first 
to become activated is the MAPK kinase kinase (Raf), which subsequently activates 
MAPK kinase (MEK1/2), which in turn is followed by phosphorylation and activation 
of MAPK (ERK1/2). ERK1/2 phosphorylates numerous substrates involved in the 
regulation of proliferation, differentiation and survival. (reviewed in [84]).
PTPRJ 
Characteristics of PTPRJ
Protein tyrosine phosphatase receptor type J, also designated as DEP-1 (high cell 
density-enhanced phosphatase-1) or CD148, is encoded by the PTPRJ gene located 
on human chromosome band 11p11. PTPRJ is a class III transmembrane protein 
tyrosine phosphatase that contains multiple fibronectin type III repeat domains in 
the extracellular portion, one transmembrane domain, and a single phosphatase 
domain in the intracellular portion [85]. PTPRJ can be activated by binding of var-
ious growth factors to its extracellular domain, and activated PTPRJ plays a role 
in several pathways such as VEGF [86], PDGFR [87-88] and HGFR [89] which are 
implicated in carcinogenesis. For instance, PDGFR mediated activation of Ras and 
Src, and to a lesser extent PI3K-PKB, can be inhibited by PTPRJ [88]. In addition, 
oncogenic Ras transformation of cells is inhibited by PTPRJ, and PTPRJ may directly 
dephosphorylate ERK1/2 [90-91].
Role of PTPRJ in colorectal cancer
Different PTPRJ haplotype associated single nucleotide polymorphisms (SNPs) have 
been identified, one of which reduces breast cancer risk [92]. However, there is no 
significant evidence for PTPRJ haplotype SNPs being either risk conferring or protec-
tive in colorectal cancer [93]. Ruivenkamp and collaborators demonstrated that one 
copy of the PTPRJ gene is deleted (LOH) in a large percentage of different sporadic 
human carcinomas, such as colorectal, breast and lung cancer [94]. Earlier research 
by the same group showed PTPRJ to be the only candidate gene for the mouse 
susceptibility locus to colon cancer, Scc1 [95]. In humans they screened sporadic 
colorectal adenomas for LOH along chromosome 11p11-11p12 and discovered the 
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PTPRJ containing region to be deleted in 49% of the carcinomas, suggesting a tumor 
suppressive role for PTPRJ. As no PTPRJ mutations were observed after sequence 
analysis of the individuals with and without LOH, it was suggested that loss of one 
copy of PTPRJ is sufficient to provide a growth advantage [94]. In line with this sug-
gestion, Balavenkatraman et al. showed that reduction of PTPRJ protein expression 
by shRNA confers growth advantage in colorectal cancer cell lines [96]. Decreased 
PTPRJ expression was indeed observed in immunohistochemical stainings of high 
grade tumors, including some adenocarcinomas [97]. Based on the above, PTPRJ 
appears to have an antiproliferative effect in epithelial cells from the colon, where 
loss of a gene copy may contribute to cancer development.
PTPRH
Characteristics of PTPRH
Receptor-type tyrosine protein phosphatase H (PTPRH), also known as stomach 
cancer-associated protein tyrosine phosphatase-1 (SAP-1) was originally identified 
as a PTP expressed in a human stomach cancer cell line. This PTP with a molecular 
weight of 107kDa is located on chromosome 19q13, and is structurally similar to PT-
PRJ [98]. It binds to Grb2, and as such may play a role in Ras signaling [99]. PTPRH is 
specifically overexpressed in human colon and pancreatic cancers [100] suggesting 
a role in carcinogenesis. In contrast, overexpression of this PTP in cultured fibro-
blasts inhibits cell proliferation, through either inhibition of growth factor-induced 
activation of MAP kinase or by caspase-dependent apoptosis [101-102]. Based on 
this, and the earlier finding that there is a reduced expression of PTPRH in advanced 
cancers [100, 103], it has also been suggested that PTPRH may act as a tumor sup-
pressor.
Role of PTPRH in colorectal cancer
As mentioned above, PTPRH overexpression has been found in colorectal cancers. 
Seo and co-workers examined the immunohistochemical PTPRH expression in spec-
imens from 65 patients, and demonstrated PTPRH expression in colonic adenomas 
showing moderate or severe dysplasia, but not in normal colonic epithelial cells or 
adenomas with mild dysplasia [100]. Others suggested PTPRH can promote intesti-
nal tumorigenesis in mice, as loss of PTPRH inhibits tumorigenesis in mice that are 
heterozygous for a mutation of APC that induces tumors of the colon [104]. The 
mutation of APC leads to stabilization and the accumulation of β-catenin, which in-
itiates transformation and promotes tumorigenesis through activation of transcrip-
tion factor 4 (reviewed in [105]). It thus appears that PTPRH cooperates with the 
canonical Wnt-signaling pathway in the formation of tumors, although the exact 
mechanism remains elusive. 
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PTPN13
Characteristics of PTPN13
Non-receptor type protein tyrosine phosphatase 13 (PTPN13), also known as FAP-1 
and PTPL1, is a cytoplasmic PTP located on chromosome 4q21 and the largest among 
all PTPs with a molecular weight of 270 kDa [106-109]. It contains a phosphatase 
domain in the C-terminal portion and many non-catalytic domains, including five 
PSD-95/Drosophila disc large zonula occludens (PDZ) domains, an N-terminal kinase 
non-catalytic C-lobe (KIND) domain [110] and a four-point-one/ezrin/radixin/moes-
in (FERM) domain [111]. These non-catalytic domains can interact with several dif-
ferent proteins, causing PTPN13 to have diverse functions. For instance, the third 
PDZ domain (PDZ2) intracellularly inhibits FasR-mediated apoptosis by interacting 
with the cytoplasmic death domain of Fas receptors [109]. In addition, PTPN13 is a 
negative modulator of Src-ERK signaling in cancer cells [112].
Role of PTPN13 in colorectal cancer
Several studies in colorectal cancer have shown conflicting results for the role of 
PTPN13, as either a tumor suppressive or an oncogenic protein (reviewed in [113]). 
Elevated levels of PTPN13 expression have been seen in Ewing’s sarcoma family tu-
mors (ESFT), as it is a direct transcriptional target of the ESFT oncogene, EWS-FL11 
[114]. In the same light, Yao et al. reported a high incidence of PTPN13 expression 
in colon carcinomas, and demonstrated that this is related to resistance to FasR-me-
diated apoptosis, thus acting as a survival mechanism and enhancing tumor growth 
[115]. In complete contrast, others found that ectopic expression of PTPN13 en-
hances, rather then decreases, apoptotic cell death in colon adenocarcinomas, sug-
gesting a more tumor suppressive role for PTPN13 [116]. These observations are 
further supported by the previously mentioned reports by Wang et al. and Korff et 
al., who identified PTPN13 among the PTPs most frequently mutated in colorectal 
cancer, suggesting they are likely to act as tumor suppressor genes [8-9]. 
PTPα
Characteristics of PTPα
PTPα is a transmembrane tyrosine phosphatase with a short, unique extracellular 
domain and two tandem catalytic domains. In comparison to other receptor-like 
PTPs which are often restricted to a lineage-specific expression, PTPα is widely ex-
pressed [117-118]. Two isoforms of PTPα exist, only differing in their extracellular 
domain, which arise by alternative splicing. The major substrates of PTPα are the 
Src family kinases (SFKs) [119-120]. By dephosphorylating the inhibitory COOH-ter-
minal tyrosine residue of SFKs, PTPα is capable of activating Src family members 
such as Src and Fyn. 
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Role of PTPα in colorectal cancer
Tabiti et al. first explored the possible involvement of PTPα in colorectal cancer by 
looking at the mRNA levels of PTPα in tumors compared to adjacent healthy colon 
mucosa [121]. In the Dukes’ D stage carcinoma they found a 2- to 10-fold increase 
in mRNA levels. As mentioned above, a large fraction of human colon cancers pres-
ent with increased Src protein tyrosine kinase activity. RNAi against PTPα reduces 
Src specific activity in different breast cancer and colorectal cancer cell lines, which 
suppresses anchorage-independent growth and induces apoptosis [122]. More re-
cently, Krndija et al. reported that in normal tissue PTPα expression was restricted 
to smooth muscle cells, whereas over 70% of the colon cancer samples showed 
expression of PTPα, supporting a role for PTPα in colorectal cancer, and identifying 
this PTP as a potential target for treatment [123].
Cell cycle proteins
Cdc25
Characteristics of Cdc25
Cdc25 (cell division cycle) phosphatase is a family of human cyclin-dependent ki-
nase activating phosphatases composed of three different members, Cdc25A, Cd-
c25B, and Cdc25C. They serve as Cdk/cyclin-activating phosphatases, by removing 
inhibitory phosphates from the threonine and/or tyrosine residues of these cell 
cycle proteins. This action is imperative for normal cell cycle progression [124]. Cd-
c25A is expressed in late G1 phase, where it is essential for G1/S transition through 
the activation of the cyclin E/CDK2 complex, while Cdc25B and C mainly regulate G2 
and G2/M transition [125]. 
Role of Cdc25 in colorectal cancer
Different studies have indicated that unlike Cdc25C, Cdc25A and B may have onco-
genic potential. Cdc25A and B overexpression has been observed in different cancer 
cell lines and human tumors, suggesting that these phosphatases are implicated in 
human neoplasms [126]. Hernández et al. examined the structure and expression 
of Cdc25A, B, C, and several splicing variants in a series of 34 paired tumor and nor-
mal colorectal tissues. They observed Cdc25B mRNA overexpression in 56% of the 
tumors, whereas Cdc25A and C were overexpressed in 12% and 26% of cases, re-
spectively [127]. Takesama et al. confirmed a 60% overexpression of Cdc25B mRNA 
level by RT-PCR in colorectal carcinoma [128]. In their unpublished data of a prelim-
inary study they found that Cdc25B expression was relatively low in hepatocellular 
carcinoma and in esophageal squamous cell carcinoma, although these carcinomas 
frequently expressed Cdc25A at high levels. They imply that high levels of Cdc25B 
may be a characteristic to colorectal carcinoma. and went on to demonstrate high 
Cdc25B in CRC as an independent predictive factor of death with a relative risk 
of 3.7. As this risk is higher than the relative risk for lymph node metastasis (2.4), 
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which is considered one of the strongest predictors of poor prognosis in colorectal 
carcinoma, they proposed Cdc25B as a novel prognostic marker in patients with 
colorectal carcinoma. On the other hand, Talvinen et al. did not find statistical evi-
dence for Cdc25B as a good marker for colorectal carcinoma [129]. Clearly, further 
studies are required to specify the role of Cdc25 in CRC. 
Conclusions
Protein phosphorylation and dephosphorylation, and in particular phosphorylation 
on tyrosine, plays an important role in several cellular processes, such as the con-
trol of cell proliferation, adhesion and migration. These processes are controlled 
by a tight balance between protein tyrosine kinases (PTKs) and protein tyrosine 
phosphatases (PTPs). So far, most of the research has focussed on the PTKs. In part, 
this is probably due to an historical cause, as the first PTP was only purified [130] 
ten years after the first PTK [131]. A variety of PTKs have since been linked to tum-
origenesis, and overexpression of PTK activity results in malignant transformation 
[132]. Because of their antagonizing role on PTKs, PTPs have long been thought to 
act solely as tumor suppressors. However, emerging evidence, some of which has 
been discussed in this review, suggests that PTPs act in different roles, both as tu-
mor suppressor genes and oncogenes. Thanks to comprehensive screens, such as 
those from Wang et al. and Korff et al. [8-9], the role of PTPs in colorectal cancer 
is starting to receive more attention. Here, we discuss the role of different PTPs in 
colorectal cancer (summerized in Table 2). Based on the studies included, we con-
clude that PTPs not only play an imperative role in oncogenesis, but that some of 
these phosphatases may form an attractive target in the battle against colorectal 
cancer. 
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Phosphatase Role in colorectal cancer Ref.
PTEN
Tumor suppressor gene, acts a negative regulator of the 
PI3K/PKB/mTOR pathway by converting PtdIns(3,4,5)P3 
(PIP3) to PtdIns(4,5)P2 (PIP2).
[17-20]
SHIP2 Possible oncogene, as PtdIns(3,4)P2 may actually be 
necessary for full activation of PKB.
[27-28]
PRL-3 Oncogene, increased in metastatic colorectal tumors. [37]
LMWPTP Oncogene, increased levels in colorectal tumors with 
negative predictors.
[52-53]
PP2A Tumor suppressor gene, mutations in subunit A results 
in defective binding and impaired function.
[60-62]
PTPRT Tumor suppressor gene, trough interaction with paxillin 
and STAT3
[65-66]
PTP1B Oncogenic role, by activating Src-family members. [78-79]
PTPRJ Tumor suppressive role, LOH in the PTPRJ containing 
region is deleted in 49% of the CRCs.
[92]
PTPRH Oncogenic role, possibly through the canonical 
Wnt-pathway.
[98, 100, 
102]
PTPN13 Dual role, through Fas mediated apoptosis [8-9, 113-
114, 131]
PTPα
Oncogene, upregulation in colorectal carcinomas by 
increasing Src activity.
[119, 
121]
CDC25B Oncogene, prognostic marker for survival. [124-127]
Table 2. PTPs discussed in this review with their potential role in colorectal cancer.
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Abstract
Background: Low-risk patients suffering from prostate cancer are currently placed 
under active surveillance rather than undergoing radical prostatectomy. However, 
clear parameters for selecting the right patient for each strategy are currently not 
available, and new biomarkers as well as treatment modalities are needed. Low 
molecular weight protein tyrosine phosphatase could present such a target.
Objective: To correlate expression levels of LMWPTP in primary PCa to clinical out-
come, and determine the role of LMWPTP in prostate tumor cell biology.
Design, Setting, and Participants: ACP1 expression was analyzed on microarray 
datasets, which were subsequently used in an Ingenuity Pathway Analysis. Immu-
nohistochemistry was performed on a tissue micro array containing material of 
481 PCa patients, of which the clinicopathological data were recorded. PCa cell line 
models were used to investigate the role of LMWPTP on cell proliferation, migra-
tion, adhesion and anoikis resistance. 
Outcome Measurements and Statistical Analysis: The association between LM-
WPTP expression and clinical and pathologic outcomes was calculated using chi-
square correlations and (multivariable) cox regression analysis. Functional conse-
quences of LMWPTP overexpression or downregulation were determined using 
migration and adhesion assays, confocal microscopy, western blotting and prolifer-
ation assays.
Results and Limitations: LMWPTP expression is significantly increased in human 
prostate cancer (PCa), and correlates with earlier recurrence of disease and reduced 
patient survival (HR:1.99; P<0.001, and HR:1.53; P=0.04). Unbiased Ingenuity anal-
ysis comparing cancer and normal prostate suggests migratory propensities in PCa. 
Indeed, overexpression of LMWPTP increases PCa cell migration, anoikis resistance 
and reduces activation of Fak/Paxillin, corresponding to decreased adherence.
Conclusions: Overexpression of LMWPTP in PCa confers a malignant phenotype, 
with worse clinical outcome. Prospective follow-up should determine the clinical 
potential of LMWPTP overexpression.
Patient summary: These findings implicate LMWPTP as novel oncogene in prostate 
cancer, and could offer the possibility of using this protein as biomarker or target for 
treatment in this disease. 
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Introduction
Kinases and phosphatases that control intracellular phosphorylation are critical 
regulators of cell proliferation, adhesion, migration and death. Deregulation of on-
cogenic kinases has been shown to contribute to cancer development. In general, 
it is assumed that phosphatases, by counteracting kinase activities, act as tumor 
suppressors. However, a dual role for the Low Molecular Weight Protein Tyrosine 
Phosphatase (LMWPTP) in tumor cell biology is emerging. Enhanced expression of 
LMWPTP has been correlated to poor prognosis for some human tumors [1]. This 
may be related to the fact that this 18kDa protein tyrosine phosphatase interacts 
with cancer related molecules such as PDGFR, β-catenin, EphA2, JAK2 and STAT5, 
resulting in a positive effect on cell growth and proliferation signaling [2–7]. 
Prostate cancer (PCa) is one of the most frequently diagnosed cancers in males 
[8]. There are several treatment strategies available for non-metastasized prima-
ry prostate tumors, i.e. radical prostatectomy, radiation therapy (either external 
beam or brachytherapy), and active surveillance. However, while several treatment 
guidelines are available, prognostic biomarkers to aid clinical decision making are 
warranted. Furthermore, since prostate cancer is highly metastatic to the bone and 
lymph nodes, new treatments should be directed at avoiding this progression to-
wards metastatic clinical state. The aim of this study was to examine expression lev-
els of LMWPTP in primary PCa, correlate these to clinical phenotype, and to study 
the role of LMWPTP in prostate tumor cell proliferation, migration and stromal cell 
interaction. 
 
Materials and Methods
Gene expression profiling and pathway analysis. 
Use of clinical samples was approved by the Erasmus Medical Center Medical Ethics 
Committee according to the Medical Research Involving Human Subjects Act in pro-
tocol MEC-2004-261. Samples and Affymetrix analysis are described in [9]. Differ-
entially regulated genes, their log2 fold change and associated p-value for LN-PCa, 
TURP and PCa as compared against NAP were filtered for a p-value ≤ 0.05, then the 
corresponding expression values and p-value were imported into Ingenuity Path-
way Analysis software for an unbiased analysis of the functional role of ACP1 in 
canonical pathways (supplementary material). 
Immunohistochemistry 
FFPE tissue sections from seven non-prostate cancerous patients and fifteen radi-
cally resected prostate cancer patients with a Gleason score of at least 4+3=7 were 
immunohistochemically stained for LMWPTP (ACP1 antibody, sc-100343, Santa 
Cruz Biotechnologies, Dallax, Tx) ([10] and supplement). In addition, a tissue mi-
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croarray (TMA) of 481 PCa patients [11] was stained. All patients had undergone 
radical prostatectomy for their disease without previous adjuvant therapy and were 
evaluated for Gleason score, pT-stage and surgical margins. Biochemical recurrence 
was defined as an increase in serum PSA after two different measurements, at least 
3 months apart. In a subpopulation of these patients, local recurrence as suspected 
by clinical presentation was confirmed by needle-biopsy. Death and death due to 
disease were registered by the physician who last treated the patient. We tested 
the hypothesis that increased LMWPTP status is related to a more invasive tumor 
(Gleason score and pT-stage) using Rank-sum and χ2 tests, and whether increased 
LMWPTP expression is predictive for worse clinical outcome using Cox regression 
analysis with the following covariates; age and PSA at diagnosis, Gleason score, pT-
stage, Surgical margins, and LMWPTP status. Patient selection and statistics were 
performed as described in supplement. 
Cell culture and transfections
Cells (PC3, DU145, PNT2C2, MG63) were cultured as described in supplementa-
ry material. Overexpression plasmid pCS2+MT-LMWPTP was a kind gift from Prof. 
J. den Hertog, Hubrecht Institute, Utrecht, The Netherlands. Transfection of the 
LMWPTP construct was performed using Lipofectamine™ 2000 from Invitrogen 
(Bleiswijk, The Netherlands) according to the manufacturer’s directions (see sup-
plement). Analyses were performed 48h after transfection.
LMWPTP immunoprecipitation and phosphatase assay
LMWPTP activity assays were performed as described in [12] and supplement. 
Migration Assays
Transwell migration assay was performed as described in [13] and supplement. In 
scratch-wound assays, cell monolayers were scratched with a pipette tip, washed 
twice and photographs were taken (Axiovert200M microscope,Carl Zeiss, BV, the 
Netherlands) to analyze the percentage of open wound area at 24h (Image J soft-
ware).
Adhesion assay
Cells in serum-free medium were allowed to adhere to rat-tail type I collagen (Sig-
ma, St-Louis, MO) coated, bovine serum albumin (BSA) blocked plates for 10, 30 and 
60 min. The attached cells were stained with Cristal Violet, and absorbance after 
extraction with 10% acetic acid was measured.
Fluorescence immunohistochemistry
PC3 cells were grown on coverslips, transfected and fixed with 3.7% formaldehyde. 
Fixed cells were permeabilized and blocked in PBS/0.1% Triton X-100/10%FBS, 
stained with 200ng/mL DAPI (4’, 6’-diamidino-2-phenylindole, Sigma, St Louis, 
MO) and actin filaments visualized with 10µg/mL phalloidin-TRITC (tetramethyl 
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Figure 1. Gene expression profiling shows increased ACP1 mRNA expression in PCa, which corre-
sponds to increased LMWPTP protein levels. A) Using gene expression array data of a previously 
described cohort of patient samples collected at the EMC, expression of ACP1 (transcript 2466141, 
NM_007099) was compared between tumor tissue (PCa, n=56), lymph node metastasis of PCs (LN-
PCa, n=12), TURP (n=10) and adjacent normal prostate tissue (NAP, n=12, p = 0.0008 by ANOVA). Sig-
nificantly higher expression of ACP1 mRNA expression was observed in prostate tumor and LN-PCa 
compared to NAP (***=0.0002; **=0.003, RMA normalized expression values). (B-E) 15 PCa patients 
with Gleason score >7 and 7 healthy controls were selected for staining. Representative examples 
of immunohistochemistry of three individual patients (B-D), and one healthy control (HC) (E) are 
shown. Magnification of 10X and inset of 40x are presented. (F-G) The number of cells exhibiting 
nuclear and cytoplasmic staining as well as intensity of staining were scored (**= 0.0055; *=0.014). 
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Rhodamine Isothiocyanate; Sigma St-Louis, MO). Upon mounting in Mowiol DAB-
CO aqueous mounting medium (Vector Laboratories, Burlingame, CA), images were 
acquired using an epifluorescence microscope Axiovert200M (Carl Zeiss, BV, The 
Netherlands). 
Western blotting
Protein extraction and blotting were performed as described in [14] and supple-
ment. 
Co-culture with stromal cells
Transfected PC3 cells were labeled with 1µM CFSE (carboxyfluorescein diacetate 
succinimidyl esther; Molecular Probes, Eugene, OR). Cells were resuspended in 
F12K medium and added on top of a confluent MG63 cell monolayer. After 24h the 
suspension-cell fraction and adherent-cell fraction were analyzed by flow cytom-
etry (FACS Canto, BD Biosciences, Bedford, MA) and 10000 events were acquired. 
The total number of CFSE-labeled PC3 cells was calculated by reference of a known 
number of beads (BD Bioscience, San Jose, CA) in the tubes. 
Cell cycle analysis
Cell cycle analysis was performed as described [15]. Cells were stained for 1h in so-
dium citrate-dihydrate (1g/L) solution, containing 20µg/mL propidiumiodide, 0.1% 
triton X-100 and 100µg/mL ribonuclease A. Cell cycle distributions were analyzed 
using Modfit LT software (verity software House, Topsham, ME, USA)
Zymography Analysis
Proteolytic activity of MMP-2 and MMP-9 was assayed by gelatin zymography as 
described by Souza et al [16] and supplement.
 
Results
ACP1 mRNA and protein are overexpressed in primary human prostate cancer
Using gene expression array data from a cohort of patient samples [9] we observed 
a significantly higher mRNA expression of the LMWPTP gene ACP1 in primary pros-
tate tumors, compared to normal adjacent prostate (NAP) (transcript 2466141, 
NM_007099, p=0.0001, Figure 1A). In addition, increased levels of ACP1 mRNA 
were found in prostate tumor cells metastasized to the lymph nodes (p=0.0024) as 
compared to NAP tissue, showing that enhanced ACP1 expression in prostate tumor 
cells is maintained after metastasis. 
To validate whether increased ACP1 mRNA levels in PCa correspond to increased 
protein levels, we performed immunohistochemistry on PCa biopsy tissue sections 
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Overall LMWPTP low expression
LMWPTP high 
expression
Parameter Median (quart)or N (%)
Median (quart) 
or N (%)
Median (quart) 
or N (%) p-value
Number of Pts 481 314 147
Age at diagnosis 64 (61-67) 64 (61-67) 65 (61-67) 0.33
PSA at diagnosis
Total 5.2 (3.6-7.8) 5.1 (3.5-7.7) 5.4 (3.9-8.9) 0.17
<10 ng/ml 418 (87%) 277 (88%) 125 (85%)
>10 ng/ml 62 (13%) 37 (12%) 21 (15%)
FU time (months) 113 (89-139) 119 (98-137) 112 (74-137) 0.52
Gleason score
<7 265 (56%) 187 (60%) 69 (47%) 0.013 *
3+4 = 7 152 (28%) 95 (30%) 49 (33%)
4+3 = 7 35 (6%) 16 (5%) 16 (11%)
>7 28 (5%) 15 (5%) 13 (9%)
Surgical margin
Negative 362 (75%) 239 (76%) 108 (73%) 0.54
Positive 119 (25%) 75 (24%) 39 (27%)
pT-stage
T2 344 (72%) 239 (76%) 92 (63%) 0.005 **
T3a 92 (19%) 46 (15%) 41 (28%)
T3b 17 (4%) 10 (3%) 7 (5%)
T4 28 (6%) 19 (6%) 7 (5%)
Lymph node  
positive
1 (0.2%)a 0 1 n.a.
KI-67
<1% 353 (73%) 246 (78%) 107 (73%) 0.23
1-5% 40 (8%) 27 (9%) 19 (13%)
>5% 9 (2%) 5 (2%) 4 (3%)
unknown 73 (17%) 36 (11%) 17 (12%)
Table 1. Clinicopathological characteristics of Tissue Micro Array (TMA), divided according to 
LMWPTP intensity (High/Low). (* p<0.05; ** p<0.01)
a. Since lymph node metastasis was only observed in 1 patient, lymph node metastasis was not 
taken into account in the further analysis.
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(Gleason score ≥7) and non-cancerous prostate sections (examples shown in Figure 
1B-E). Staining of LMWPTP is evident in both the nucleus and the cytoplasm, and 
significantly increased in PCa as compared to either NAP or healthy controls (Figure 
1F-G). 
Increased LMWPTP expression is correlated to worse clinical outcome 
Next, we performed LMWPTP immunohistochemical staining on a tissue micro ar-
ray (TMA) containing representative cores of 481 prostate cancer patients who un-
derwent radical prostatectomy (Table 1), with at least 2 cores per patient. Median 
follow-up of the TMA cohort is 113 months. Patients were divided in two groups 
based on intensity of LMWPTP staining (examples in Figure S1). High intensity of 
LMWPTP staining was significantly associated with well-known parameters for pros-
tate cancer aggressiveness, such as Gleason score (P=0.01) and pT-stage (P=0.005) 
(Table 1). Furthermore, high LMWPTP expression in prostate cancer correlates to 
earlier biochemical and local recurrence (Logrank; P<0.001 and P=0.05), an incre-
mentally increased prostate cancer related death (Logrank; P=0.005) (Figure 2), and 
significantly reduced overall patient survival (Logrank; P=0.017) (Figure S2). In mul-
tivariate analysis, high LMWPTP expression resulted in a significant hazard ratio for 
time to biochemical (N=119; HR:1.99; P<0.001 ), and time to death (overall) (N=109; 
HR: 1.53; P=0.04) (supplementary tables S1-S3), suggesting a role for LMWPTP in 
increasing tumor aggressiveness. Due to the limited number of events for local re-
currence (N=21) and prostate cancer related death (N=12), we could not perform 
multivariate analysis, however in univariate analysis high LMWPTP status results 
in HRs of 2.35 and 4.77, respectively (0.98-5.66; P=0.056, and 1.44-15.84; P=0.01), 
Tables S2 and S4. Staining of the proliferation marker KI-67 (examples in Figure S3) 
Figure 2. Increased LMWPTP expression is correlated to worse clinical outcome.
LMWPTP staining intensity within the TMA was divided in two groups (High expression [>1.5] in green 
/and Low expression [<1.5] in blue) and correlated to clinical characteristics. Kaplan Meier curves for 
Time to biochemical recurrence (A), Time to local recurrence (B), and time to death due to prostate 
cancer (C), reveal a significant correlation between high LMWPTP expression and these clinical param-
eters. (P = logrank test)
63
LMWPTP in prostate cancer
did not correlate to LMPWTP intensity, nor did it correlate to poor outcome or serve 
as independent prognostic marker for any clinical parameter. These data suggest 
that in our cohort, signaling induced by LMWPTP is more conductive to aggressive 
tumor behaviour of PCa cells than their proliferative capacity. 
Identification of canonical pathways regulated by ACP1
Using the Ingenuity network platform, we performed an unbiased analysis of 
ACP1-related signaling differences in PCa in comparison to NAP. The top canonical 
pathways which are statistically significant for each result set (PCa-NAP, TURP-NAP 
and LN-PCa-NAP) were determined in IPA (Figure S4A-B), demonstrating a signif-
icantly differential expression of Ephrin Receptor Signaling (ERS) (-log[p-value] > 
4.0), with only two other pathways achieving greater significance. Closer inspec-
tion of the ERS pathway (Figure 3) revealed the protein-protein interaction between 
Ephrin-B and LMWPTP (or ACP1) in IPA, but the regulatory effect of ACP1 deter-
mined by Stein et al. [17] lacked in the canonical pathway. We amended this path-
way to include ACP1, which regulates Ephrin-A (EphA) [18–20]. MAP analysis of the 
Figure 3. MAP analysis using the ERS pathway with differentially expressed genes from PCa ver-
sus NAP results. Schematic representation the Ephrin-Receptor Pathway (ERS), comparing the PCa 
and NAP datasets. Pink and green are up- and down-regulated genes respectively, with blue and or-
ange representing the negative and positive outcomes predicted by IPA based on the differentially 
expressed genes in prostate cancer. Note the increased prediction of migration and reduced prediction 
of proliferation based on the presence of related gene interactions in PCa.
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amended ERS pathway was consistent between all PCa datasets (Figure 3, Supple-
mentary figures S5-6), with the overriding outcome that cell migration is predicted 
to be upregulated in PCa, TURP and LN-PCa as compared to NAP, through regulation 
of cytoskeletal rearrangement mediators. Furthermore, STAT3 expression is down-
regulated, and the STAT3-pathway as known in IPA is predicted to be inhibited in 
PCa. While Jak-STAT signaling is upregulated in many cancers, Spiotto and Chung 
showed that in prostate cancer loss of STAT3 transcriptional activity is correlated to 
oncogenic potential and disease progression [21]. Furthermore, proliferative poten-
tial is predicted to be downregulated. 
These unbiased predictions were validated by definition of a set of known LM-
WPTP-interacting genes (supplementary table S5), again predicting STAT3 pathway 
inhibition, and demonstrating increased IGF1 and drug resistance pumps expres-
sion in conjunction with ACP1 expression (Figure S7).
Overexpression of LMWPTP in PC3 prostate cancer cells increases migration
To study the effect of LMWPTP on PCa cell growth, we overexpressed this phos-
phatase in the prostate cancer cell line PC3. Changes in cell morphology (i.e. loss 
of spindle shape) suggested that overexpression of LMWPTP may enhance cell 
proliferative capacity (Figure S8A). However, no changes in G1, S and G2/M cell 
cycle distribution of LMWPTP-overexpressing cells were observed (Figure S8B). 
When filamentous actin (F-actin) was visualized using phalloidin-TRITC staining, 
LMWPTP-overexpressing cells were not only rounded, but displayed an F-actin dis-
tribution along the periphery of the cell, resembling lamellipodia and indicative of 
migratory cells (Figure S8C). 
We therefore analyzed migration in three different prostate cell lines and showed 
that overexpression of LMWPTP augmented chemokinesis capacity of PC3, DU145 
and PNT2C2 prostate cells >twofold (Figure 4A-D). The PNT2C2 prostate cell line, 
derived from non-tumorigenic prostate epithelial cells, is regarded as less malig-
nant than PC3 or DU145, which were derived from prostate tumors. Spontaneous 
random migration of PNT2C2 cells is minimal compared to PC3 and DU145 (Figure 
4E), consistent with a lower LMWPTP expression and activity in these cells com-
pared to PC3 cells (Figure 4F). Indeed, when LMWPTP expression was reduced in 
PC3 cells by siRNA, a 31% reduction in migration of these cells was observed (Fig-
ure S9A, B). Accordingly, in LMWPTP silenced PCa cells, matrix metalloproteinase 2 
(MMP-2) was less active (Figure S9C, D), indicative of decreased invasive potential. 
When the low LMWPTP expression observed in PNT2C2 cells was further reduced 
by siRNA, their migratory capacity, as measured in wound closing assays, was also 
diminished (Figure 4G). Together, these results demonstrate that overexpression of 
LMWPTP in prostate tumor cells results in their enhanced migration.
65
LMWPTP in prostate cancer
Figure 4. LMWPTP promotes PCa cell migration. A) PCa cell lines were transfected with either empty 
vector (control) or LMWPTP and Transwell migration of CellTracker Green labeled cells was measured 
over time. Values represent the number of cells on the bottom side of the insert. Representative 
examples of migrating PC3 cells (A) DU145 (B) and PNT2C2 (C) are shown. (D) Quantification of mi-
gratory PNT2C, DU145 and PC3 cells at t=180 min. (E) Migration of untransfected PC3, DU145 and 
PNT2C2 cells compared side-by-side. Spontaneous random migration of PNT2C2 cells is minimal when 
compared to the tumor lines PC3 and DU145 (129.3% RFU at t=180 min vs 192.2% and 178.5 %, re-
spectively). (F) LMWPTP activity was compared between PCa cell lines with the highest and lowest mi-
gratiory response (PC3 and PNT2C2). LMWPTP activity was immunoprecipitated from equal amounts 
of protein, and specific phosphatase activity was measured. In addition, equal amounts of protein (as 
determined by Tubulin staining) were assessed for LMWPTP expression by western blot analysis. (G) 
PNT2C2 cells were transfected with either Scrambled siRNA or siRNA against LMWPTP. As these cells 
migrate too slow to detect a further reduction with transwell migration, we performed a scratch assay. 
Reducing LMWPTP in PNT2C2 cells decreased the speed with which the induced scratch is healed.
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Modulation of LMWPTP expression affects actin-cytoskeletal-related signaling 
and adhesive properties 
Next, we investigated the signaling moieties involved in cytoskeletal rearrangement. 
The vasodilator-stimulated phosphoprotein (VASP) is involved in the regulation of 
actin nucleation, with phosphorylation on Ser239 inhibiting actin accumulation and 
affecting filopodia formation during migration [22]. Overexpression of LMWPTP in 
PC3 cells reduced phosphorylation of VASP on Ser239, while downmodulation of 
LMWPTP increased it (Figure 5B).
Furthermore, phosphorylation of Focal adhesion kinase (Fak) and its target Paxil-
lin, two proteins involved in cytoskeletal rearrangement [23] were reduced upon 
overexpression of LMWPTP, and increased when LMWPTP was silenced (Figure 
5A-C). Cytoskeletal signaling in LMWPTP-overexpressing cells being consistent with 
reduced inhibition of actin nucleation and affected cell adhesive properties, we sub-
sequently measured adhesion of PC3 cells on collagen I-coated plates. Overexpres-
sion of LMWPTP significantly reduced cell adherence to collagen (Figure 5D). How-
ever, in vivo, adhesion of cells is modulated through integrin binding and matrix 
proteins. When non-adherent LMWPTP-overexpressing PC3 cells were replated on 
MG63 osteoblastic cells, these floating PC3 cells adhered efficiently to this stromal 
cell line (Figure 5E, F). Furthermore, the total number of viable PC3 cells in MG63 
co-cultures was enhanced upon overexpression of LMWPTP (Figure 5G), showing 
that LMWPTP mediates anoikis-resistance in PC3 cells, one of the tumor hall-marks 
required for metastatic potential. 
 
Discussion
An oncogenic rather than tumor suppressive role for phosphatases has been postu-
lated before [1,24]. Overexpression of LMWPTP alone is sufficient to drive transfor-
mation of epithelial cells, and increased levels of LMWPTP have been reported in 
several human tumors, including neuroblastoma and breast cancer [19,25]. In this 
study, we show for the first time that LMWPTP is overexpressed in prostate tumor 
biopsies, which corresponds to a significantly worse clinical outcome - i.e. earlier 
time to recurrence and to disease-related death, suggesting that this staining could 
potentially function as a prognostic marker, and may help with the identification of 
patients eligible for the active surveillance strategy. However, the number of events 
for PCa related death in our study was low, and prospective follow-up studies will 
need to show the clinical implications of this phosphatase in prostate cancer. Inter-
estingly, our data (KI-67 staining and IPA analysis) suggest that invasive potential 
rather than proliferation confers tumor aggressiveness. Our in vitro studies support 
a role for LMWPTP in cellular migration and anoikis-independence, through modu-
lation of adhesion-associated cytoskeletal signaling. These data fit well with earlier 
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Figure 5. Modulation of LMPWTP expression affects cytoskeletal signaling and influences adher-
ence-dependent cell survival. LMWPTP expression in PC3 cells was increased with overexpression 
vectors or decreased with siRNA. Functional activity of LMWPTP protein was evident from decreased 
JAK phosphorylation in LMWPTP overexpressing cells and decreased p-JAK2 in LMWPTP knockdown 
cells (A). Next, phosphorylated Fak (A), phosphorylated VASP (B), and phosphorylated Paxillin (B,C) 
were determined by Western blot analysis. Equal loading was confirmed by anti-Actin antibodies. 
Representative examples of experiments are shown. D) Control vector or LMWPTP transfected PC3 
cells were plated on collagen-I coated wells. Non-adherent cells were removed at different time inter-
vals, and presence of adherent cells was determined by MTT assay. LMWPTP over-expression reduc-
es the number of adherent cells. E) Non-adherent LMWPTP over-expressing cells were labelled with 
CFSE and re-plated on either stromal cells or empty wells. After 24h, non-adherent cells were gently 
removed, the culture was trypsinized, and the number of fluorescent cells was determined by flow cy-
tometry. Floating LMWPTP over-expressing cells are viable and adhere well to stromal cells. F) Control 
vector and LMWPTP transfected PC3 cells were labelled with CFSE and plated on either stromal cells 
(Stroma +) or empty wells (Stroma -). Adherence of LMWPTP over-expressing cells to empty wells is 
significantly decreased compared to control cells. Adherence to stroma is more efficient than adher-
ence to empty wells, for both control and LMPTP expressing cells. G) The total number of viable PC3 
cells in co-cultures of PC3LMWPTP cells with stromal cells is higher than in co-cultures of PC3control 
cells with stromal cells. Fluorescent PC3 cells were determined by flow cytometry. 
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studies showing increased migration and reduced Fak activity upon overexpression 
of LMWPTP in fibroblasts [19]. 
Thus far, relatively few other phosphatases have been found to perform an onco-
genic function in PCa. The prostatic acid phosphatase (PAP) was shown to be highly 
expressed in metastatic PCa, and enhanced expression of the dual specificity phos-
phatase (DUSP)-1 was found to be inversely correlated with apoptosis in PCa, and 
is likely involved in early phases of neoplastic transformation [26,27]. LMWPTP may 
now be added to this list.
Conclusions
We report that expression of the phosphatase LMWPTP is increased in primary 
prostate tumor, which leads to a worse clinical outcome. Overexpression of LM-
WPTP in PCa affects cytoskeletal signaling, increases anoikis resistance and enhanc-
es migratory potential. Our data indicate that LMWPTP could potentially be used 
as biomarker, and a future treatment target for prostate cancer. Future prospective 
studies will need to confirm the clinical implications of our findings. 
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Supplementary Figures 
Supplementary Figure 1. Immunohistochemical analysis of LMWPTP expression on tissue micro ar-
ray (TMA). Representative cores of prostate specimens, stained for LMWPTP expression. Since most 
epithelial cells were positive for the staining, we focused on LMWPTP intensity. Low intensity (A,B,C), 
was scored as scored as +1, intermediate intensity (C,D,E) were scored as +2, and high intensity (F,G,H) 
scored as +3.
Supplementary Figure 2. Increased LMWPTP expression is correlated to worse clinical outcome. 
Patients were divided into three groups according to the intensity of their LMWPTP staining (Low ex-
pression in blue / intermediate in green / high in red) and LMWPTP expression was correlated to clin-
ical characteristics. Kaplan Meier curves for Time to biochemical recurrence, Time to local recurrence, 
and Time to death due to prostate cancer confirmed an increase in time to recurrence and death upon 
increasing LMWPTP expression. 
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Supplementary Figure 3. Representative cores of prostate cancer specimens, stained for the prolif-
eration marker KI-67. Representative cores of prostate specimens stained for KI-67. Expression was 
absent in A and B, in C less than 5% of the nuclei were positive (indicated by arrows), while in D around 
50% of the nuclei are positive for the marker.
Supplementary figure 4. Differentially regulated canonical pathways identified using IPA. 
A) Hierarchical clustering of canonical pathways in the 3 datasets (LN-PCa-NAP, TURP-NAP and PCa-
NAP). B) Close-up of the top canonical pathway identified with log-values.
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Supplementary figure 6. MAP analysis using the ERS pathway with differentially expressed genes 
from LN-PCa-NAP results. Pink and green are up- and down-regulated genes respectively with blue 
and orange representing the negative and positive predicted outcome the differentially expressed 
genes in TURP
Supplementary figure 5. MAP analysis using the ERS pathway with differentially expressed genes 
from LN-PCa-NAP results. Pink and green are up- and down-regulated genes respectively with blue 
and orange representing the negative and positive predicted outcome the differentially expressed 
genes in LN-PCa
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Supplementary figure 7. MAP analysis of target network based on the known interactions and 
experimentally validated connections of ACP1 (or LMWPTP) stored within the IPA platform. 
Gene expression patters of PCa vs NAP. Associations known in IPA are indicated with arrows. Not all 
literature-described associations are annotated in IPA, these are represented as separately from the 
IPA-drawn network, but correspond with the expected increase in multidrug resistance pumps in PCa, 
which is in agreement with literature indicating a role for LMWPTP in drug resistance.
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Supplementary figure 8. LMWPTP overexpression alters PCa phenotype. 
A) PC3 prostate cancer cells over-expressing LMWPTP show a rounded phenotype compared to con-
trol vector transduced cells. Fewer cells are seen per field of view. B) PC3 cell cycle progression is 
not affected by overexpression of LMPWTP. Cell cycle analysis of control vector and LMWPTP overex-
pressing cells was determined by staining with propidium iodine, followed by flow cytometry. C) Cells 
transfected with either control vector or LMWPTP were stained with phalloiding-TRITC to visualize 
F-actin, and DAPI nuclear stain. LMWPTP overexpressing cells are rounded, lose their characteristic 
spindle-shape and gain lammelipodia-like actin structures at the periphery of the cell.
76
Chapter 3
Supplementary figure 9. Modulation of LMWPTP expression influences PCa cell migration and 
MMP2 activity. (A) Representative example of PC3 cells transfected with scrambled siRNA, siRNA 
against MAPK1 or siRNA against LMWPTP, and used in the migration assay. (B) Whereas siRNA against 
MAPK1 did not affect PC3 migratory response, PC3LMWPTPsiRNA cells presented 129% RFU after 
180 min, compared to 187%RFU in control cells. C) Equal amounts of protein from each sample were 
applied to gel zymography. The activity of MMP-9 and MMP-2 was measured by densitometry of the 
gelatin zymography in PC3 cells, showing reduced MMP-2, but not MMP-9 activity. D) Quantification 
of gelatin zymography of MMP activity in PCa cells (n=2).
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Supplementary table 2. Univariate cox-regression analysis for time to local recurrence.  
(number of events = 21)
Parameter Univariate analysis
HR (95% CI) p-value
Age 0.96 (0.87-1.05) 0.37
PSA 1.03 (1.01-1.05) 0.002
Gleason score
*<7 1 0.001
3+4 = 7 1.79 (0.58-5.55)
4+3 = 7 8.78 (2.83-27.28)
>7 6.06 (1.51-24.30)
pT-stage
*pT2 1 0.02
pT3a 0.55 (0.12-2.44)
pT3b 1.59 (0.21-12.19)
pT4 4.31 (1.53-12.19)
Surgical margin 4.10 (1.73-9.75) 0.001
LMWPTP status 2.35 (0.98-5.66) 0.056
Cox-regression analysis with continuous variables age and PSA level, and categorical variables Gleason score and 
pT-stage, where * represents the category of reference.
Supplementary Tables
Parameter Multivariate analysis
HR (95% CI) p-value
Age 1.023 (0.98-1.07) 0.339
PSA 1.02 (1.01-1.03) 0.009
Gleason score
*<7 1 0.001
3+4 = 7 1.50 (0.91-2.38)
4+3 = 7 3.41 (1.85-6.30)
>7 1.94 (0.95-4.00)
pT-stage
*pT2 1 <0.001
pT3a 1.12 (0.68-1.84)
pT3b 3.16 (1.57-6.37)
pT4 2.89 (1.60-5.21)
Surgical margin 2.32 (1.55-3.48) <0.001
LMWPTP status 1.99 (1.36-2.91) <0.001
Cox- regression analysis with continuous variables age and PSA level, and categorical variables Gleason score,and 
pT-stage, where * represents the category of reference.
Supplementary table 1. Multivariable cox-regression analysis for time to biochemical recurrence. 
(number of events = 119)
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Supplementary table 3. Multivariable cox-regression analysis for time to overall death.  
(number of events = 109)
Parameter Multivariate analysis
HR (95% CI) p-value
Age 1.10 (1.05-1.16) <0.001
PSA 1.02 (1.00-1.03) 0.02
Gleason score
*<7 1 0.11
3+4 = 7 1.29 (0.83-2.02)
4+3 = 7 2.08 (1.13-3.81)
>7 1.02 (0.37-2.78)
pT-stage
*pT2 1 0.06
pT3a 0.51 (0.30-0.87)
pT3b 0.44 (0.15-1.29)
pT4 0.63 (0.29-1.37)
Surgical margin 1.10 (0.71-1.72) 0.68
LMWPTP status 1.53 (1.03-2.27) 0.04
Cox-regression analysis with continuous variables age and PSA level, and categorical variables Gleason score and 
pT-stage, where * represents the category of reference.
Supplementary table 4. Univariate cox-regression analysis for time to prostate cancer related 
death. (number of events = 12)
Parameter Univariate analysis
HR (95% CI) p-value
Age 1.05 (0.92-1.20) 0.46
PSA 1.03 (1.01-1.05) 0.001
Gleason score
*<7 1 0.001
a3+4 = 7 -
4+3 = 7 14.80 (3.70-59.28)
>7 13.23 (2.66-65.78)
pT-stage
*pT2 1 0.005
pT3a 3.06 (0.61-15.31)
pT3b 5.86 (0.61-56.60)
pT4 13.18 (3.09-56.15)
Surgical margin 1.29 (0.387-4.31) 0.68
LMWPTP status 4.77 (1.44-15.84) 0.01
Cox-regression analysis with continuous variables age and PSA level, and categorical variables Gleason score and 
pT-stage, where * represents the category of reference. (a) not analyzable due to lack of events.
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Supplementary table 5. Gene list used to construct an ACP1-related Target Network in IPA.
Genes involved in migra-
tion
Genes involved in prolifera-
tion/apoptosis
Possible ACP1 upstream/
downstream targets
RhoA TP53 ZAP70
PAK BAD FYN
Vimentin BCL2 LCK
Rac1 CDK1 CTNNB1
CDC42 MYC EphA2
EGFR KRAS EphB1
Actn1 PIK3CA EphB2
Vasp PTEN IRS-1
Ezr AKT1 STAT3
Cofilin STAT5
FAK
SRC
PDGFRA
JAK2
IGF1R
ABCB1
ABCB4
ABCC1
ABCC4
ABCC5
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Supplementary material and methods
Gene expression profiling 
Use of clinical samples was approved by the Erasmus Medical Center Medical Eth-
ics Committee according to the Medical Research Involving Human Subjects Act 
in protocol MEC-2004-261. Initial treatment of primary tumors was radical prosta-
tectomy. Hematoxilin/eosin-stained, frozen tissue sections were evaluated by two 
pathologists (T.van der Kwast and G.J.L.H. van Leenders). Samples were collected 
between 1984 and 2001, and specimens containing >70% tumor tissue or speci-
mens without the presence of cancer (normal adjacent prostate (NAP)) were se-
lected [1]. The samples with and without PCa are from different specimens. RNA 
from 30 consecutive, 30-μm tissue sections obtained from primary resected pros-
tate cancers (PCa, n=56), lymph node metastasis (LN-PCa; n=12), Transurethral re-
sected prostates (TURP; n=10) and normal adjacent prostate (NAP; n=12) samples 
were isolated using RNA-Bee (Campro Scientific, Berlin, Germany). The lymph node 
tissue itself was not analyzed, so comparison of LN-PCa is compared to NAP. The tu-
mor percentage of two flanking sections and one internal section was determined. 
RNA for microarray analysis were processed according to the protocol of the sup-
plier (Affymetrix, Santa Clara, CA, USA). Expression profiles were determined us-
ing GeneChip Human Exon 1.0 ST (Affymetrix) at the Erasmus Center for Biomics, 
Erasmus Medical Center, and ServiceXS (Leiden, the Netherlands) (GSE41410 and 
GSE59745) [2]. Microarray data were RMA normalized using Partek Genomics Suite 
(Partek Inc, St Louis, MO, USA). Next, we also performed an analysis of the ACP1 ex-
pression levels in prostate cancer compared to normal prostate using the Oncomine 
tool, using publicly available databases (website). 
Ingenuity Pathway analysis
Gene array data generated as described above were analysed as follows: differen-
tially regulated gene list, their log2 fold change and associated p-value for LN-PCa, 
TURP and PCa as compared against NAP were filtered for a p-value ≤ 0.05, then 
the corresponding expression values and p-value were imported into the Ingenuity 
Pathway Analysis software (IPA; Ingenuity Systems, Redwood City, CA) [3]. A rank 
list of canonical pathways from IPA's library of canonical pathways, based on statis-
tical significance was determined independently for each PCa result set (PCa-NAP, 
LN-PCa-NAP and TURP-NAP) with a Fisher's exact test to determine the probability 
that each biological function assigned to that data set was due to chance alone. The 
threshold for a significant pathway is determined as the corrected p-values based 
on the Benjamini-Hochberg method of accounting for multiple testing [4] and set 
maximum False Discovery Rate of 5%.
Subsequently IPA’s Comparison Analysis was used to rank the most common signif-
icant pathways which were determined from the differentially expressed genes for 
all three data set comparisons (PCa-NAP, LN-PCa-NAP and TURP-NAP). To assess the 
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functional role of ACP1 in prostate cancer, the most significant canonical pathway(s) 
containing ACP1 common to all three results sets was used for Molecule Activity 
Predictor (MAP). MAP is used to interrogate canonical pathways (and networks) 
and to generate hypotheses by selecting a molecule of interest, indicating up or 
downregulation, and simulating directional consequences of downstream mole-
cules and the inferred activity upstream in the pathway (or network). The three 
PCa results sets (PCa-NAP, LN-PCa-NAP and TURP-NAP) were used as quantitative 
measures for MAP analysis.
In parallel and as a validation to the predictions generated from the canonical path-
way analysis, a set of genes was defined by the authors based on their knowledge 
of the literature with respect to the functional aspects of ACP1 (STAT-signaling [5], 
growth factor signalling [6], drug resistance [7]), or their involvement in cell prolif-
eration or migration. These genes were used to generate a network based on the 
known interactions and experimentally validated connections stored within the IPA 
platform. MAP analysis was repeated as with the canonical pathway analysis to de-
termine if ACP1 has a functional role in this network.
Patient Information
We selected all men from the European Randomized Study of Screening for Pros-
tate Cancer (ERSPC), Rotterdam section, who had undergone radical prostatectomy 
as part of the normal clinical care for non-metastasized prostate adenocarcinoma 
in Erasmus Medical Center between 1987 and 2010 [8]. In this study, men aged be-
tween 55 and 74 years were invited for a screening visit every 4 years. Recruitment 
and randomization started in December 1993 and ended December 1999. Up until 
May 1997, patients with a serum prostate-specific antigen (PSA) level of ≥4.0 ng/
ml, an abnormal digital rectal examination and/or abnormal transrectal ultrasound 
underwent lateralized sextant prostate needle-biopsies. As from May 1997, a biop-
sy was indicated by a PSA level of ≥3.0 ng/ml or abnormal digital rectal examination 
and/or transrectal ultrasound.
Directly after surgery, radical prostatectomy specimens were transported on ice 
to the pathology department. After fixation in neutral-buffered formaldehyde, the 
radical prostatectomy specimens were routinely cut in 4-mm transverse slices with 
additional perpendicular slicing of the apex and basis to allow optimal evaluation of 
surgical margins, and totally embedded in paraffin. Hematoxylin/eosin (HE) slides 
were microscopically evaluated by two board-certified pathologists with expertise 
in urological pathology. Histological slides of all patients (n=509) were retrieved 
from the pathology archives together with corresponding paraffin blocks contain-
ing the largest tumor volume (with tumor of at least 0.5 cm in diameter per paraffin 
block). In 28 cases, the tumor diameter was less than 0.5 cm, or no paraffin tissue 
was available, resulting in 481 patients to be included. Median age at diagnosis was 
64 (55-75) years, median PSA at time of diagnosis was 5.2 ng/ml (IQR 3.6-7.8 ng/
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ml). Gleason score was <7 in 265 (56%), 3+4=7 in 152 (28%), 4+3=7 in 35 (6%), and 
>7 in 28 (5%) cases, respectively. Extra-prostatic progression (pT3/4) was observed 
in 137 (28%) cases and surgical margins were positive in 119 (25%) cases. Only one 
of the patients (0.2%) had positive lymph nodes, and all the patients were distant 
metastasis free (since this was a contraindication for radical prostatectomy), and 
therefore these variables were excluded from further analysis (clinicopathological 
characteristics are listed in table 1).
Clinical follow-up was recorded after each control at our outpatient clinic, and data 
were transmitted to the central study database. Use of samples for research pur-
poses was approved by the Erasmus Medical Center Medical Ethics Committee ac-
cording to the Medical Research Involving Human Subjects Act (MEC-2004-261).
Immunohistochemistry 
The FFPE tissue sections were immunohistologically stained for LMWPTP (ACP1 an-
tibody, sc-100343, Santa Cruz Biotechnologies, Dallax, Tx) as described [9]. Briefly, 
5µm sections were deparaffinized in xylene and rehydrated through graded alco-
hols. Antigen-retrieval was performed by boiling the slides in citrate buffer pH 6.0 
for 15 minutes. Endogenous peroxidases were blocked by immersing the slides 
for 10 minutes in 3% H2O2 in phosphate buffered saline (PBS). Next, slides were 
blocked by incubation in PBS/10% goat serum for one hour at room temperature. 
Primary antibody was added 1:800 in blocking buffer and incubated overnight at 
4°C. Envision goat anti-mouse-horseradish peroxidase (Dako) was used as second-
ary antibody. The slides were scored for percentage and intensity of positive epi-
thelial cells in the cancerous tissue as well as the directly adjacent normal prostate 
tissue. 
TMA analysis and statistics
Scoring ability of the staining was assessed by a trained urological pathologist (GL), 
after which the tissue micro array sections were scanned by a Hamamatsu Nano-
zoomers virtual microscope. Next, TMA was scored independently by two research-
ers (EH and JL; kappa =0.65), and number of positive epithelial cells as well as inten-
sity of the staining was recorded. The intensity of LMWPTP expression was scored 
as negative (0; very low or no staining), weak (1+; intensity just above background 
level), moderate (2+; clearly visible at low magnification) and strong (3+; striking at 
low magnification). For each patient on the TMA, at least two tissues cores were 
available. Based on the average intensity of the staining, two patient groups were 
formed using arbitrarily chosen cut-off points (low <1.5 and high >1.5). When di-
viding our patients group into three groups, cut-off points of <1, 1<x<2, and >2 are 
used. 
We tested the hypothesis that increased LMWPTP status is related to a more inva-
sive tumor and therefore correlated to prostate cancer parameters such as Gleason 
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score and pT-stage, and that increased expression is predictive of worse clinical out-
come. Statistical associations between expression of LMWPTP (as categorical var-
iable) and continuous clinico-pathological parameters (age and PSA at the time of 
diagnosis) were tested using independent sample rank sum test, and with categori-
cal parameters (Gleason score, pT-stage, surgical margins, KI-67) using Pearson’s χ2 
test. 
To determine whether LMWPTP expression was predictive for biochemical recur-
rence, local recurrence, overall death or disease-specific death, we used univariate 
and multivariate Cox regression with following covariates; age at diagnosis and PSA 
at diagnosis (as continuous variables), Surgical margins and LMWPTP status (as cat-
egorical variables), Gleason score and pT-stage as multiple categories (Gleason <7, 
Gleason 3+4=7, Gleason 4+3=7, Gleason >7), (pT-stage pT2a, pT3a, pT3b, pT4). We 
have checked the linearity of age and PSA at diagnosis assumption by adding quad-
ratic terms (AGE*AGE; PSA*PSA) to the model, and performed a restricted cubic 
splines analysis with 4 knots based on the method by F.E. Harrel [10], which were 
all not significant. Due to the low number of events in the local recurrence (N=21) 
and prostate cancer related death group (N=12), we could not perform a multivar-
iate analysis, and therefore only reported the univariate analysis. The proportion-
ality assumption for LMWPTP positive versus negative cases was visually assessed 
in Kaplan–Meier curves. P-value <0.05 was considered significant. All statistics were 
performed using SPSS 21 (SPSS, Chicago, IL, USA).
 
Cell lines
PC3 (purchased from ATCC) and DU145 cells (obtained from Prof Dr Jack Schalken, 
Radboud University Medical Center, Nijmegen, the Netherlands) were cultured in 
F12K medium, supplemented with 10% fetal bovine serum (FBS, PAA, Etobicoke, 
Ontario, Canada). PNT2C2 cells were kindly provided by Professor N. J. Maitland, 
University of York, York, UK, and cultured in RPMI1640 (PAA, Etobicoke, Ontario, 
Canada), containing 10% FBS. MG63 osteoblastic cells, a kind gift from Dr. R. van 
Bezooyen, LUMC, Leiden, the Netherlands, were cultured in Dulbecco’s Modified 
Eagles Medium (DMEM, PAA, Etobicoke, Ontario, Canada) containing 10% FBS. All 
cell cultures were supplemented with 100U/ml penicillin, 100mg/ml streptomycin, 
and propagated at 370C in a 5% CO2 humidified atmosphere.
Cell culture and transfections
Overexpression plasmid pCS2+MT-LMWPTP was a kind gift from Prof. J. den Hertog, 
Hubrecht Institute, Utrecht, The Netherlands. Transfection of the LMWPTP con-
struct was performed using Lipofectamine™ 2000 from Invitrogen (Bleiswijk, The 
Netherlands) according to the manufacturer’s directions. Briefly, 3x105 cells were 
seeded in a 6-well plate and after 24h, transfections were performed in serum free 
media using LMWPTP (4μg DNA/well) or negative control (4μg DNA/well) expres-
sion vectors. Four hours later, the medium was replaced for media containing 10% 
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FBS for 24h. For LMWPTP knockdown, cells were transfected with 5nM of siRNA 
(Qiagen, Germantown, MD) in a 6-well plate using Hiperfect Transfection Reagent 
(Qiagen, Germantown, MD) according to the manufacture’s specification. All analy-
sis were performed 48h after transfection.
LMWPTP immunoprecipitation and phosphatase assay
LMWPTP activity assays were performed as described [11]. To quantify the phos-
phatase activity, cells were lysed with 200μL of Lysis Buffer (20 mM HEPES, pH7.7 
with 2.5mM MgCl2, 0.1mM EDTA, 1mM PMSF, 1mM DTT, 10µg/mL aprotinin and 
10µg/mL leupeptin) on ice for 2h. After clarifying by centrifugation, the cell extracts 
were incubated overnight at 40C under rotation with antibodies against LMWPTP 
(Abcam, Zwijndrecht, The Netherlands). A-Sepharose beads were added to cell ho-
mogenates and incubated for 2h at 40C. Cell extracts were washed 3 times with 
lysis buffer and 2 times with acetate buffer 100 mM pH5.5. The precipitate was re-
suspended in acetate buffer (100 mM pH 5.5) and immediately used for enzymatic 
assay.
The PTP activity was measured using the Protein Tyrosine Phosphatase Assay kit 
Non-Radioactive from Sigma (St. Louis, MO). Reaction medium contained 80mM 
Acetate Buffer pH5.5, and 0.2mM of PTP phosphorylated substrate. The reaction 
was carried out at 37°C for 20 minutes and stopped with an equal volume of Mala-
chite Green/Ammonium Molybdate reagent (1:100). The amount of phosphate pro-
duced in the reaction was measured at 650nm and compared to a standard curve.
Migration Assays
The migration assay was performed as described [12]. Briefly, transfected and 
non-transfected cells in 6-well plates were labeled for 1h with 10μM CellTracker 
Green (Invitrogen, Bleiswijk, the Netherlands) in serum-free medium. Subsequent-
ly, cells were incubated for 1h in medium with 10% FCS to retain the dye, washed, 
detached with trypsin and resuspended in serum-free medium. The cell suspension 
was transferred to 8μM pore size HTS FluoroBlok Cell Culture Inserts from BD Falcon 
which were inserted in a 24-well in which contained 600μL of serum free media. 
Fluorescence was measured every 2 minutes on a microplate reader (Synergy HT, 
Biotek) and the values represent the number of cells on the bottom side of the in-
sert. Migration start points were set to zero. 
Another migration assay, the scratch-wound assay was used to confirm the migra-
tory response of PNT2C2 cells. 28h after transfection with siRNA, PNT2C2 cells were 
grown to confluence in a 6-well plate, serum-starved overnight and scratched with 
a pipette tip to create a wound. After wounding, cells were washed twice with PBS 
to remove cell debris. Photographs were taken by Axiovert200M microscope (Carl 
Zeiss, BV, the Netherlands) with coupled camera (Axiocam HR, Carl Zeiss BV, the 
Netherlands), and the percentage of the open wound area at 24h was analyzed 
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using Image J software (http://rsbweb.nih.gov/ij/). 
Adhesion assay
Rat-tail type I collagen (Sigma, St-Louis, MO) 0.01% in 20mM acetic acid was used to 
coat 96-well plates for 1h at room temperature. Plates were washed with PBS and 
blocked with 3% (w/v) heat-denatured bovine serum albumin (BSA) for 1h at 37°C 
followed by washings with PBS. Cells were harvested with 0.5mM EDTA, washed in 
serum-free media, resuspended in serum-free media/0.1% (w/v) BSA and plated at 
a concentration of 2.5x104 cells per 100µl. The assay was terminated at 10, 30 and 
60 min by washing the wells twice with serum-free F12K medium. The attached 
cells were fixed and stained with Cristal Violet stain, which was extracted with 10% 
acetic acid. The absorbance was measured at OD 550nm. 
Zymography Analysis
Proteolytic activity of MMP-2 and MMP-9 was assayed by gelatin zymography as 
described by Souza et al [12]. In brief, culture medium was collected and stored at 
−20°C until further use. Samples were diluted in non-reducing buffer (0.1 M Tris-
HCl, pH 6.8, 20% glycerol, 1% SDS and 0.001% bromophenol blue), and the volume 
of the samples loaded was proportional to the protein concentration. The samples 
were resolved by SDS–polyacrylamide gel (10%) and 4% gelatin (Sigma-Aldrich). 
Protein renaturation was done using 2% Triton X-100 for 1 h followed by incubation 
with 50 mM Tris-HCl and 10 mM CaCl2 (pH 7.4) at 37°C for 18 h. Gels were stained 
with 0.5% Coomassie blue G 250 for 30 min and then washed in a 30% methanol 
and 10% glacial acetic acid solution.
Western blotting
Cells (2.5x107) were lysed on ice for 2h, in 200μL cell lysis buffer (50mM Tris-HCl, 
pH7.4, containing 1% Tween 20, 150mM NaCl, 1mM EGTA, 1mM o-vanadate, 1mM 
sodium fluoride, 1mg/ml aprotinin, 10mg/ml leupeptin, and 1mM PMSF). The pro-
tein extract was clarified by centrifugation and the protein concentration was quan-
tified using RC DC protein assay (BioRad, Hercules, CA). Equal volume of 2x con-
centrated SDS gel loading buffer (100mM Tris–HCl (pH6.8), 200mM dithiothreitol, 
4% SDS, 0.1% bromophenol blue and 20% glycerol) was added and samples were 
boiled for 10 min. Cell extracts were resolved by SDS–PAGE (12%) and transferred 
to polyvinylidene difluoride membranes. Membranes were blocked in 5% Bovine 
Serum Albumin in TBS/0.05% Tween-20 and incubated overnight at 40C with appro-
priate primary antibody at 1:1000 dilutions. After washing in TBS/0.05% Tween-20, 
membranes were incubated with antirabbit, antigoat or antimouse horseradish 
peroxidase-conjugated secondary antibodies at 1:2000 dilutions in blocking buffer 
for 1h. Detection was performed using ECL (Amersham, Buckinghamshire, United 
Kingdom) according to the manufacturer’s instructions. 
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Abstract
Phosphatases have long been regarded as tumor suppressors, however there is 
emerging evidence for a tumor initiating role for some phosphatases in several 
forms of cancer. Low Molecular Weight Protein Tyrosine Phosphatase (LMWPTP; 
acid phosphatase 1 [ACP1]) is an 18 kDa enzyme that influences the phosphoryl-
ation of signaling pathway mediators involved in cancer and is thus postulated to 
be a tumor-promoting enzyme, but neither unequivocal clinical evidence nor con-
vincing mechanistic actions for a role of LMWPTP have been identified. In the pres-
ent study, we show that LMWPTP expression is not only significantly increased in 
colorectal cancer (CRC), but also follows a step-wise increase in different levels of 
dysplasia. Chemical inhibition of LMWPTP significantly reduces CRC growth. Fur-
thermore, downregulation of LMWPTP in CRC leads to a reduced migration ability 
in both 2D- and 3D-migration assays, and sensitizes tumor cells to the chemothera-
peutic agent 5-FU. In conclusion, this study shows that LMWPTP is not only overex-
pressed in colorectal cancer, but it is correlated with the malignant potential of this 
cancer, suggesting that this phosphatase may act as a predictive biomaker of CRC 
stage and represents a rational novel target in the treatment of this disease. 
91
LMWPTP in colorectal cancer
Introduction
Colorectal cancer (CRC) is one of the most common forms of cancer in the Western 
world. Although CRC mortality has been progressively declining since 1990, it still 
remains the second most common cause of cancer death in the US and Europe 
[1]. When in a non-metastatic state, surgery of the primary tumor is considered a 
curative treatment. Unfortunately, around 20% of the CRC patients already present 
with metastatic disease, dropping the 5-year survival rate from 90% to a dramatic 
12% [2]. For this reason, treatments focusing on the prevention of this progression 
into the metastatic state are urgently called for. All cellular functions are under tight 
control of the balance between phosphorylation and dephosphorylation of pro-
teins. Like many neoplasms, disturbed protein phosphorylation patterns, indicating 
imbalanced kinase and/or phosphatase activities, are often observed in colorectal 
cancer [3]. So far, kinases have received most of the attention in cancer studies, as it 
is well established that deregulation of these enzymes can contribute to the devel-
opment of multiple neoplasms [4]. Inhibitors of kinase activities, such as EGFR- and 
BRAF-inhibitors, are amongst the novel potential treatments currently explored for 
CRC. Despite the fact that these drugs have shown some promising results [5, 6], 
there is still a need for new, additional, classes of molecules as potential targets. 
Phosphatases could present such a class. 
Generally assumed to be tumor suppressive by counteracting kinase activities, 
phosphatases have largely been ignored as viable targets for treatment. However, a 
tumor promoting role has also been suggested for certain phosphatases [7]. One of 
these is the ubiquitously expressed Low Molecular Weight Protein Tyrosine Phos-
phatase (LMWPTP), encoded by the gene ACP1. Enhanced mRNA expression of this 
phosphatase has been reported for some human tumors [8, 9]. This 18kDa protein 
tyrosine phosphatase can have a positive effect on cell growth and proliferation 
signaling by interacting with several molecules involved in these processes, such as 
Ephrin A2 receptor (EphA2) [10], β-catenin [11], platelet-derived growth factor re-
ceptor (PDGFR) [12], Janus kinase (JAK)-2 [13], and signal transducer and activator 
of transcription (STAT)-5 [14]. 
The aim of this study was to examine the expression levels and potential role of 
LMWPTP in colorectal cancer. Our study reveals a novel unexpected action of hy-
pomethylation-mediated upregulation of LMWPTP mRNA and protein levels in pri-
mary colorectal cancer and shows that this upregulation mediates chemoresistance 
and increased migration that characterizes this infaust disease.
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Materials and Methods
Gene expression profiles
Expression profiles from publicly available NCBI GEO datasets were browsed to find 
comparisons of CRC or colorectal adenoma samples to their adjacent normal tissue. 
Information on ACP1 expression was available in 2 arrays. Dataset Record GDS4382 
(transcript 215227_x_at), based on the Affymetrix Human Genome U133 Plus 2.0 
Array, was used to compare 17 paired CRC and adjacent normal tissue samples [15]. 
The same platform was used in dataset record GDS2947 (transcript 215227_x_at), 
used to compare 32 paired colorectal adenoma and adjacent normal tissue samples 
[16]. P-values were calculated per probe using Student’s t-tests. 
Patient selection
At the Erasmus MC Formalin fixed paraffin embedded (FFPE) colorectal tissue spec-
imens were collected from the department of pathology for 9 low grade dyspla-
sia (LGD) patients, 5 high grade dysplasia (HGD) patients, 7 adenocarcinoma (CRC) 
patients and 5 patients with CRC-related liver metastasis. Patients with active and 
inactive ulcerative colitis (n=8) served as controls. In addition, a tissue micro array 
was constructed at the Leiden University Medical Centre (LUMC), containing mate-
rial from 72 patients with colorectal cancer. Representative cores of healthy adja-
cent tissue were available for 65 patients, 25 patients had available adenoma cores, 
and 62 patients had representative carcinoma cores. 
Immunohistochemistry 
The FFPE tissue sections and TMA were immunohistochemically stained for LM-
WPTP (Acp1 antibody, sc-100343, Santa Cruz Biotechnologies, Dallas, Tx) as de-
scribed [17]. Briefly, 5µm sections were deparaffinized in xylene and rehydrated 
through graded alcohols. Antigen-retrieval was performed by boiling the slides in 
citrate buffer pH 6.0 for 15 minutes. Endogenous peroxidases were blocked by im-
mersing the slides for 10 minutes in 3% H2O2 in phosphate buffered saline (PBS). 
Next, slides were blocked by incubation in PBS containing 10% goat serum in for 1h 
at RT. Primary antibody was added 1:100 in blocking buffer and incubated overnight 
at 4°C. Envision goat anti-mouse-horseradish peroxidase (Dako, Heverlee, Belgium) 
was used as secondary antibody. The slides were scored for the percentage of pos-
itive epithelial cells as well as intensity of the staining on a 4 scale scoring system. 
P-values were calculated using Student’s t-tests and Wilcoxon signed-rank test for 
the paired samples. 
Cell lines
HCT116 and CACO-2 colorectal cancer cells were purchased from ATCC (Manassas, 
USA) and cultured in Dulbecco’s Modified Eagles Medium (DMEM, Lonza, Basel, 
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Switzerland), supplemented with 10% fetal bovine serum (Sigma-Aldrich, St. Louis, 
USA). EPC2-hTERT cells are cultured in Keratinocyte-SFM medium (Life technolo-
gies, Bleiswijk, NL), supplemented with Epidermal Growth Factor (EGF) and Bovine 
Pituitary Extract (BPE). All cell cultures were supplemented with 100 U/ml penicillin, 
100 mg/ml streptomycin (Life technologies, Bleiswijk, NL), and propagated at 37°C 
in a 5% CO2 humidified atmosphere. Cell lines were routinely tested for Mycoplasm 
infection using MycoAlert (Lonza, Basel, Switserland).
Cell culture and transfections
Using a lentiviral system, stably transfected LMWPTP knockdown cells were gener-
ated. In brief, HEK293T cells were transfected with LMWPTP or non-target control 
shRNA (Sigma-Aldrich, St. Louis, USA) and viral plasmid, generating virus containing 
medium. CRC cells were incubated with the conditioned medium for 48 hours after 
which transfected cells were selected using puromycin (2μg/ml, Sigma-Aldrich, St. 
Louis, USA). 
Western blotting
Subconfluent cells were lysed on ice in 2x concentrated Laemmli buffer (100mM 
Tris–HCl (pH 6.8), 200mM dithiothreitol, 4% SDS, 0.1% bromophenol blue and 20% 
glycerol) and samples were boiled for 10min. Cell extracts were resolved by SDS–
PAGE and transferred to polyvinylidene difluoride membranes (Merck chemicals 
BV, Amsterdam, the Netherlands). Membranes were blocked in 50% odyssey block-
ing buffer (LI-COR Biosciences, Lincoln, NE) in PBS/0.05% Tween-20 and incubated 
overnight at 4°C with primary antibody. After washing in PBS-T, membranes were 
incubated with IRDye® antibodies (LI-COR Biosciences, Lincoln, NE) for 1h. Detec-
tion was performed using Odyssey reader and analyzed using manufacturers soft-
ware. For antibodies used see supplementary table 1. 
Immunoprecipitation and phosphatase assay
To quantify the phosphatase activity, cells were lysed with 200µL of Lysis Buffer 
(20 mM HEPES, pH7.7 with 2.5mM MgCl2, 0.1mM EDTA, 1mM PMSF, 1mM DTT, 
10µg/mL aprotinin and 10µg/mL leupeptin) on ice for 2h. After clarifying by centrif-
ugation, the cell extracts were incubated overnight at 4°C under rotation with an-
tibodies against LMWPTP (Acp1 antibody, sc-100343, Santa Cruz Biotechnologies, 
Dallas, Tx) PTP1B (PTP1B antibody, sc-14021, Santa Cruz Biotechnologies, Dallas, Tx) 
or SHP-1 (SH-PTP1 antibody, sc-7289). A/G-Sepharose beads were added to cell ho-
mogenates and incubated for 2h at 4°C. Cell extracts were washed 3 times with lysis 
buffer and 2 times with acetate buffer (100 mM pH5.5). The precipitate was resus-
pended in acetate buffer containing PNPP as substrate. 45 min after incubation at 
37°C, equal volume of 1N HCl was added, and phosphatase activity was measured 
using a spectrophotometer at 405nm. 
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Cell viability assay
Using a colorimetric MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide assay, proliferation was measured. In brief, 10.000 cells were seeded in 96 
wells plate, after 24, 48, 72 or 96 hours 5mM MTT was added, and incubated for 2 
hours. Next, cells were resuspended in 100µl of Dimethyl sulfoxide and wavelength 
was measured using a spectrophotometer at 490 and 595nm. Each assay was per-
formed at least three times in duplicate. 
Cell cycle analysis
Cell cycle analysis was performed by staining the cells for 1h in sodiumcitrate-dihy-
drate (1g/L) solution, containing 20 µg/mL propidiumiodide, 0.1% triton-X100 and 
100 µg/mL ribonuclease A. The cell cycle distributions were analyzed using Modfit 
LT software. Each assay was performed twice.
P-Glycoprotein expression levels
P-gp expression levels were measured using standard flow cytometric analysis. 
Cells were incubated with primary anti-mouse P-gp antibody (Imunnotech, Mar-
seille, France). After washing, cells were incubated with anti-mouse FITC labelled 
antibody, and analyzed by flow cytometry. Data is shown as mean fluorescence in-
tensity (MFI).
Adhesion assay
50.000 cells were loaded into 96 wells plates and allowed to adhere for different 
time points to the plate surface either coated with fibronectin, or without coating. 
After 30 min, 1h and 1.5 hours non-adherent cells were washed away. After 1.5 
hours, MTT was added to the plate in order to quantify the amount of adhered cells. 
Cells adhering to fibronectin coating for 1.5 hours served as control. Assays were 
performed twice, with 8 duplicates averaged in each assay. 
Scratch migration assay
Cells in 6-well plates were grown to semi confluence. Using a yellow Gilson pipette 
tip simple scratch wounds were made. After washing the cells, the persisting areas 
of clear plastic were measured at 0, 24 and 48 hours using Axiovision 3.0 software 
(Carl Zeiss Vision GmbH) and the reduction in scratch wound area from time 0 was 
calculated. Each assay was performed twice, in duplicate. 
Cell migration assay “ring barrier system”
Cell migration assays were performed using the ring-barrier migration assay pre-
viously described [18]. Briefly, sterile coverslips placed in an Attofluor incubation 
chamber were coated with gelatin (1mg/ml) and incubated for 1h at 37°C, prior 
to cell seeding. A removable circular sterile migration barrier was inserted into the 
chamber, which prevents cell growth in the center of the coverslip. 4x105 HCT116 
and 2,5x105 CACO-2 knockdown and control cells were seeded around this barri-
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er and the rings were incubated at 37 °C for 24h, thereby generating a confluent 
monolayer in the periphery and a cell-free area in the center of the coverslip. After 
removing the migration barrier, time-lapse imaging was conducted at 37°C under 
humidified 5% CO2 air flow for 24h on an Axiovert 100M inverted microscopes, 
equipped with an AxioCam MRC digital cameras, using a 10X/0.30 Plan-Neofluar 
objective (Carl Zeiss B.V., Sliedrecht, Netherlands). Time-lapse movies (images taken 
every 12 min) were used to quantify cell migration using AxioVision 4.5 software. 
For each movie, 10 cells at the migration front were randomly selected and tracked 
for the analysis. The net track movement of cells in 24 h was termed ‘total migra-
tion’, while the directional movement of cells to the cell-free center of the coverslip 
was termed ‘effective migration’. Migration efficiency was determined as the per-
centage of directional movement over the total track distance. For each cell line, at 
least three independent migration assays were performed.
 
3D-migration using cell dispersion assay
Cytodex-3 microcarrier beads (Sigma–Aldrich) were mixed with 5x105 CACO-2 and 
HCT116 knockdown and control cell suspensions, considering a density of 40 cells 
per bead, and incubated at 37°C for 6h with gentle mixing. The bead suspension 
was transferred to a 25 cm2 tissue culture flask and incubated for 48h to ensure 
complete coating of beads and to remove unattached cells. Coated beads were 
embedded in 1.6mg/ml collagen gel (collagen: modified Eagle’s medium:7.5% w/v 
NaHCO3 in the ratio 8:1:1) in a 24-well plate such that each well had approximately 
150 beads. Plates were incubated at 37°C for 2h for the beads to settle in the gel 
and the polymerized gels were covered with 500μl DMEM, 10% FBS, 1% p/s. Cell 
dispersion was measured as the maximum migrated distance from the surface of 
the bead into the collagen gel. All measurements were performed using AxioVision 
4.5 software and assays were performed three times in duplicate. Two-way analysis 
of variance was performed to calculate P-values.
Immunofluorescence
Subconfluent cells, cultured on glass coverslips, were fixed 15 min in 4% paraformal-
dehyde in PBS and permeabilized in 0.1% Triton-X100 in PBS (PBS-T). Actin filaments 
were stained with 10 µg/mL phalloidin-TRITC in PBS-T. Cell nuclei were stained with 
200 ng/mL DAPI (4’, 6’-diamidino-2-phenylindole) in PBS-T for 30min and coverslips 
were mounted using Vectashield mounting medium. Immunofluorescent images 
were taken using Zeiss LSM510Meta confocal microscope with x40 OilFLUAR lens. 
Morphometric analysis was performed by measuring the length/width ratio of 26 
randomly selected cells.
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Figure 1. ACP1 mRNA and LMWPTP protein expression are increased in colorectal dysplasia and 
carcinoma as compared to non-dysplastic tissue. (A,B) Using publicly available gene expression data 
from Affymetrix platforms, ACP1 expression (transcript 215227) was analyzed in carcinoma (CRC) and 
adjacent normal colon. Significantly higher expression of ACP1 mRNA expression was observed in 
carcinoma tissues (n=17, P=0.0005 by student’s T-test). Gene expression array comparing ACP1 ex-
pression in colorectal adenoma to normal adjacent tissue shows increased ACP1 mRNA expression in 
cancer tissues (n=32, P<0.0001) (C). Tissues of patients with inactive ulcerative colitis (UC, n=8), low 
grade dysplasia (n=8), high grade dysplasia (HGD, n=6), colorectal cancer (CRC, n=12) and CRC liver 
metastasis (n=5) were stained for LMWPTP by immunohistochemistry. Representative examples (10x 
and 40x magnifications) of UC, LGD, HGD, CRC and liver metastasis are shown. (D,E) LMWPTP staining 
was scored for percentage of positive intestinal epithelial cells as well as intensity of staining and 
statistical analysis was performed using Mann-Whitney t-test. (*P >0.05; ** P >0.01, *** P >0.001).
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Results
ACP1 mRNA expression is increased in colorectal adenomas and carcinomas.
To understand the role of LMWPTP in colorectal cancer, we first investigated the 
gene expression levels of ACP1 using publicly available microarray datasets from 
Affymetrix Platforms. Expression of the LMWPTP encoding gene ACP1 (transcript 
215227) was compared between CRC and normal adjacent colonic tissue (n=17), 
and found to be significantly increased in the carcinoma group (P=0.0005, Figure 
1A). Colon cancer follows the adenoma to carcinoma sequence, and most cancers 
arise from dysplastic adenomas. Therefore, we also examined ACP1 expression lev-
els in adenoma samples and again observed an increased mRNA expression in these 
samples (n=32) compared to their normal adjacent colon tissue (P<0.0001, Figure 
1B). 
LMWPTP protein is overexpressed in primary colorectal cancer samples. 
Next, we examined whether the increased ACP1 expression corresponds to in-
creased protein levels of LMWPTP in CRC samples. Immunohistochemistry was 
performed on tissue sections of biopsies of low grade dysplasia (LGD; n=9), high 
grade dysplasia (HGD; n=7) adenocarcinoma (n=12) and controls (n=8) (Figure 1C). 
LMWPTP expression in intestinal epithelial cells (IEC) was limited to 9±9% of cells 
in non-cancerous tissues. In contrast, expression of LMWPTP was significantly in-
creased with subsequent levels of dysplasia (41±33% and 80±29% positive IEC in 
LGD and HGD, respectively), with up to 100% of LMWPTP-positive IECs in adeno-
carcinoma (Figure 1D). In addition to increasing numbers of positive cells, the in-
tensity of the staining also increased in the untransformed-to-colorectal cancer se-
quence (0.44±0.18, 0,72±0.36, 1.50±0.79 and 3.14±0.90 in control, LGD, HGD, and 
CRC respectively, Figure 1E). Furthermore, LMWPTP overexpression is preserved in 
liver-metastasized CRC tumor cells, with 100% of IECs highly positive for this phos-
phatase (note that the normal liver tissue stains negative for LMWPTP) (n=5). 
To validate these results using a different technique, we examined LMWPTP ex-
pression in 6 paired freshly frozen tumor and normal adjacent tissues by Western 
blotting, again demonstrating a significant increase in the total levels of this phos-
phatase in the tumor tissue (Figure 2A,B). 
To confirm the increased LMWPTP protein expression in a larger sample group, 
the staining was subsequently performed on a tissue micro array (TMA) containing 
samples of 72 colorectal adenoma and/or carcinoma patients (Table 1; represent-
ative samples shown in Figure 2C). After excluding poor quality cores, 62 cores of 
CRC tissue, 25 cores of adenoma tissue and 65 cores of healthy adjacent tissue 
were available for analysis. Again, the cores were scored for percentage positive 
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Figure 2. LMWPTP protein expression is increased in CRC as compared to paired normal adjacent 
tissue, and expression increases during the canonical progression sequence from normal tissue via 
adenoma to carcinoma. (A) Freshly frozen paired tumor (T) and normal adjacent (N) colonic tissue 
samples of 6 patients were lysed, and LMWPTP expression was determined using western blot anal-
ysis. β-Actin served as loading control. (B) Quantification of western blot using Li-Cor Odyssey soft-
ware (*P<0.05; **P<0.01). (C) IHC analysis of LMWPTP on a tissue micro array (TMA) of patients with 
colorectal cancer (n=65), colorectal adenoma (n=25), and healthy adjacent tissue (n=62). Represent-
ative stainings (20x and 40X inset) of CRC , adenoma and healthy tissue. (D-E) Staining was scored for 
percentage of LMWPTP positive IEC as well as intensity. Statistical analysis using Mann-Whitney t-test. 
(F) Percentage positive IEC were compared in patients from whom normal, adenoma and CRC tissue 
were all available (n=15, Wilkinson paired t-test) (*P< 0.05; **P<0.01; ***P < 0.001). 
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IECs and intensity of the staining. The mean percentage positive IEC was 27±3% in 
normal adjacent tissues compared to 64±4% in adenoma and 90±3% in carcinoma 
(P<0.001, Figure 2D). In addition, the intensity of the staining similarly increased 
from healthy tissue to adenoma and CRC (0.63±0.05, 1.22±0.10 and 1.90±0.09, re-
spectively, P<0.001, Figure 2E). For 15 patients there was material available for all 
three stages. In these patients, a significant increase in LMWPTP expression from 
normal to adenoma, and adenoma to carcinoma tissue was observed (37±6%, 
67±7% and 97±1%, respectively, P<0.001, Figure 2F), suggesting a role for LMWPTP 
in the oncogenic transformation of colonic epithelial cells. Due to the high expres-
sion of LMWPTP in all our carcinoma samples, we were unable to correlate clini-
cal parameters such as Dukes’ stage or patient survival to LMWPTP expression in 
cancer. However, when correlating patient survival to LMWPTP expression in their 
normal tissue, a higher LMWPTP expression in healthy tissue was significantly cor-
Table 1. Patients characteristics of tissue micro array.
Parameter Mean (SD) or N (%)
Number of Patients 72 (100%)
Healthy cores available 65 (90%)
Adenoma cores available 25 (35%)
Carcinoma available 62 (86%)
Age at presentation
Mean 69.85 (11.8)
Median 70
Range 30-92
Sex, N (%)
Male 37 (51.4%)
Female 35 (48.6%)
Dukes’ stage
A 1 (1%)
B 38 (47%)
C 23 (28%)
D 10 (12%)
Status
Living 44 (61%)
Non-CRC-related death 13 (18%)
CRC-related death 15 (21%)
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related to increased disease related mortality (Spearmans rho correlation P=0.026, 
Figure S1A). These data suggest either that there are infiltrating tumor cells present 
in what we denominate as normal adjacent tissue, or that an increased LMWPTP 
expression in normal cells is predictive or conductive to cellular transformation. 
Together, these results show that LMWPTP is overexpressed in a stepwise manner 
from normal tissue to carcinoma.
One of the mechanisms which may contribute to upregulation of LMWPTP expres-
sion levels, could be based on an altered methylation pattern of ACP1. Using an 
in silico analysis with the online database MENT (http://mgrc.kribb.re.kr:8080/
MENT/) [19], we observed that ACP1 is hypomethylated in colon cancer as com-
pared to normal colonic tissue (N=680; P<0.0001), providing a possible explanation 
for the observed upregulation of gene expression (Figure S1B). 
Figure 3. Effects of chemical inhibition and knockdown of LMWPTP on the oncogenic potential of 
colorectal cancer cells. (A) Immunoprecipitated phosphatases (LMWPTP, PTP1B and SHP-1) from 
HCT116 lysates were incubated with the only known inhibitor of LMWPTP, PLP, resulting in reduction 
of LMWPTP phosphatase activity in LMWPTP precipitates, while enzymatic activity of the two other 
PNPP phosphatases remain unaffected upon PLP treatment. (B) Treatment of CRC cell lines (HCT116 
and CACO-2) with PLP dose-dependently reduced viable cell numbers as determined by MTT assay, 
while non-transformed cell lines (EPC2-hTERT and PBMCs) are hardly effected. (C) Propidium-iodine 
staining of CACO-2 cells followed by FACS analysis shows that PLP treatment induces a G0/G1 cell cycle 
arrest. (D) PLP treatment of CRC cells results in apoptosis, as shown by FACS analysis with Annexin V/
PI staining on CACO-2 cells treated either with 500uM PLP or vehicle. (E) Stably transfected cell lines 
were created, by lentiviral transfection of HCT116 and CACO-2 cells with shRNA against LMWPTP, 
resulting in approximatly 50% reduction of LMWPTP expression compared to non-target controls. (F) 
LMWPTP knockdown does not affect overall cell proliferation as shown by MTT assay.
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Effect of inhibition of LMWPTP on cell survival
As our data in primary CRC indicates that an increased LMWPTP expression may 
contribute to tumor progression, we wondered whether inhibition of LMWPTP 
might reverse any of the oncogenic processes involved. The only LMWPTP inhibitor 
available to date is PLP, an active derivative of Vitamin B6, which has been shown 
to inhibit LMWPTP activity by interacting with the Asp129 site [20]. To confirm the 
effectiveness and selectivity of this compound, we precipitated LMWPTP and two 
other phosphatases with activity towards the substrate PNPP (SHP-1 and PTP1B) 
from CRC cells and demonstrated that the phosphatase activity of LMWPTP was in-
deed decreased in the presence of PLP, while the activity of SHP-1 and PTP1B were 
unaffected (Figure 3A and S2A). Next, we treated CRC cells (CACO-2 and HCT116), 
as well as the non-transformed human gastrointestinal epithelial cell line EPC2-
hTERT and freshly isolated PBMCs, with this compound and assessed cell viability. 
As shown in Figure 3B, PLP dose-dependently reduced viable cell numbers of the 
CRC lines, while non-transformed cells are hardly affected by this treatment. PLP 
induced a G0/G1 cell cycle arrest in the cancer cells (Figure 3C and S2C). Further-
more, PLP treatment concomitantly caused apoptosis in CRC cells, as shown by an 
increased Annexin V staining (Figure 3D and S2B). Thus, these data suggest that 
chemical inhibition of LMWPTP may reduce CRC growth. 
As PLP may have some off-target effects (LMWPTP is not the only molecular target 
to be inhibited by this compound), we decided to further investigate the effect of 
inhibition of LMWPTP by specifically reducing its expression. We employed shRNA 
against ACP1 to stably knock down LMWPTP in HCT116 and CACO-2 cells, which 
reduced the expression of this phosphatase by 50% (Figure 3E). However, while 
chemical inhibition of LMWPTP affected cell viability and cell cycling, knockdown 
of LMWPTP did not (Figure 3F and S2D-F). This is perhaps not surprising, as knock 
down of LMWPTP was not complete, and the creation of stable cell lines would 
necessarily select for cells escaping cell death. 
LMWPTP induces drug resistance
Whilst not inducing cell death, knock down of LMWPTP in CRC lines allowed us to 
further investigate the role of LMWPTP in other oncogenic processes. We started 
by determining some of the molecular targets of LMWPTP. Figure 4A shows that 
knock down of LMWPTP resulted in the downregulation of several cancer-associ-
ated signaling pathways. Most noticeably, we observed a reduced phosphorylation 
of the epidermal growth factor receptor (EGFR) and diminished phosphorylation of 
protein kinase B (PKB) both on the threonine 308 and serine 473 sites in LMWPTP 
knockdown cells (Figure 4A). In addition to proliferation, these molecules are im-
plicated in cell survival, and we therefor speculated that LMWPTP knockdown cells 
might be more susceptible to cytostatic agents. Indeed, treatment of CRC cells with 
5-fluorouracil (5-FU), a commonly used chemotherapeutic, caused a dose depend-
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ent decrease in viable cell numbers, which was significantly more pronounced in 
LMWPTP knock down cells (Figure 4B and S3A). Thus, silencing of LMWPTP confers 
drug sensitivity of CRC cells, possibly through loss of EGFR and PKB activity. Oth-
er mechanisms used by tumor cells to escape drug effects include the expression 
and regulation of multidrug resistance efflux pumps. These include p-glycoprotein, 
also known as multidrug resistance protein 1 (MDR1), which transports several 
substrates across the extracellular membrane. Interestingly, P-gp was expressed on 
CACO-2 cells, and its expression was reduced upon silencing of LMWPTP (Figure 
4C). In contrast, HCT116 cells did not express this particular efflux pump (and hence 
no decrease was observed in LMWPTP knock down cells), suggesting that different 
mechanisms may contribute to drug sensitivity in different CRC lines (Figure S3B). 
LMWPTP targets migration signaling
Colorectal cancer is a frequently fatal disease because of its high propensity to mi-
grate and invade other tissues, preventing curative surgical treatment. Cellular mi-
gration is dependent on the tight regulation of assembly and disassembly of focal 
adhesion sites. This process is mediated the by the formation of a FAK–Src complex, 
and phosphorylation of FAK-associated substrates such as paxillin and p130cas, all 
known to be required for cell motility [21]. Our biochemical analysis of LMWPTP 
deficient cells revealed reduced FAK Tyr-397 phosphorylation in these cells, sug-
gesting that LMWPTP may function in this pathway to promote FAK Tyr-397 phos-
phorylation and the formation of membrane extensions characteristic of migrating 
cells (Figure 4A). We therefore investigated the effects of LMWPTP downregula-
Figure 4. LMWPTP influences cell survival pathways and desensitizes colorectal cancer cells to 
chemotherapy. (A) Western blot analysis of LMWPTP knockdown and control cells reveals reduced 
phosphorylation of Epidermal Growth Factor Receptor (EGFR), Protein Kinase B (PKBt and PKBs) and 
FAK in the knockdown cells. (B) CACO-2 LMWPTP knockdown and control cells were treated with 
increasing concentrations of 5-fluorouracil and cell viability was assessed by MTT assay after 96h. 
CACO-2 knockdown cells were more susceptible to 5-fluorouracil as compared to control (*P<0.05). 
(C). P-glycoprotein expression on CACO-2 cells was determined by FACS analysis, using anti-P-gp and 
anti-mouse-FITC antibodies. P-gp expression is reduced upon LMWPTP knockdown in CACO-2 cells, as 
shown by FACS mean fluorescence intensity (MFI). 
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Figure 5. Modulation of LMWPTP results in impaired migration and invasion in colorectal cancer 
cells. (A,B) HCT116 cell migration was measured by scratch assays, simple scratch wounds were made, 
and pictures are taken at 0h, 24h, and 48h. Persistent area of clear plastic was measured and statis-
tical analysis was performed using student’s T-test. (C,D) Two-dimensional migration was analyzed 
using a ring-barrier system. HCT116 cell migration on gelatin was tracked during 24h, with locations 
being captured using time-lapse microscopy every 12min (x=start, line=cell track)(C). Quantification of 
migrated path indicates that the total migration and velocity were significantly reduced in LMWPTP 
knockdown cells. Effective migration and thereby efficiency are even further reduced. (D; *P<0.05; 
**P<0.01; ***P<0.001). (E,F) Beads were coated with either CACO-2 LMWPTP knockdown or control 
cells for 24 hours, and embedded in a collagen gel matrix. Cells were allowed to invade the collagen 
matrix, and pictures were taking at 0h, 24h, and 48h (examples in E). The cell dispersion from the bead 
(arrow) into the collagen matrix was measured, and a trend towards reduced invasion was observed 
in LMWPTP knockdown cells. Data represents at least four beads (F). 
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tion in colorectal cancer cell lines on their ability to migrate. Confluent plates of 
CACO-2 and HCT116 cells were scratched using a pipet tip, and cell migration into 
the wound was assessed after 24h and 48h. LMWPTP knock down cells showed a 
significant delay in the ability to migrate into the empty space (Figure 5A-B and 
Fig S4A-B, N.B. that HCT116 is a slower migrating cell line). To verify the positive 
role of LMWPTP in cell migration, we used a second, different approach to inves-
tigate cellular movement, which does not rely on wounding the CRC monolayer. 
Using time-lapse microscopy of cell migration we again observed that CACO-2 and 
HCT116 LMWPTP knockdown cells are significantly impaired in their total migra-
tion, and thereby also the cell velocity. Strikingly, the effective migration, which is 
defined as the directional movement of the cells to the cell-free center, was even 
more reduced (Figure 5C-D and S4C-D). We subsequently went on to assess the role 
of LMWPTP on migration in a 3D-setting, representing the invasive capacity of these 
cells. Beads were coated with CACO-2 and HCT116 knockdown or control cells, and 
were settled in a collagen matrix. Cell dispersion from the bead into the surround-
ing collagen matrix was measured. Although not reaching statistical significance, 
we observed a trend towards reduced invasive capacity upon LMWPTP knock down 
for both cell lines (Figure 5E-F and S4E-F). Together these data demonstrate that 
knocking down LMWPTP in colorectal cancer cells reduces their migratory capacity, 
and is especially important for directional cell migration. 
Different mechanisms for reduced migratory responses in CRC cells
As both CACO-2 and HCT116 cell lines demonstrated reduced FAK activity and sub-
sequent migration upon LMWPTP knock down, we next set out to further examine 
the underlying mechanism of this reduced migration. First we investigated the ad-
hesive capacity of these cell lines, adhesion being indispensable for proper migra-
tion, and FAK being a major regulator of this process. As shown in Figure 6A, full 
adherence of CACO-2 non-target cells to the glass surface was reached after 30 
minutes and 1h, while only 50% of the knockdown cells adhered to the bottom of 
the wells within these time points (P>0.05). In contrast, HCT116 cells were much 
slower to adhere, and no differences could be observed between LMWPTP knock 
down and control cells (Figure S5A). 
Next, we employed confocal microscopy to investigate the actin distribution as well 
as cellular morphology of the cells. We found alterations in the cytoskeletal F-actin 
composition in HCT116 cells downregulated for LMWPTP. Loss of LMWPTP resulted 
in a more stretched appearance of cells, suggestive of a less migratory phenotype 
(Figure 6B). This is also reflected by our morphometric analysis (Figure 6C), which 
reveals a significantly higher length/width ratio in the LMWPTP knockdown cells 
(1.1±0.02 in control cells and 1.7±0.18 knockdown cells; P<0.0001). In contrast, 
CACO-2 cells, which have a cuboidal appearance, did not show the stretching in 
the knockdown cells observed in the HCT116 cell line (Figure S5B). These results 
105
LMWPTP in colorectal cancer
indicate that while the net effect of LMWPTP on migration is similar in CACO-2 and 
HCT116 cell lines, the underlying mechanisms differ, emphasizing the heterogeneity 
of CRC.
Discussion
In this study we identify LMWPTP overexpression as a mediator for increased 
chemoresistance and migration in colorectal cancer. We show for the first time, that 
LMWPTP protein expression is drastically increased in primary colorectal cancer 
samples as compared to normal adjacent tissue. LMWPTP expression appears to 
follow a step-wise increase from healthy tissue, to dysplastic adenoma, and to carci-
noma. Deregulated transcription and translation is a common phenomenon of can-
cer cells, and many signaling pathways can concomitantly be affected in malignant 
cells. However, analysis of other phosphatases in CRC sections does not indicate a 
general upregulation of PTPs in this tumor type (unpublished results), indicating a 
specific oncogenic role for LMWPTP in the transformation of colon epithelial cells. 
While the cause of the specific upregulation of ACP1 mRNA has yet to be identified, 
interestingly, an initial database analysis (MENT methylation and expression data-
base) suggests that this gene is hypomethylated in adenoma and cancer samples. 
Thus far, while several phosphatases have been shown to act as tumor suppressors, 
few phosphatases have been implicated as oncogenes in colorectal cancer. Phos-
Figure 6. LMWPTP influences cell adhesion and cell morphology. (A) CRC cell adhesion was deter-
mined by MTT assay of adherent cells after indicated time points, with fibronectin (FN) coating serving 
as control. CACO-2 LMWPTP knockdown cells adhere less than control cells (*P<0.05; **P<0.01). (B,C) 
Confocal microscopy of Phalloidin-rhodamine stained cells was employed to examine cell morphology. 
Immunofluorescence reveals a more elongated morphology in HCT116 LMWPTP knockdown cells as 
compared to control (B). To quantify the changes in morphology, the ratio between the length and 
width of the cells was calculated, with a higher ratio indicating a more elongated shape. Non-tar-
get control cells have a significantly lower ratio compared to LMWPTP knockdown cells. (1.1±0.02 vs 
1.7±0.18, n=26; P<0.0001) (C)
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phatase of regenerating liver-3 (PRL-3), also known as PTP4A3, was shown to be 
upregulated in up to 100% of CRC liver metastasis cases, and is overexpressed in 
primary tumors [22]. Furthermore, PRL-3 can promote migration and invasion by 
enhancing MMP2 activity [23]. Similarly, the phosphatase SAP-1 has been shown 
to be overexpressed in colorectal tumors, and especially promotes the tumorigenic 
potential of intestinal epithelial cells [24, 25]. Likewise, PTPα is capable of activat-
ing Src protein kinase activity in colorectal cancer, further supporting the idea that 
phosphatases not only act as inhibitors of oncogenic kinases, but can function as 
tumor promoters as well [26]. To this relatively short list, we may now add LM-
WPTP. Although these other phosphatases may also be implicated in the colorectal 
cancer process, convincing demonstration of their dysregulation in a large cohort 
of well-characterized colon cancer patients as well as detailed mechanistic insight 
into their exact role in the cancer process is largely lacking. In contrast, LMWPTP 
appears a bona-fide mediator of the CRC invasiveness and chemoresistance. 
 
After our initial finding that LMWPTP is significantly overexpressed in colorectal 
cancer, we evaluated the effect of LMWPTP in vitro. Up to now, the most potent 
compound known to inhibit LMWPTP activity is the active form of vitamin B6, PLP. 
Interestingly, earlier reports have shown that both vitamin B6 and PLP serum lev-
els are inversely correlated with colorectal cancer risk [27]. Our data suggest that 
inhibition of LMWPTP through Vitamin B6 may provide one possible explanation 
for these findings. Indeed, in pituitary cells PLP has been shown to induce cell cy-
cle arrest [28], which corresponds well with the cell cycle block and apoptosis ob-
served in our study, and suggests that LMWPTP inhibition may be a valuable avenue 
for treatment of CRC. Earlier reports have suggested that LMWPTP could modu-
late chemoresistance of cancer cells [29]. The current treatment protocol for ad-
vanced CRC contains chemotherapy, such as 5-fluorouracil. Typically, the first course 
of chemotherapy is highly beneficial, but tumor cells tend to make use of several 
mechanisms to escape the therapy and become resistant. We now show that LM-
WPTP could be involved in these mechanisms in CRC. In addition to an increased 
sensitivity to chemotherapy, LMWPTP knock down cells showed a great reduction 
in phosphorylated EGFR and PKB, making it tempting to speculate that decreased 
activity of these survival signals contributes to drug-sensitivity of these cells. In ad-
dition, multidrug resistance pumps, such as P-gp are often upregulated on cancer 
cells and can contribute to decreased drug-sensitivity of tumors [30, 31]. Our study 
suggests that LMWPTP can act on these transporters as well, thereby contributing 
to the chemoresistance of CRC cells. 
In this study, we observed clear differences between HCT116 and CACO-2 cells. 
While LMWPTP knock down conferred drug sensitivity in both cell lines, no modu-
lation of P-gp was observed in HCT116 cells, suggesting different underlying mech-
anisms. In addition, while migratory and invasive behavior was impaired in both 
LMWPTP knock down cell lines, the molecular pathways contributing to migratory 
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defects appeared to differ. Both cell lines demonstrated reduced phosphorylation 
of the focal adhesion kinase FAK. This kinase, by forming a complex with p120Ras-
GAP and p190RhoGAP (p190A), leads to phosphorylation of p190A, resulting in 
polarity cues and increased directional movement [32]. Impaired formation of the 
Ras-Rho complex as a result of LMWPTP downmodulation may thus contribute to 
the inefficient cell movement and polarity observed in our migration assays. FAK 
is a major regulator in the adhesion to matrix, which is also essential for proper 
migration. However, while we observed adhesion defects in LMWPTP knock down 
CACO-2 cells, the same was not observed in HCT116 cells. This second LMWPTP 
knock down cell line selectively demonstrated a changed morphology and F-actin 
rearrangement, characteristic with sessile behavior of cells. These latter findings 
are reminiscent of (colorectal) cancer cells in which a more rounded morphology 
as a result of overexpression of RhoA correlated to increased ability to migrate in 
vitro and metastasize in vivo [33]. Thus, while inhibition of LMWPTP in both of these 
colorectal cancer lines appears beneficial in terms of reducing cell growth, drug re-
sistance and metastatic potential, the mechanisms through which this is achieved 
may rely on genetic identity of the tumor cells. These data highlight the need for 
personalized medicine in cancer treatment, as different genetic backgrounds may 
affect the usefulness of treatment regimens as well as the molecular mechanisms 
behind them. This was recently very clearly demonstrated by the report of a selec-
tive benefit of mTOR inhibitors only in patients carrying PTEN-deficient tumors [34].
In summary, we show that low molecular weight protein tyrosine phosphatase is 
overexpressed in primary human colorectal cancers at both mRNA and protein level 
and that this phosphatase can function as an oncogene, by enhancing the migra-
tion, adhesion and chemoresistance in colorectal cancer cells. Together, this indi-
cates that LMWPTP expression is a determining factor in the malignant potential of 
colorectal cancer, and suggests that this phosphatase provides a target in the fight 
against this devastating disease.
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Supplementary Figures 
Supplementary figure 1. LMWPTP upregulation is related to ACP1 hypo-methylation and corre-
sponds to patient survival in normal adjacent colonic tissue. (A) Analysis of percentage LMWPTP 
positive IECs in normal adjacent tissue cores, related to patient outcome. Patient group is divided 
in patients still alive or suffering a non-CRC-related death, and patients deceased due to colorectal 
cancer. (B) In silico analysis of ACP1 methylation in colorectal cancer and normal colonic tissue, using 
MENT database. ACP1 is significantly hypo-methylated in colorectal cancer as compared to normal 
tissue (-0.24032; P>0.00001). 
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Supplementary figure 2. Effects of chemical inhibition and knockdown of LMWPTP on colorectal 
cancer cells. (A) Immunprecipitated phosphatases (LMWPTP, PTP1B and SHP-1) from CACO-2 lysates 
were incubated with the only known inhibitor of LMWPTP, PLP, resulting in reduction of LMWPTP 
phosphatase activity, while the two other PNPP phosphatases remain unaffected upon PLP treatment. 
(B) Treatment of HCT116 cells with 500uM of PLP induces apoptosis as determined by Annexin V/Pi 
FACS analysis. (C) Treatment of HCT116 cells with PLP induces cell cycle arrest as determined by ploid-
ity through FACS analysis of propidium iodide staining. (D) MTT analysis shows that stable knockdown 
of LMWPTP in CACO-2 cells does not affect viable cell numbers in culture. (E,F) Analysis of cell cycle 
by propidium iodide staining shows no differences between LMWPTP knockdown and control cells for 
CACO-2 (E) and HCT116 (F) CRC cell lines. 
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Supplementary figure 3. LMWPTP knockdown sensitizes colorectal cancer cells to chemotherapy. 
(A) HCT116 knockdown and control cells were treated with increasing concentrations of 5-fluorouracil 
(5-FU) for 96 hours. Knockdown cells are more susceptible to 5-fluorouracil treatment as compared to 
non-target control cells. (B) In contrast to CACO-2 cells, HCT116 cells show little P-glycoprotein expres-
sion, as determined by FACS analysis.
114
Chapter 4
Supplementary figure 4. Downmodulation of LMWPTP results in reduced migration and invasion 
in colorectal cancer cells. (A,B) CACO-2 cell migration was measured by scratch assays, where simple 
scratch wounds were made, and pictures are taken at 0h, 24h, and 48h. Persistent area of clear plastic 
was measured and statistical analysis was performed using student’s T-test. (C,D). Two-dimension-
al migration was analyzed using a ring-barrier system. CACO-2 cell migration on gelatin was tracked 
during 24h, with locations being captured using time-lapse microscopy every 12min (x=start, line=cell 
track)(C). Quantification of migrated path indicates that the total migration and velocity were signifi-
cantly reduced upon LMWPTP knockdown. Effective migration and thereby efficiency are even further 
reduced. (D; *P< 0.05; **P<0.01; ***P<0.001). (E,F) Beads were coated with either HCT116 knock-
down or control cells for 24h, and embedded in collagen gel matrix. Cells were allowed to invade the 
matrix, and pictures were taking at 0h, 24h, and 48h (examples in E). The cell dispersion from the bead 
(arrow) was measured and quantified in F. Data represents at least four beads (F). 
115
LMWPTP in colorectal cancer
Supplementary figure 5. LMWPTP influences cell adhesion and cell morphology. (A) CRC cell adhe-
sion was determined by MTT assay of adherent cells at indicated timepoints, with fibronectin (FN) 
coating serving as control. HCT116, a slow migrating cell line, does not show reduced adhesion upon 
LMWPTP knockdown. (B) Confocal microscopy of Phalloidin-rhodamine stained CACO-2 cells was em-
ployed to examine cell morphology. The more stretched appearance upon knockdown of LMWPTP in 
HCT116 cells was not observed in CACO-2 cells, which have a more cuboid appearance, form clumps 
when cell numbers are low and grow out as complete sheets as cell numbers increase.
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Supplementary Tables
Supplementary table 1. Summary of primary antibodies
Antibody Dilution Company Catalog number
Mouse-anti-ACP1α/β 1:500 Santa Cruz sc-100343
Rabbit-anti-Tubulin 1:10000 Abcam Ab-6046
Mouse-anti-Actin 1:2500 Santa Cruz Sc-47778
Rabbit-anti-phospho-AKT (T308) 1:1000 Cell signaling #2965
Rabbit-anti-phospho-AKT (S473) 1:1000 Cell signaling #9271
Rabbit-anti-phospho-EGFR (Y1068) 1:1000 Cell signaling #3777
Rabbit-anti-phospho-FAK (Y397) 1:1000 Invitrogen 44-625G
P-Glycoprotein 1:20 Immunotech 1864
Phalloidin-Rhodamin 1:200 Invitrogen R415
DAPI (4’, 6’-diamidino-2-phenylindole) 1:1000 Sigma D9542
Supplementary table 2. Summary of secondary antibodies
Antibody Dilution Company Catalog number
HRP-conjugated goat-anti-mouse IgG 
(EnVisionTM)
n/a DAKO K4007
HRP-conjugated goat-anti-Rabbit IgG 
(EnVisionTM)
n/a DAKO K4011
Goat-anti-rabbit IgG IRDye 800 1:10000 Westburg 926-32211
Goat-anti-rabbit IgG IRDye 680 1:10000 Westburg 926-68072
Goat-anti-mouse IgG DyLight 488 1:50 Biolegend 405310
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Abstract
Phosphatases are key regulators of cellular signaling and as such play an important 
role in nearly all cellular processes governing diseases, including cancer. However 
due to their highly conserved structure and highly charged and reactive catalytic 
site, they have been regarded as “undruggable”. Fortunately, during the recent Eu-
rophosphatase meeting (Turku, Finland), it became most clear that phosphatases 
can no longer be ignored as potential targets in cancer therapy. Since reactivation 
of tumor suppressor phosphatases or direct inhibition of phosphatases acting as 
oncogenes is becoming available, this class of enzymes can now be considered as 
feasible drug targets.
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Introduction
A delicate balance between protein kinases and protein phosphatases regulates 
many different processes to maintain tissue homeostasis. Alterations in phospho-
rylation patterns are linked to numerous diseases, and are a common phenomenon 
in several types of cancer, making this an interesting target for therapeutic inter-
vention. In the last decades, much of the attention was focused on targeting the 
kinases, resulting in over 20 kinase inhibitors currently used in the clinic [1]. How-
ever, the equally important phosphatases were neglected for a long time. In part, 
this is probably due to historical reasons, as the first PTP was only purified ten years 
after the first protein tyrosine kinase (PTK), but another very important reason is 
that phosphatases have been long been regarded as “undruggable”. This is in part 
due to the close similarity of the catalytic domains of phosphatases, which argues 
against the use of catalytic domain inhibitors due to specificity issues. However, the 
greatest challenge in the development of phosphatase inhibitors is to identify in-
hibitory compounds with pharmacologically acceptable bioavailability. Due to their 
highly charged active sites, most of the inhibitory compounds contain negatively 
charged nonhydrolyzable phosphotyrosine (pTyr) mimetics, limiting the cell-perme-
ability of the designed compounds [2]. The recently held Europhosphatase meeting 
has made it clear that phosphatases should no longer be ignored, and are in fact 
feasible targets for cancer treatment, with the potential to aid the resistance to 
other targeted treatment strategies. Europhosphatase 2015 was the fifth meeting 
in the EMBO Conference Series on Protein Phosphatases. This biannual meeting 
brings together over 180 participants with a wide range of backgrounds and re-
search fields, all with a special interest in phosphatases. This years’ conference had 
special emphasis on the importance of the equilibrium between phosphatases and 
kinases (phosphoswitches) in regulating tissue homeostasis in different physiolog-
ical and pathological conditions, amongst which cancer. This report highlights the 
latest findings on this class of enzymes in the oncological field as presented at this 
meeting, with special attention to phosphatases as treatment targets in cancer. 
Catalytic mechanisms phosphatase families
Based on their structure, phosphatases are subdivided into distinct functional and 
structural superfamilies, all with their own catalytic mechanism. Within the protein 
tyrosine phosphatases (PTPs), four distinct families can be distinguished: class I, II 
and III Cys-based PTPs, and the Asp-based tyrosine phosphatases, represented by 
the EYA-family. They all carry the highly conserved active “PTP-signature” motif C(X-
)5R, and (apart from the Asp-bases PTPs) use the same basic catalytic mechanism, 
in which the cysteine residue in the signature motif executes a nucleophilic attack 
on the phosphate group in the substrate. Simultaneously, a conserved acidic resi-
due plays two critical roles in catalysis. First, it acts as a general acid, adding a pro-
ton to the leaving group oxygen in the substrate. Second, it serves as a general base, 
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activating a water molecule to promote hydrolysis of the phosphoenzyme interme-
diate (extensively reviewed in [3,4]). The aspartate-based tyrosine phosphatases 
family, carry out catalysis differently from the other PTP families, since they use an 
aspartic acid residue rather than a cysteine in the active site, for a cation-dependent 
nucleophilic attack on the phosphoryl group of the substrate [5].
The protein serine/threonine phosphatases (PSPs) are subdivided into three main 
families, the phosphoprotein phosphatases (PPPs), the metal-dependent protein 
phosphatases (PPMs), and Mg2+-dependent FCP family. Unlike the PTPs, which are 
large multi domain proteins, the PPPs are comprised of multiple individual subunits 
to form holoenzymes. This way the PPP-family, which amongst others includes PP1 
and PP2A, can potentially form hundreds of different holoenzymes by combining a 
small number of conserved catalytic domains with a very large number of regula-
tory subunits, each with different biological functions. Therefore, inhibition of the 
catalytic subunit of PPPs might not be feasible, but targeting the subunits which re-
strict access to the active site may be possible. The PPM family, with their prototyp-
ical member PP2C, do not have regulatory subunits, but instead contain additional 
domains and conserved sequence motifs for substrate specificity. They were iden-
tified on the basis of the requirement for an exogenous divalent ion (Mg2+, Mn2+) 
for activity, as well as for the insensitivity to okadaic acid, a known inhibitor of PPPs. 
Both the PPMs and the PPPs use metal-activated water molecules as nucleophiles 
to catalyze dephosphorylation (extensively reviewed by Yigong Shi [6]).
Tumor suppressor phosphatases as potential targets for treatment
Due to the emerging knowledge of the structure, protein complexes (holoenzymes) 
and catalytic function of protein phosphatases, the possibility of targeting these 
enzymes using small molecules is gaining interest. Intuitively, phosphatases that 
act as tumor suppressor are less suitable for targeting, since inhibition of their en-
zymatic activity would be expected to result in further activation of the oncogenic 
pathways involved. However, rather than inhibiting these enzymes, reactivation of 
tumor suppressive phosphatases is now emerging as a potential strategy in cancer 
treatment. As described above, most serine/threonine phosphatases exert their 
function by forming a holoenzyme complex with scaffolding proteins and regula-
tory units together with the catalytic unit, making the holoenzyme an interesting 
target for chemical manipulation. In addition, the activity of most phosphatases is 
under the regulation of other proteins, offering the possibility of activating a spe-
cific phosphatase via manipulation of one of its upstream regulators. However, it is 
important to realize that targeting or reactivating tumor suppressor phosphatases 
is only useful when the original function of the protein is not disrupted due to inac-
tivating or truncating mutations, as is the case for the well-known tumor suppressor 
phosphatase PTEN - in such cases, there is obviously no protein to reactivate. 
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PP2A reactivation as cancer treatment
Much of the attention at the Europhosphatase 2015 meeting was directed at the 
known tumor suppressor group of protein phosphatase 2A (PP2A) enzymes [7]. To-
gether with PP1, the PP2A family of phosphatases accounts for more than 90% of 
Ser/Thr phosphatase activity in human tissues and cells. PP2A phosphatases consist 
of a holoenzyme containing a scaffold A subunit, a catalytic C subunit, and one of 
many possible regulatory B subunits. They have a well-established role as tumor 
suppressor by counteracting diverse kinase-driven oncogenic pathways. Although 
mutations in PP2A are almost never found in human cancer, overexpression of its 
inhibitor CIP2A, or downregulation of its promotor PTPA is often observed. There-
fore, the possibility of targeting PP2A reactivation as possible cancer treatment was 
extensively discussed at the conference (e.g. by Goutham Narla, Case Western Re-
serve University, Pepper Pike, US and Rosalie Sears of the Oregon Health and Sci-
ence University, Portland, US). It is known that PP2A negatively regulates oncogenic 
MEK/ERK and PI3K/PKB signaling. The work presented by Sears et al now demon-
strates that via its B56 regulatory subunit, PP2A also dephosphorylates the Serine 
62 site of c-Myc, thereby enhancing its oncogenic activity and providing further ra-
tionale for the use of PP2A activators. Such activators have been described before, 
and indeed, the use of several of these small molecule PP2A activators resulted in 
a reduction of c-Myc Ser62 phosphorylation, and reduced the oncogenic poten-
tial of breast cancer cells both in vitro and in vivo. Goutham Narla and colleagues 
performed a screen on FDA-approved drugs in order to find novel PP2A activators. 
Whole transcriptome and pathway analyses were performed on the potential small 
molecule activators of PP2A, again showing that these agonists inhibit multiple on-
cogenic pathways including ERK, PKB, and c-Myc. Together these studies show that 
targeting PP2A, either by stimulating its activity, or by blocking inhibitors such as 
CIP2A, is a promising therapeutic opportunity in human cancer. Furthermore, it also 
encourages investigation into the potential for the reactivation of other known tu-
mor suppressor phosphatases as treatment target.
Other phosphatases with tumor suppressive potential
Other phosphatases for which such an application could be feasible in the future are 
the dual specificity phosphatases (DUSPs), also known as MAP kinase phosphatases 
(MKPs), so named because they can dephosphorylate both tyrosine and serine/
threonine residues. They are, amongst others, key negative regulators of the RAS-
RAF-ERK pathway. Stephen Keyse et al (University of Dundee, Dundee, United King-
dom) demonstrated a novel tumor suppressive function for DUSP5, by regulation 
of ERK signaling activity. DUSP5 expression in the nucleus causes translocation of 
ERK2 to the nucleus and serves as anchor protein for the inactive kinase. They now 
demonstrated that DUSP5 knockout mice show twice as many tumors as their WT 
counterparts in a DMBA/TPA skin carcinogenesis model, providing clear evidence 
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that this phosphatase is a potential target for therapeutic agonists. Although spe-
cific DUSP inhibitors are available, the search for DUSP agonists is as yet ongoing. 
One of the phosphatases previously identified by Newton and colleagues as tumor 
suppressor is PHLPP, which targets the well-known oncogenic PKB pathway. In the 
current meeting, Anne Castro (CRBM-CNRS, Montpellier, France) described a novel 
mechanism of PHLPP modulation through the oncogenic kinase Greatwall. Although 
the direct role of this kinase in human cancer is not yet investigated, Greatwall is 
known to promote cell proliferation by controlling mitotic division via inhibition of 
the phosphatase PP2AB55. Castro et al now report that this kinase also mediates 
degradation of the PHLPP phosphatase, again leading to phosphorylation of the cell 
survival kinase PKB on Ser374. These findings indicate Greatwall as novel regulator 
of PHLPP, and suggest that inhibition of Greatwall or stimulation of PHLPP may in-
hibit oncogenesis.
Two other non-receptor type PTPs are also found to act as tumor suppressor genes, 
mostly by affecting migration and epithelial to mesenchymal transformation, a mi-
grating tumor cell hallmark. André Veilette (IRCM, Montreal, Canada) discussed 
PTPN12, also known as PTP-PEST, previously described to be a positive regulator of 
migration in endothelial and immune cells. However, Veilette et al now show that in 
an ErbB2-driven breast cancer animal model, PTPN12 deficiency leads to enhanced 
tumor development and metastasis. In vitro, PTPN12-deficient cells show enhanced 
cell migration and invasion. Likewise, Yeesim Knew-Goodall and colleagues (SA Pa-
thology and University of South Australia, Adelaide, Australia) showed that while 
knockdown of PTPN14 (or PTPpez) hardly affects the proliferation of primary breast 
tumor cells, it can significantly promote metastasis by altering protein trafficking. In-
jection of PTPN14 knockdown cells or even conditioned medium from PTPN14-defi-
cient cell cultures promoted the growth and metastasis of breast cancer xenografts. 
Indeed, loss of catalytically functional PTPN14 increased the secretion of growth 
factors and cytokines, such as IL-8, and increased the abundance of EGFR at the 
cell surface of cancer cells. Therefore PTPN14 can prevent metastasis by restricting 
trafficking of both soluble and membrane-bound proteins. In line with this theory, 
PTPN14 expression was found to be decreased in invasive breast cancer, and patient 
survival was worse in low expressing tumors. While there are already a number of 
phosphatases known to act as tumor suppressors, the above phosphatases can now 
be added to this list of potential treatment targets. 
Oncogenic phosphatases
Nowadays, it is becoming more clear that dephosphorylation of proteins and lipids 
does not necessarily terminate cellular signaling, but can also activate signaling. For 
example, oncogenic Src kinase is kept in an inactive state by its phosphorylation at 
Tyr527 and dephosphorylation of this residue by SHP1 or PTP1B relieves this inhibi-
tion. Therefore, as for oncogenic kinases, efforts have now been directed towards 
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the development of small molecule inhibitors of phosphatases. This has been quite 
an endeavor, with rather limited success so far, mostly due to low inhibitor selectivi-
ty. However, by combining large drug screens of existing drugs, with a more detailed 
knowledge of the crystal structures of these proteins, development of more direct-
ed small molecules is now being improved. For instance, Zhong-Yin Zhang (Indiana 
University School of Medicine, Indianapolis, United States) is developing selective 
inhibitors by combining ligands that can target both the active PTP site together 
with the unique peripheral binding sites, resulting in more specific inhibitors. On 
the other hand, Nicholas Tonks (Cold Spring Harbor Laboratory, Cold Spring Harbor, 
United States) used a different approach, aiming to develop allosteric inhibitors that 
bind to unique sites on the enzyme distinct from the active site. Targeting these 
unique, non-catalytic segments that are unrelated to any other member of the PTP 
family will create inhibitors highly selective for the specific phosphatase. 
PTP1B inhibition as breast cancer therapy
Due to the efforts of three independent groups in the phosphatase field, Benjamin 
Neel (University Health Network/Princess Margaret Cancer Center, Toronto, Can-
ada), Michel Tremblay (McGill University, Montreal, Canada) and Nicholas Tonks 
(Cold Spring Harbor Laboratory, Cold Spring Harbor, United States), it has become 
clear that PTP1B can be a feasible target for cancer (and diabetes) treatment. Dur-
ing this conference these groups again provided valuable novel insights in the on-
cogenic role of this phosphatase. Neel described a novel role for PTP1B in breast 
cancer, showing that PTP1B depletion results in increased hypoxia and necrosis in 
breast cancer cells, which were subsequently more sensitive to hypoxia-induced 
cell death. Interestingly however, none of the known hypoxia pathways were affect-
ed in PTP1B knockdown cells. Instead, PTP1B seems to regulate the RNF213 pro-
tein, which in turn can control the activity of α-ketoglutarate dioxygenases, thereby 
controlling the tumor cell response to hypoxia. This novel PTP1B/RNF213 hypoxia 
pathway appears to be imperative for the survival of breast cancer cells. Nicholas 
Tonks also discussed the role of PTP1B in breast cancer, focusing on the recent de-
velopment of an enzymatic inhibitor of this phosphatase called ‘Trodusquemine’ or 
‘MSI-1436’. This small molecule inhibitor induces a conformational change of PTP1B 
by binding to the disordered C-terminus of the protein, thereby reducing its enzy-
matic activity. This inhibitor was employed in a mouse model of HER2-dependent 
breast cancer. Strikingly, Trodusquemine treatment significantly reduced tumor for-
mation and completely abrogated cancer metastasis. Due to these very promising 
results, the first clinical trials with this compound will be started soon. This treat-
ment strategy might not only be worthwhile in the setting of breast cancer, since 
Tremblay and colleagues have previously shown that PTP1B is an androgen recep-
tor (AR) regulated phosphatase, capable of promoting the progression of prostate 
cancer. Moreover, in his work presented at this conference, he showed a frequent 
amplification of the PTP1B-encoding chromosomal region 20q13 in metastatic pros-
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tate cancer, often in co-occurrence with amplification of the AR. Interestingly, they 
presented that AR can bind and upregulate the genes within this commonly am-
plified 20q13 region, such as PTP1B, resulting in a more aggressive tumor. While 
these data argue for a tumor-promoting role for PTP1B, the reverse was true in a 
PTEN null background. When PTP1B was removed from PTEN-deficient mice, which 
were subsequently fed a high fat diet, the initial tumor and its growth became much 
more aggressive. Thus, caution is required when implementing PTP1B inhibitors for 
cancer treatment– they may not be useful in PTEN-deficient tumors.
Development of PTP inhibitors against SHP2
Another phosphatase known to act as oncogene is the Src-homology 2 domain-con-
taining phosphatase 2 (SHP2). Activating SHP2 mutations are found in leukemia 
and solid tumors which can promote invasion, proliferation and loss of cell polar-
ity. Zhong-Yin Zhang (Indiana University School of Medicine, Indianapolis, United 
States) presented a novel strategy for the discovery of PTP inhibitors by exploring 
existing drug databases, using SHP2 as an example. By screening the Johns Hopkins 
Drug Library for compounds capable of inhibiting SHP2, he found that Cefsulodin, 
a third generation β-lactam antibiotic, acts as a reversible and competitive SHP2 
inhibitor. X-ray crystallography of SHP2 in complex with Cefsulodin was used as a 
guide for the subsequent design of cefsulodin-based SHP2 inhibitors, resulting in 
compounds with high specificity and low IC50-values. Since SHP2 phosphatase ac-
tivity is required for the full activation of the Ras-pathway, EGF-induced ERK1/2 acti-
vation was assessed in the presence of these compounds. As expected, these inhib-
itors effectively reduced the phosphorylation of ERK in a dose-dependent manner. 
Likewise, cell survival of a number of human cancer cell lines was also reduced upon 
the use of these SHP2 inhibitors. Furthermore, as eluded to by Zhang, using the 
same strategy, other PTP inhibitors with promising specificity and IC50-values have 
now been developed, amongst which an inhibitor against Low Molecular Weight 
PTP (LMWPTP). Interestingly, our own work, presented at this conference, demon-
strates that LMWPTP can play an oncogenic role in prostate cancer. This enzyme 
enhances the metastatic potential of prostate cancer cells, resulting in a worse pa-
tient survival. We showed that LMWPTP can be used as a biomarker and potential 
treatment target for this disease. Prostate cancer may not be the only tumor to 
potentially benefit from LMWPTP inhibitors, as we have previously demonstrated 
a role from LMWPTP in leukemic cells, and have shown that LMWPTP is also over-
expressed and active in primary colorectal cancer specimens, where it also contrib-
utes to migratory behavior of cells. 
Other phosphatases with oncogenic potential
In addition to LMWPTP, phosphatase of regenerating liver 3 (PRL-3) is overexpressed 
in colorectal cancer metastasis and acts as oncogene in cell proliferation and migra-
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tion. However, the underlying mechanism remains to be elucidated. Maja Köhn (Eu-
ropean Molecular Biology Laboratory, Heidelberg, Germany) reported on the role of 
PRL-3 in cell polarity, a fundamental process in tumor progression. Overexpression 
of this phosphatase increases cell migration, and results in fully specified lumens in 
3D-cultures, a phenotype which could be reversed with their newly developed PRL-
3 phosphatase activity inhibitor, providing additional evidence that with this novel 
inhibitor, PRL3 becomes a druggable target. 
Members of the SIX family of homeodomain proteins promote cell proliferation 
through the regulation transcription of multiple cell cycle genes involved in G1/S 
and G2/M transitions, as well as S-phase progression. As presented during this Euro-
phosphatase conference (Heidi Ford, University of Colorado, Aurora, United States), 
some of these proteins do not have their own transcriptional activation domain, but 
require a family of co-activators to mediate transcriptional activation; the Eya1-4 
phosphatases. Eyas are pro-tumorigenic and overexpressed in many forms of can-
cers including glioblastoma, ovarian cancer, and breast cancer. This overexpression 
is commonly correlated with earlier recurrence and decreased overall survival. This 
oncogenic potential is linked to the transcriptional activity of the Eya/SIX1 complex, 
but also requires EYA tyrosine phosphatase activity. By making use of high-through-
put screening, Ford et al identified several small molecule inhibitors that specifically 
target the Six/Eya complex, as well as inhibitors of Eya2 phosphatase activity per se. 
Interestingly, these compounds decreased cell viability and migration potential in 
several cancer models overexpressing the Six/Eya2 complex. 
Serine/threonine/tyrosine-interacting protein (STYX) is a catalytically inactive pro-
tein, homologous to the dual-specificity phosphatases (DUSPs) family. Since it does 
not possess phosphatase activity it is called a “pseudophosphatase”, which means 
they are able to signal in the absence of enzymatic activity. Hesso Farhan (University 
of Konstanz, Kreuzlingen, Switserland) previously showed that STYX can regulate 
ERK signaling, however in the current meeting he presented that STYX can bind 
with, and negatively regulate the F-box protein FBXW7. This protein is a tumor sup-
pressor gene which is altered in 10-15% of all human cancers. Farhan showed that 
indeed FBXW7 was significantly downregulated, in breast cancer, concomitant with 
an overexpression over the pseudophosphatase STYX. However, it is as yet unclear 
how inhibition of STYX may be brought about.
Concluding remarks
In an era where kinase inhibitors are emerging as part of daily clinical practice, 
resistance to these targeted therapies is becoming an ever larger problem. New 
strategies for combating cancer from multiple angles will therefore be imperative. 
Phosphatases can no longer be ignored as a novel therapeutic option. Fortunately, 
it is now becoming clear that targeting phosphatases is indeed a feasible option in 
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cancer treatment. Inhibition of oncogenic phosphatases or the reactivation of tu-
mor suppressor phosphatases seems within reach. For most of the potential target 
phosphatases presented here, substantial basic research still needs to be performed 
before the leap from bench to clinic can be made. However, with the development 
of PTP1B inhibitors and PP2A activators, the first phosphatase-based clinical can-
cer therapies will be available soon. With only a few of the more than 100 phos-
phatases in the human genome investigated to date as potential targets for cancer 
treatment, there is hope that an increased attention of the scientific community 
directed towards this interesting class of enzymes may uncover additional thera-
peutic targets, as was in previous decades the case for the kinases.
187
Phosphatases as drug targets
References
1.  Zhang JM, Yang PL, Gray NS. Targeting cancer with small molecule kinase 
 inhibitors. Nat Rev Cancer [Internet]. 2009;9(1):28–39. 
2.  Shen K, Keng YF, Wu L, Guo XL, Lawrence DS, Zhang ZY. Acquisition of a Specific   
 and Potent PTP1B Inhibitor from a Novel Combinatorial Library and Screening   
 Procedure. J Biol Chem. 2001;276(50):47311–9. 
3.  Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, Osterman A, et al. Protein   
 tyrosine phosphatases in the human genome. Cell. 2004. p. 699–711. 
4.  Kolmodin K, Aqvist J. The catalytic mechanism of protein tyrosine phosphatases  
 revisited. FEBS Lett. 2001;498(2-3):208–13. 
5.  Blevins MA, Towers CG, Patrick AN, Zhao R, Ford HL. The SIX1-EYA transcriptional
  complex as a therapeutic target in cancer. Expert Opin Ther Targets.    
 2015;19(2):213–25. 
6.  Shi Y. Serine/Threonine Phosphatases: Mechanism through Structure. Cell.   
 2009;139(3):468–84. 
7.  Sablina A a, Hahn WC. The role of PP2A A subunits in tumor suppression. Cell Adh  
 Migr [Internet]. 2007;1(3):140–1. 

Chapter 8
β-catenin signaling dosage dicatates 
tissue-specific tumor predisposition 
in Apc-driven cancer
Elvira R.M. Bakker1, Elmer Hoekstra1, Patrick F. Franken2, Werner Helven-
steijn1, Carolien H.M. van Deurzen3, Wendy van Veelen1, Ernst J. Kuipers1, 
Ron Smits1
1. Department of Gastroenterology and Hepatology. Erasmus MC, University
 Medical  Center Rotterdam, The Netherlands.
2. Department of Pathology, Erasmus MC, University Medical Center Rotterdam, 
 The Netherlands.
3. Department of Internal medicine, Erasmus MC, University Medical Center 
 Rotterdam, The Netherlands.
Oncogene. 2013 Sep 19;32(38):4579-85.
190
Chapter 8
Abstract
Apc-driven tumor formation in patients and Apc-mutant mouse models is generally 
attributed to increased levels of β-catenin signaling. We and others have proposed 
that a specific level of β-catenin signaling is required to successfully initiate tumor 
formation, and that each tissue prefers different dosages of signaling. This is illus-
trated by APC genotype-tumor phenotype correlations in cancer patients and by 
the different tumor phenotypes displayed by different Apc-mutant mouse models. 
Apc1638N mice, associated with intermediate β-catenin signaling, characteristically 
develop intestinal tumors (<10) and extra-intestinal tumors including cysts and des-
moids. Apc1572T mice associated with lower levels of β-catenin signaling, are free 
of intestinal tumors but instead develop mammary tumors. Although the concept of 
β-catenin signaling dosage and its impact on tumor growth among tissues is gaining 
acceptance, it has not been formally proven. Additionally, alternative explanations 
for Apc-driven tumor formation have been proposed. To obtain direct evidence for 
the dominant role of β-catenin dosage in tumor formation and tissue-specific tu-
mor predisposition, we crossed Apc1638N mice with heterozygous β-catenin knock-
out mice, thereby reducing β-catenin levels. Whereas all Apc1638N;Ctnnb1+/+ mice 
developed gastrointestinal tumors, none were present in the Apc1638N;Ctnnb1-/+ 
mice. Incidence of other Apc1638N-associated lesions including desmoids and cysts 
was strongly reduced as well. Interestingly, Apc1638N;Ctnnb1-/+ females showed an 
increased incidence of mammary tumors, normally rarely observed in Apc1638N 
mice, and histological composition of the tumors resembled that of Apc1572T-re-
lated tumors. Hereby, we provide in vivo genetic evidence confirming the dominant 
role of β-catenin dosage in tumor formation and in dictating tumor predisposition 
among tissues in Apc-driven cancer.
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Introduction
The Wnt/β-catenin signaling pathway represents one of the main regulatory mech-
anisms to retain tissue homeostasis in the adult organism by balancing self-renew-
al, differentiation and apoptosis in several adult stem cell niches [1]. Underscoring 
the relevance of this pathway, many tumor types exhibit enhanced Wnt/β-catenin 
signaling that strongly contributes to tumor growth. In the Wnt/β-catenin signaling 
pathway, the adenomatous polyposis coli (APC) protein is a central component reg-
ulating the degradation and concomitantly the transcriptional activity of β-catenin 
in the nucleus. As depicted in Figure 1A, several motifs in the central domain of 
APC are responsible for regulating intracellular β-catenin levels. Four 15 amino acid 
repeats (AAR) bind β-catenin, whereas seven 20-AARs are involved in both binding 
and downregulation. Interspersed within those 20-AARs are three binding sites for 
Axin required for an optimal recruitment of APC into the destruction complex. Inac-
tivation of APC perturbs the formation of the β-catenin degradation complex, lead-
ing to increased nuclear translocation and target gene expression, thereby affecting 
important cellular decisions and favoring a genetic program that initiates tumor 
formation. In case of colorectal cancer, a small subset (~1-2%) of tumors acquires 
activating mutations in β-catenin itself, whereas most others result from inactivat-
ing biallelic APC mutations [2]. The vast majority of these APC mutations result in 
truncated proteins that lack all Axin binding motifs while retaining between one and 
three 20-AARs. As a result, these truncated proteins still have residual activity in 
downregulating β-catenin signaling. Accordingly, an inverse correlation is observed 
between the number of retaining 20-AARs and the resulting level of β-catenin sig-
naling, i.e. more repeats means a lower β-catenin signaling level to the nucleus. 
Based on these observations, we and others have proposed that APC mutations do 
not occur entirely randomly but rather occur in respect to one another to reach an 
optimal level of enhanced β-catenin signaling, described as the 'just-right' signaling 
model [2–6]. According to this model, levels beneath the optimal β-catenin signa-
ling window will not provide cells with sufficient activation of target genes to gain 
growth advantage and trigger tumor formation, whereas levels exceeding the opti-
mal window will trigger apoptosis instead. As reviewed in Albuquerque et al, opti-
mal β-catenin signaling dosages favoring tumorigenesis differ throughout the body, 
indicated by different APC genotypes that are observed in tumors on different loca-
tions [2]. Both sporadic as well as familial forms of desmoid and duodenal tumors 
contain APC mutations retaining 2-3 20AARs associated with moderate β-catenin 
signaling activation. On the other hand, most colorectal tumors are associated with 
shorter truncating proteins resulting in higher levels of β-catenin signaling. Interest-
ingly, correlations are observed even within the colorectal tract, where right-sided 
colon tumors generally retain more 20-AARs than left-sided ones [2,7,8]. Although 
in human breast cancer patients mutations in β-catenin or APC are rarely found, 
aberrant activation of β-catenin signaling is observed frequently [9]. 
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Phenotypes of Apc-mutant mouse models strongly support Apc genotype-tumor 
phenotype correlati ons (Figure 1B). ApcMin/+ mice have high levels of β-catenin sig-
naling and develop intesti nal tumors at high multi plicity (>100). Animals carrying 
the hypomorphic Apc1638N mutati on, associated with intermediate β-catenin sig-
naling, characteristi cally develop intesti nal tumors at lower multi plicity (<10) and in 
parallel show a high suscepti bility for extra-intesti nal tumor types such as cutane-
ous cysts and desmoid tumors [10]. The Apc1572T mouse model, associated with 
lower levels of β-catenin signaling, is free of intesti nal tumors but instead develops 
mammary tumors with high penetrance, in additi on to cysts and desmoids albeit 
with reduced numbers compared to Apc1638N/+ mice [11]. Taken together, this indi-
cates that ti ssue-specifi c dosages of β-catenin signaling are required to effi  ciently 
Figure 1. APC structure and associated β-catenin signaling dosage. (A) Structure of the Apc protein 
containing multi ple regulatory domains. (B) Truncated Apc in diff erent Apc-mutant mouse models. 
The number of remaining 20-AARs is inversely correlated with the β-catenin signaling dosage and 
associated with tumor development in diff erent ti ssues. (C) Windows of β-catenin signaling dosages 
associated with specifi c tumor types in Apc-mutant mouse models. Whereas intesti nal tumorigenesis 
requires high to moderate β-catenin signaling, cysts and desmoid development is associated with 
moderate β-catenin signaling and mammary tumors occur with the low level of β-catenin signaling 
as observed in Apc1572T mice. Figure modifi ed from [2] with permission of BBA Reviews on Cancer. 
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trigger tumorigenesis, where intestinal tumors are associated with higher levels of 
β-catenin signaling than cysts and desmoids, which in turn are associated with high-
er β-catenin signaling than mammary tumors (Figure 1C). 
Although the concept of β-catenin signaling dosage and its impact on tumor growth 
among tissues is gaining acceptance, tissue-specific tumor predisposition has not 
been formally proven to be a direct consequence of β-catenin signaling dosage. 
Furthermore, alternative explanations for APC-driven tumor formation have been 
proposed. APC is a large, multifunctional protein and in addition to downregulating 
β-catenin signaling it is implicated in various other cellular processes, as APC can af-
fect chromosomal segregation, cytoskeletal organization and bind C-terminal bind-
ing protein (CtBP) [12–16]. Here, we provide direct genetic evidence for the dom-
inant role of β-catenin in tumor formation and establish the impact of β-catenin 
signaling dosage in dictating tissue-specific tumor predisposition. To this aim, we 
reduced the pool of available β-catenin in Apc1638N/+ (Apc1638N) mice by heterozy-
gous β-catenin (Ctnnb1) knockout. Consequently, gastrointestinal tumor formation 
was completely prevented while mammary tumor predisposition was enhanced, 
shifting the phenotype towards the Apc1572T-related tumor phenotype.
Materials and methods
Cells and β-catenin reporter assay
Mouse embryonic fibroblasts (MEFs) were isolated from embryos of embryonic day 
(E)13.5-15.5, cultured and transfected as described previously [17]. The β-catenin 
reporter assay was performed as described previously [17]. Assays were performed 
in duplicate three times. 
Mouse strains
Mouse strains (C57BL/6J) used in this study were: Apc+/1638N, CAG-Cre and Ctnnb1-/+ 
[10,18]. Ctnnb1fl/+ males (gift from Dr. J. Huelsken) had been crossed previously with 
CAG-Cre females, obtaining Ctnnb1-/+ knockout mice. Subsequently, these Ctnnb1-/+ 
mice were crossed with Apc+/1638N, resulting in compound heterozygous Apc+/1638N/
Ctnnb1-/+ animals and corresponding single transgenic controls Apc+/1638N/Ctnnb1+/+. 
All mice were maintained under specific pathogen-free conditions at the animal 
facility of the Erasmus Medical Centre. Mice were examined for tumor formation at 
the age of 8 months. All experiments were approved by the Animal Ethics Commit-
tee and carried out in accordance with Dutch and international legislation. 
Histology and immunohistochemistry
Tissues were washed in PBS and fixed overnight in 4% PBS-buffered paraformalde-
hyde at 4°C. Paraffin embedding and Haematoxylin Eosin (HE) staining were per-
formed according to routine protocols. For immunohistochemistry, antigen retriev-
al citrate pH6 preceded staining for SMA (1:200, DAKO), Cytokeratin-14 (1:10000, 
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Covance) and CD44 (1:1000, BD Biosciences), Tris-EDTA pH9 for β-catenin (1:2000, 
Epitomics), Cyclin D1 (1:200, Vector Laboratories) and Ki67 (1:200, DAKO) and 0.1% 
pronase for Cytokeratin-8 (1:800, DSHB). 
 
RNA isolation, cDNA synthesis and quantitative PCR
RNA was isolated from cultured MEFs followed by cDNA generation using iScript 
cDNA Synthesis Kit (Bio-Rad). Quantitative PCR was performed with TaqMan Gene 
Expression Assays (Applied Biosystems) and run in the IQ5 Real time PCR detection 
system (Bio-Rad). Expression levels were corrected for expression of Actb. Assay 
was performed in duplicate three times.
Results and discussion
The Apc1638N mouse model is a representative model to investigate intestinal can-
cer, where mice characteristically develop about 1-7 gastrointestinal tumors [19]. In 
addition, these mice are highly susceptible for extra-intestinal tumor types including 
desmoids and cutaneous cysts [10]. To reduce their dosage of β-catenin, we crossed 
Apc1638N/+ mice with Ctnnb1-/+ knockout mice [18]. First, non-tumorigenic intestinal 
tissues were characterized of both Apc1638N/+/Ctnnb1+/+ and Apc1638N/+/Ctnnb1-/+ mice. 
Haematoxylin Eosin (HE) staining showed normal intestinal histology in both groups 
(Figure 2A). Also, no discernible alterations in β-catenin protein expression were 
detected using β-catenin immunohistochemistry (Figure 2A). These results were in 
line with expectations, since normal tissues only harbor the heterozygous germline 
Apc-mutation and intestinal tissue homeostasis of mice harboring the Apc1638N 
mutation is also unaltered compared to that of wildtype mice [20]. Furthermore, 
β-catenin immunohistochemistry is not a very sensitive technique to detect dif-
ferences in β-catenin protein expression and to determine associated alterations 
in β-catenin signaling. To verify reduced β-catenin signaling as a consequence of 
heterozygous Ctnnb1 knockout, we used a more sensitive approach. For this, β-cat-
enin reporter assays were performed to measure the intrinsic β-catenin signaling 
of mouse embryonic fibroblasts (MEFs) that we generated of embryos of the differ-
ent genotypes. In the absence of Apc mutation, levels of β-catenin signaling were 
low and not detectably reduced by heterozygous β-catenin knockout (Figure 2B). 
Apc1638N/+ MEFs showed slightly enhanced β-catenin signaling, and here, heterozy-
gous β-catenin knockout clearly resulted in reduced β-catenin signaling. Moreover, 
Apc1638N/+ MEFs with heterozygous β-catenin knockout showed intrinsic β-catenin 
signaling levels that approached the β-catenin signaling dosage as observed in Ap-
c+/1572T MEFs. Comparable results were obtained when we assessed β-catenin sign-
aling by determining RNA levels of the β-catenin target gene Axin2 in these MEFs 
(Figure 2C). In the absence of Apc mutation, Axin2 levels were slightly reduced by 
heterozygous β-catenin knockout. Apc1638N/+ MEFs showed enhanced Axin2 levels, 
which again were reduced by heterozygous β-catenin knockout, reaching levels 
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Figure 2. Heterozygous β-catenin knockout reduces β-catenin signaling. (A) HE and β-catenin staining 
of non-tumorigenic intestine, showing no gross differences between groups. (B) β-catenin reporter 
assay of MEFs of Apc+/+ or Apc+/1638N genotype, each in combination with Ctnnb1+/+ or Ctnnb1-/+, in ad-
dition to Apc+/1572T, and (C) Axin2 mRNA expression in these MEFs determined by quantitative PCR. 
Two bars per genotype indicate two individual MEF lines that were used. (D) β-catenin staining of an 
intestinal tumor of an Apc+/1638N mouse. Nuclear β-catenin staining is clearly detected.
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comparable to those observed in Apc+/1572T MEFs. Together these data verify that 
heterozygous β-catenin knockout indeed substantially reduces β-catenin signaling 
in Apc1638N mice, moreover, in such a way that β-catenin signaling levels approach 
the β-catenin dosage of Apc1572T mice. These observations are in line with those 
of Buchert et al, who showed that halving β-catenin levels consistently reduced 
β-catenin signaling in various Apc-mutant MEFs [21].
We then determined β-catenin expression in the intestinal tumors that developed 
in the Apc1638N mice, since Phelps et al have proposed that following Apc loss, 
activation of oncogenic KRAS is required to impose nuclear accumulation of β-cat-
enin [14]. In the Apc1638N intestinal tumors, we clearly detected nuclear β-catenin 
staining in the epithelial tumor cells in addition to membranous β-catenin expres-
sion (Figure 2D), in accordance with previous results [22]. Importantly, Apc1638N 
intestinal tumors and those of other Apc-mutant models do not spontaneously 
acquire Ras mutations [23–25]. This shows that oncogenic Ras is not required for 
nuclear accumulation in mouse intestinal tumors, which recently has also been con-
firmed for human colorectal tumors [26,27]. 
Subsequently, we examined tumor phenotypes of 8-months aged Apc1638N/Ctn-
nb1+/+ and Apc1638N/Ctnnb1-/+ mice. Strikingly, whereas all 19 Apc1638N/Ctnnb1+/+ 
mice developed gastrointestinal tumors as characteristic for Apc1638N mice, none 
of the 21 Apc1638N/Ctnnb1-/+ mice developed any gastrointestinal tumor nor was 
any microlesion detected (Figure 3A). This provides direct evidence for the absolute 
requirement of a sufficiently enhanced β-catenin level for intestinal tumorigenesis. 
The complete absence of intestinal tumors in mice with heterozygous β-catenin 
knockout precluded us to compare β-catenin and associated signaling character-
istics in intestinal tumors between groups following second hit Apc mutation. Ap-
c1638N-associated extra-intestinal lesions were still observed in Apc1638N/Ctn-
nb1-/+ mice with characteristic gender-specific distribution, although with a clearly 
reduced incidence (Figure 3B,C). Desmoid numbers were reduced from 8.6 ± 3.0 to 
0.2 ± 0.4 in females and from 61.4 ± 14.4 to 19.1 ± 8.1 in males (Figure 3B). Histo-
logical appearance of the desmoids was similar in both groups, showing abundant 
collagen fibers interspersed by fibroblast-like cells, as has been described for Ap-
c1638N mice previously [10]. Cyst numbers were lowered from 5.6 ± 3.8 to 0.4 ± 
0.6 in females and from 29.8 ± 19.5 to 2.4 ± 1.5 in males (Figure 3C). Thus, reducing 
β-catenin levels in Apc1638N mice prevented gastrointestinal tumor formation and 
significantly reduced the incidence of other lesions associated with the Apc1638N 
mouse model. Most strikingly, we observed that half of the Apc1638N/Ctnnb1-/+ 
females developed mammary lesions, reflecting a strongly enhanced incidence of 
mammary lesions following heterozygous β-catenin knockout (Figure 3D). Normal-
ly, mammary lesions are rarely observed in Apc1638N mice but are characteristic 
for Apc1572T mice. Our findings nicely illustrate that by reducing β-catenin in Ap-
c1638N mice, the tumor phenotype shifts towards an Apc1572T-related phenotype, 
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Figure 3. Heterozygous β-catenin knockout prevents gastrointestinal tumor formation but predis-
poses for mammary tumors in Apc1638N mice. Compound heterozygous Apc+/1638N; Ctnnb1-/+ animals 
and corresponding single transgenic Apc+/1638N control mice were examined for tumor formation at the 
age of 8 months. Number of (A) gastrointestinal tumors (B) desmoids and (C) cysts per mouse, distin-
guishing distribution in females (left) and males (right). ***p<0.001 (Student t-test) (D) Proportion of 
females with/without mammary tumor development. *p<0.05 (Chi-square test).
198
Chapter 8
which is associated with a relatively lower activation level of β-catenin signaling. 
This confirms that β-catenin signaling dosage by itself dictates tissue-specific tumor 
predisposition in Apc-mutant mice. 
The mammary lesions we observed in Apc1638N/Ctnnb1-/+ mice were relatively 
small, showing an average diameter of 2.6 ± 1.4 mm, compared to those gener-
ally observed in Apc1572T mice, reaching 2 cm3 by 4-5 months of age [11]. In ac-
cordance with this relatively mild mammary tumor phenotype in our Apc1638N/
Ctnnb1-/+ mice, metastases were not observed. Microscopic characterization of the 
identified mammary lesions revealed a heterogeneous histology, displaying glandu-
lar and squamous regions, keratinizing components and inflammatory cells (Figure 
4A). Immunohistochemical analyses further established the heterogeneity of the 
mammary tumors found in Apc1638N/Ctnnb1-/+ mice. Hence, staining for cytoker-
atin-8 confirmed luminal epithelial differentiation, cytokeratin-14 indicated areas 
of squamous differentiation and smooth muscle actin showed myoepithelial cell 
types (Figure 4A). This histological composition is virtually identical to that of the 
mammary lesions observed in Apc1572T mice [11]. In the mammary lesions of the 
Apc1638N/Ctnnb1-/+ mice, staining for Ki67 revealed moderate proliferation (Fig-
ure 4B). Expression of β-catenin was observed in epithelial cells displaying mem-
brane-bound and nuclear β-catenin (Figure 4B). Accordingly, expression of the 
Wnt/β-catenin targets CD44 and Cyclin D1 was observed in the epithelial compart-
ment of Apc1638N/Ctnnb1-/+ mammary lesions (Figure 4B). Thus, Apc1638N/Ctn-
nb1-/+ mice develop heterogeneous mammary tumors resembling those observed in 
Apc1572T mice histologically and showing active Wnt/β-catenin signaling. 
Our data show that by reducing β-catenin levels, the characteristic Apc1638N-re-
lated intestinal tumor phenotype shifts towards mammary tissues, where tumors 
typically develop in Apc1572T mice [11]. Also, the reduced incidence of cysts and 
desmoids is in accordance with that observed in Apc1572T mice. The mammary 
tumors observed in Apc1638N/Ctnnb1-/+ mice resembled those of Apc1572T mice 
histologically, although remaining smaller. We propose that in Apc1638N mice fol-
lowing loss of the wild type Apc allele required for tumor initiation, we reduced 
the β-catenin dosage by heterozygous β-catenin knockout to levels approaching 
those associated with Apc1572T mice, thereby enabling successful mammary tu-
morigenesis [10,11,28]. However, the exact β-catenin signaling level preferred to 
sustain fully penetrant mammary tumor growth and metastasis may not have been 
reached most optimally, explaining the smaller tumors observed in Apc1638N/Ctn-
nb1-/+ mice compared to Apc1572T mice. 
Uncovering this shift in tumor phenotype from the gastrointestinal tract towards 
mammary tissues following β-catenin dosage reduction provides direct in vivo evi-
dence that β-catenin dosage by itself dictates tissue-specific tumor predisposition 
in the setting of Apc-driven cancer. This is in accordance with previously described 
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APC genotype–tumor phenotype correlations and associated β-catenin signaling 
dosages among Apc-mutant mouse models and sporadic and familial cancer pa-
tients [2]. Comparably, tissue-specific biological output being determined by spe-
cific dosage has been reported for the proto-oncogene c-Myc as well, which is one 
of the main target genes of β-catenin signaling [29,30]. In line with our findings, 
Buchert et al presented specific β-catenin signaling thresholds being important for 
hepatic and intestinal tumorigenesis [21]. Hence, they showed that hepatic tumor 
formation as observed in a hypomorphic Apc-mutant model was prevented by het-
erozygous Ctnnb1 knockout [21]. In addition, following heterozygous Ctnnb1 loss 
they observed a reduced intestinal tumor incidence and multiplicity in an Apc-mu-
tant mouse model associated with a relatively high β-catenin signaling dosage [21]. 
We currently show that intestinal tumor formation is even prevented completely 
by reducing β-catenin levels below a hypothetical threshold, using the Apc1638N 
mouse model associated with intermediate β-catenin signaling dosage. Importantly, 
we hereby demonstrate that for Apc-driven tumor formation in the gut, enhanced 
β-catenin signaling is absolutely required. These results contradict suggested alter-
native explanations for Apc-driven cancer and strongly argue against the model pre-
sented by Phelps et al, who recently proposed that APC-driven tumor formation is 
independent of β-catenin, but instead requires the transcriptional corepressor CtBP 
[10]. CtBP has been shown to interact with APC at its 15-AARs thereby competing 
with β-catenin binding, and CtBP’s levels appear to increase upon Apc loss in early 
adenomas [14,15]. In their paper, Phelps and coworkers suggest that in contrast 
to CtBP, nuclear β-catenin cannot be detected following Apc loss alone using im-
munofluorescence, and suggested the additional activation of oncogenic KRAS to 
impose nuclear accumulation of β-catenin [14]. As discussed by Fodde and Tom-
Figure 4. Characterization of Apc1638N/Ctnnb1-/+ mammary tumors. (A) HE staining reveals heter-
ogeneous histology. Immunohistochemical staining for Cytokeratin-8 showing luminal epithelial dif-
ferentiation, cytokeratin-14 indicating squamous differentiation and smooth muscle actin showing 
myoepithelial cells. (B) Ki67 indicating moderate proliferation and β-catenin staining revealing mem-
brane-bound and nuclear localization. Active Wnt/β-catenin signaling is further indicated by the ex-
pression of Cyclin D1 and CD44.
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linson, nuclear staining of β-catenin is a reliable indicator of active Wnt signaling, 
but its absence does not exclude the robust activation of β-catenin target genes 
[27]. Using immunoperoxidase-based methods most investigators detect nuclear 
β-catenin accumulation in early adenomas, independent of KRAS mutation status 
[26,27]. As described above, nuclear β-catenin can be detected in Apc1638N intes-
tinal tumors (Figure 2D), while K-, N-, or H-Ras mutations are not found in these 
tumors [23]. In addition, whereas oncogenic CTNNB1 mutations have been detect-
ed in a large number of tumor types and expression of oncogenic β-catenin leads 
to the development of numerous tumors in the mouse intestine, equivalent data 
indicating tumor-initiating capacity of CtBP do not exist. Furthermore, as CtBP binds 
the more N-terminal located 15-AARs of APC, it can not explain the selection of 
specific truncated APC proteins retaining between 1-3 20-AARs that is observed in 
tumors, whereas this is the case for β-catenin [2,31]. The same argument holds true 
for the C-terminal microtubular functions of APC, which are completely lost in all 
APC-mutant proteins. Although loss of these C-terminal regions has been implicat-
ed in disturbed cell migration and chromosomal segregation [12,13], Apc-mutant 
mouse studies have shown that the C-terminal domains of Apc do not influence 
intestinal tumorigenesis. Hence, Apc1638T mice lacking the C-terminal regions of 
Apc but retaining an axin-binding repeat remain tumor-free [32], and the tumor 
phenotype of Apc1322T mice expressing a truncated Apc retaining only 1 20-AAR is 
not influenced by reintroduction of the C-terminal regions of Apc [33]. 
Although our findings provide genetic evidence for the dominant role of β-catenin 
signaling dosage in dictating tissue-specific predisposition for Apc-driven tumori-
genesis, mechanisms underlying tissue preferences for specific levels of β-catenin 
signaling remain largely unknown. In the intestine, β-catenin signaling is one of the 
main regulatory pathways, however, it operates in concerted action with multiple 
other signaling routes. This complex interplay is poorly understood. Other tissues 
including the mammary gland have unique architectural organizations and other 
signaling pathways are likely to play a role into different degrees. Unravelling how 
the complexity of all those signaling pathways influences which β-catenin signaling 
dosage dictates tissue-specific tumor predisposition in Apc-driven tumorigenesis 
represents a challenge for future investigation. 
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Summary
Cancer is a generic term for a group of diseases all characterized by abnormal, un-
controlled cell proliferation, due to a disturbance in the cellular signaling pathways 
which tightly control tissue homeostasis. These signaling pathways are under strict 
regulation of two opposing enzymes; kinases and phosphatases. Indeed, alterations 
in phosphorylation patterns is a common phenomenon in several types of cancer, 
making this an interesting target for therapeutic intervention. As such, the impor-
tance of protein kinases in health and disease has been extensively investigated. 
These studies are boosted by the wide ranging efforts made to develop a large pan-
el of clinically promising kinase inhibitors. In contrast, extensive knowledge of the 
equally important group of phosphatase enzymes is still lacking. Therefore the aim 
of this thesis was to study the role and possible clinical applications of phospha-
tases in cancer. Our findings will be summarized and discussed in this chapter. We 
will also provide future perspectives and issues that need to addressed in additional 
studies.
In chapter 2 we have prepared a comprehensive review on the action of protein ty-
rosine phosphatases in colorectal cancer, focusing on the consequences of altered 
expression of phosphatases, and their potential as targeted treatment. Phospha-
tases have long been regarded as tumor suppressor genes, since dephosphoryla-
tion events were thought to primarily result in termination of signaling. Indeed, 
phosphatases can act as important negative regulators of phosphorylation patterns. 
However, what becomes clear in chapter 2, is that phosphatases do not only act as 
signal transduction inhibitors, but can also play positive roles in cellular processes. 
As such, their role in pathogenesis may need to be redefined. 
One of the phosphatases for which a possible oncogenic role is proposed in chapter 
2 is low molecular weight protein tyrosine phosphatase (LMWPTP). In chapters 3 
and 4 we further studied the role of this phosphatase in prostate and colorectal 
cancer. We showed that while LMWPTP is expressed in normal prostate epithelial 
cells, its expression was significantly increased in prostate cancer. Interestingly, high 
LMWPTP expression in prostate cancer was correlated to a worse clinical outcome 
i.e. earlier time to recurrence and disease-related death, suggesting that LMWPTP 
acts as an oncogene in prostate cancer, and could potentially be used as a prognos-
tic marker. Furthermore, LMWPTP expression did not correlate to the proliferation 
marker KI-67, suggesting that the signaling induced by LMWPTP is more conductive 
to other PCa tumor cell characteristics than their proliferative capacity. This was 
further supported by our in vitro studies, in which we show that overexpression 
or downregulation of LMWPTP in prostate cancer cell lines regulates the migration 
potential of these cells, without affecting the cell proliferation. 
Similar results were obtained in chapter 4, where we studied the role of LMWPTP 
in colorectal cancer. While in healthy prostate tissue the LMWPTP expression was 
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quite abundant, the expression in normal colonic epithelial cells was rather limit-
ed. However, all the colorectal cancer samples showed a massive overexpression 
of this phosphatase in the intestinal epithelial cells. Furthermore, the expression 
followed a step-wise increase in different levels of dysplasia, again suggesting a role 
for LMWPTP in the oncogenic transformation of colorectal epithelial cells. Next, we 
investigated the effect of LMWPTP on colorectal cancer cells in vitro. As observed 
in prostate cancer cells, LMWPTP downregulation in colorectal cancer cells reduced 
cell migration and invasion. Furthermore, LMWPTP interfered with cell survival sig-
naling pathways, while we observed no effect on the proliferation of these stably 
transfected cell lines. On the other hand, treatment with the only known inhibitor 
of LMWPTP resulted in CRC cell death. Furthermore, we found that LMWPTP down-
regulation made CRC cells more susceptible to the chemotherapeutic agent 5-flu-
orouracil, possibly a result of reduced activation of survival signals. In addition, we 
also observed that LMWPTP can directly interact with multidrug resistance pumps, 
such as P-glycoprotein. In summary, we found that LMWPTP acts as an oncogene in 
both prostate and colorectal cancer, mostly by increasing the metastatic potential 
of the epithelial cells. 
Another phosphatase for which a role in cancer has been proposed is protein tyro-
sine phosphatase 1B (PTP1B). Interestingly, it has been shown that PTP1B acts as 
tumor suppressor gene in lymphomas and hepatocellular carcinoma, while it plays 
an oncogenic role in breast cancer and prostate cancer. A tumor promoting role for 
PTP1B in colorectal cancer has also been proposed, although its contribution to cel-
lular cancer hallmarks and signaling remained unclear. Therefore, in chapter 5, we 
further elucidated the role of the PTP1B phosphatase in CRC. We show that protein 
tyrosine phosphatase 1B is overexpressed in colorectal cancer on both protein and 
mRNA level, which corresponds with significantly reduced patient survival. Further-
more, PTP1B is an independent prognostic marker for disease free survival, and 
a borderline significant independent predictor for overall survival. Of even more 
importance, we show that not only the expression, but also the intrinsic enzymatic 
activity of PTP1B is greatly increased in the colorectal tumors. In vitro, this results in 
a more malignant phenotype by enhancing the proliferation, migration, and anoikis 
resistance of intestinal epithelial cells. Interestingly, PTP1B downregulation also re-
duced the levels of β-catenin signaling dosage, a critical driver of colorectal cancer 
carcinogenesis which was further pursued in chapter 8. Together these data suggest 
that targeting the activity of this phosphatase could be a viable treatment option 
for CRC, and a step forward in the fight against colorectal cancer.
Phosphorylation and dephosphorylation does not only take place on protein resi-
dues, but also on lipids. PI3-kinase acts as an oncogene by phosphorylating mem-
brane bound inositol lipids to produce phosphatidylinositol(3,4,5) triphosphate 
(PIP
3
), which subsequently recruits and allows activation of PKB. Dephosphorylation 
of PIP
3
 is therefore generally assumed to terminate PKB signaling, as is the case for 
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the well-known tumor suppressor gene and lipid phosphatase PTEN, which hydro-
lyses PIP
3
 to produce PI(4,5)P
2
. The action of the lipid phosphatase SHIP2 resembles 
that of PTEN, however, the hydrolysis product of SHIP2 is not PI(4,5)P
2
 but PI(3,4)
P
2
. Interestingly, PI(3,4)P
2
 has an even higher affinity for PKB than PIP
3
, and is re-
quired for full activation of this kinase. Thus, both PIP
3
 and PI(3,4)P
2 
are suggested 
to play a role in cancer development, suggesting that SHIP2 could be a possible 
oncogene rather than tumor suppressor. We therefore investigated the role of this 
phosphatase in colorectal cancer in chapter 6. We found that the expression and 
intrinsic phosphatase activity of SHIP2 is increased in human colorectal cancer, and 
that increased expression within a large cohort of CRC patient is correlated to a 
worse patient survival. SHIP2 enhances cell migration and invasion, and reduces cell 
adhesion in colorectal cancer cells. Furthermore, treatment with a SHIP2 activity in-
hibitor resulted in dose-dependent cell death, and this inhibitor sensitizes CRC cells 
to chemotherapy treatment. These data led us to conclude that SHIP2 is another 
phosphatase which contributes to the malignant potential of CRC, and may present 
yet another therapeutic target for this disease.
After our discovery that phosphatases indeed pose as potential treatment targets, 
we looked at the realistic possibility of targeting such phosphatases in cancer in 
chapter 7. For a long time researchers and industry were not interested in phospha-
tases as potential therapeutic option, since they were regarded as “undruggable” 
due to their high similarity. However, based on novel data presented at the Euro-
phosphatase conference 2015, it is becoming clear that due to increasing knowl-
edge of crystal structures and mechanisms-of-action, the possibility of targeting 
these enzymes is no longer in the realm of fantasy. Intuitively, phosphatases that 
act as tumor suppressor are less suitable for targeting, since inhibition of their en-
zymatic activity would be expected to result in further activation of the oncogenic 
pathways involved. However, rather than inhibiting these enzymes, reactivation of 
tumor suppressive phosphatases is now emerging as a potential strategy in cancer 
treatment. Even so, in the previous chapters, we identified phosphatases acting as 
oncogenes rather than tumor suppressor genes. Therefore, as previously done for 
oncogenic kinases, efforts are now directed towards the development of small mol-
ecule inhibitors of such phosphatases. This has already lead to the development of 
PTP1B activity inhibitors with promising success in vitro and in vivo, which will soon 
be tested in clinical trials. Furthermore, small molecule inhibitors against oncogenic 
phosphatases SHP2 and LMWPTP are under development. Hopefully these novel 
compounds directed against phosphatases can broaden the spectrum of targeted 
therapies, providing additional options for personalized medicine in cancer therapy.
In chapter 8, we studied the canonical Wnt/β-catenin signaling pathway. The vast 
majority of CRC cases arise as a result of aberrant activation of this signaling path-
way due to APC or β-catenin mutations resulting in enhanced β-catenin -induced 
proliferation. Most mutations in APC result in a truncated protein which loses the 
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ability to downregulate β-catenin signaling. However, depending on the location of 
the APC mutation, residual β-catenin downregulation may occur. Accordingly, there 
is an inverse correlation between the length of the truncated protein and amount 
of β-catenin signaling. The distribution of the several APC-mutations along different 
tissues or tumor locations do not seem to occur in an entirely random fashion, but 
appear selected to reach an optimal window of signaling. This is described as the 
“just-right” signaling model. This model proposes that signaling levels beneath the 
optimal window will not give a growth advantage, while exceeding levels will re-
sult in apoptosis of the affected cell. The concept of the just right signaling dosage 
for β-catenin in tumor development is gaining a lot of acceptance, however direct 
evidence was still lacking. Therefore in chapter 8, we aimed to formally prove this 
concept by lowering the β-catenin signaling dosage in an APC-mutant mouse mod-
el, shifting the signaling window towards a different tumor phenotype. By crossing 
APC1638N mice with heterozygous β-catenin knockout mice, we were able to re-
duce the β-catenin signaling in this model to a level comparable to that in APC1572T 
mice. While all the APC1638N mice developed gastrointestinal tumors, none were 
present in the gastrointestinal tract of the heterozygous β-catenin knockouts. Strik-
ingly, the female 1638N/ heterozygous β-catenin knockout mice developed mam-
mary tumors, which are observed in APC1572T mice, but rarely in APC1638N mice, 
thereby providing direct in vivo genetic evidence for the dominant role for β-catenin 
signaling dosage in tumor formation.
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General discussion
This thesis offers novel insights into the role of phosphatases in cancer. While ab-
errant phosphorylation is often studied with respect to kinases, phosphatases are 
somewhat overlooked. We believe that the data described in this thesis demon-
strate that a closer look to the phosphatases is warranted. 
Phosphatase overexpression
Genetic alterations that regularly occur in cancer include mutations, copy num-
ber loss/deletion, and copy number amplification [1] studies of different stages of 
colorectal neoplasia may shed light on the genetic alterations involved in tumor 
progression. We looked for four genetic alterations (ras-gene mutations and allelic 
deletions of chromosomes 5, 17, and 18. Gain-of-function alterations may increase 
the expression or activity of an oncogene [2,3], while loss-of-function mutations 
can silence a tumor suppressor gene. In the studies described in this thesis, we 
have observed overexpression in cancer samples of three distinct phosphatases. In 
these cancer types, overexpression of other oncogenes, such as COX-2, c-Myc but 
also PI3K, PKB, STAT3 and its phosphorylation are described to be increased [4–8]. 
Figure 1. Expression patterns of all phosphatases in carcinoma tissue compared to normal colonic 
tissue in the TCGA colorectal cancer 2 dataset. Almost as many phosphatases are upregulated as are 
downregulated in colorectal cancer.
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So how is it that both these oncogenes and the phosphatases that are tradition-
ally regarded as negative modulators of these oncogenic pathways are increased 
in these tumors? It is tempting to speculate that their upregulation is a general 
phenomenon of cells turning malignant, where transcriptional machinery goes hay-
wire, as it is known that deregulated transcription and translation is a common 
event in cancer cells, resulting in the concomitant dysregulation of many signal-
ing pathways [9]. To address this notion, we analyzed the expression pattern of all 
known phosphatases, based on the TCGGA colorectal 2 dataset [10](Figure 1A-B). 
We observed that almost as many phosphatases are significantly upregulated as 
are downregulated in colorectal cancer. This shows that overexpression of a certain 
phosphatase is not based on a general increase in transcription, but a specific event 
in the development of cancer. Off course this dataset describes the overall upreg-
ulation in a group of tumors, and it not representative of the events happening in 
a single tumor. However, while our studies showed LMWPTP expression was in-
creased in all the colorectal cancer samples we analyzed, PTP1B and SHIP2 expres-
sion differ drastically between different individual tumors, with some tumors being 
completely negative for one or the other. Since we analyzed the expression of SHIP2 
and PTP1B on the same cohort, we could also compare individual tumors. Again, 
we observed discrepancies in expression patterns of both phosphatases, with some 
being negative for one, and positive for the other. Another interesting observation 
made in this cohort, is that the expression of SHIP2 is correlated to MSI-status, 
while this was not the case for PTP1B. Interestingly, BRAF mutations are commonly 
associated with mismatch repair tumors, and recently it has been shown that for 
effective treatment of these colorectal tumors a concomitant BRAF and PI3K/mTOR 
blockade is required [11]. Since we showed that SHIP2 is a regulator of the PI3K/
mTOR pathway, we can speculate that SHIP2 inhibitors can be an important addi-
tion for these tumors. Altogether, this suggests that certain mutations or activated 
pathways benefit from the upregulation of a specific phosphatase.
Of course this raises the question, how are these phosphatases upregulated? Muta-
tions in phosphatase genes are described for a number of phosphatases, however 
most of these are inactivating mutations in the tumor suppressor phosphatases 
[12,13], which result in disturbed negative feedback of cancer signaling. While mu-
tations in PTP1B are found, the gene is most frequently overexpressed through am-
plification of the chromosome 20q13 region. Furthermore, epigenetic mechanisms 
such as methylation can also play a role in the regulation of expression. We ob-
served a hypomethylation of LMWPTP in colorectal cancer as compared to normal 
colon tissue, providing a possible explanation for the increased LMWPTP expression 
in CRC. However, such alterations for PTP1B and SHIP2 are not observed, and other 
mechanisms are likely to contribute to the upregulation of these proteins. Another 
hypothesis is these phosphatases are not upregulated as a result of mutations or 
amplifications in the gene itself, but as cellular response to overactive oncogen-
ic signaling. Cells will generally attempt to maintain homeostasis, and counteract 
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these hyperactive pathways, by increasing negative mediators of cellular signaling. 
Nevertheless, the upregulated phosphatases provide growth and metastasis advan-
tage for the tumor cell and is therefore maintained. As yet, the actual mechanism 
for upregulation of LMWPTP, PTP1B and SHIP2 remains to be elucidated, and likely 
differs between phosphatases as well as individual tumors.
As described in chapters 4 and 5, phosphatases are not only regulated through their 
expression, but also through their activity. There are many post-translational mech-
anisms for modulating phosphatase activity [14,15]. Phosphatases can be phos-
phorylated themselves, resulting in a change in their activity, as has been described 
for both LMWPTP and SHIP2 [16–18]. However, there are also other mechanisms 
for phosphatase modulation, such as inactivation by reactive oxygen species, as is 
the case for LMWPTP and PTP1B [19–21]. Based on the expression and activity pat-
terns we observed in our studies, it seems that the intrinsic activities of the studied 
phosphatases are specifically upregulated, irrespective of their expression patterns, 
and hence the overall enhanced effect of these phosphatases is not the result of an 
overactive transcriptional machinery in general.
Figure 2. Expression patterns of the 10 most up- and downregulated phosphatases in carcinoma 
tissue compared to normal colonic tissue in the TCGA colorectal cancer 2. 
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The effect of phosphatases on the process of metastasis
Interestingly, for all three phosphatases studied in this thesis, we found significant 
effects on cell adhesion and migration. Cell adhesion and migration are dynamic 
multi-step processes, that require quick and precise regulation [22]. Since phos-
phorylation is a rapid and reversible modification process, this is an ideal system for 
the control of these dynamic events [23]. Cell migration is composed of 4 integrated 
steps which together result in coordinated cellular movement, and all of these steps 
are tightly regulated by phosphorylation. To start migration, cells become asymmet-
ric and polarized – they form a clear distinction between cell front and rear. This is 
done via the protrusion of lamellipodia and filopodia at the leading edge of the cell. 
Lamellipodia are broad, flat, sheet-like structures, whereas filopodia are thin, cy-
lindrical, needle-like projections. Following these protrusions, cells form new sites 
of cell attachment to the extracellular matrix (ECM) via focal complexes or focal 
adhesion, which link the ECM to the cells actin skeleton. Next, through the force 
generated by actomyosin interactions, the cell body contracts and translocates in 
the direction of the leading edge. The final phase of cell migration is a release of 
cell contact at the rear end of the cell and recycling of membrane receptors from 
the rear to the front of the cell. Phosphatases play instrumental roles in regulating 
the timing, duration and localization of all these independent events. In our studies, 
we observed that knockdown of LMWPTP, PTP1B, and SHIP2 all reduce cancer cell 
migration. However, while knockdown of LMWPTP and PTP1B both also resulted 
in a reduced cell adhesion, this was not the case for SHIP2 downregulation. SHIP2 
knockdown cells apparently adhered more efficiently to culture plates as compared 
to the control cells. While cell migration and adhesion are closely linked, they are 
not the same. As described above, in order to efficiently migrate, the leading edge 
of the cell needs to form new complexes and adhere to the extracellular matrix, 
while on the other hand cells also need to efficiently release the rear end. The adhe-
sion assay as described in our work does not distinguish between these two events. 
Signaling in a migrating cell acquires a local intracellular gradient. For instance, PI3K 
and Rac GTPase activity are found at the leading edge of the cell, whereas Rho GT-
Pase activity is required for the retraction of the uropod during migration [22]. It 
is conceivable that differences in cellular localization of the studied phosphatases 
influences their effect on cellular adhesion. For instance, as PI3K signaling needs to 
be terminated at the trailing edge of the cell during migration [24], SHIP2 might be 
found at the uropod, where reducing its activity may thus decrease the detaching 
capacity of the cell. It would be of interest to further study the subcellular localiza-
tion of these phosphatases, and their interaction with the Rac and Rho GTPases. 
Nevertheless, both a too strong and a too weak attachment of cells may hamper 
cellular migration, which may explain why, despite differences in effect on adhesion, 
SHIP2, PTP1B and LMWPTP knockdown all result in a reduced migratory response. 
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Phosphatases and their substrates
Besides the influence of the studied phosphatases in relation to cellular migra-
tion and adhesion, we also tried to elucidate which cellular signaling cascades are 
under the influence or regulation of our target proteins. We have found several 
important cancer related signaling pathways altered upon the knockdown of our 
phosphatases of interest. However, there are still some interesting discrepancies, 
or unexplained findings. For instance, in LMWPTP knockdown CRC cells, we found 
that phosphorylation - and thus activation - of PKB and EGFR was reduced. This is 
of course of interest, since both are known to be frequently mutated/upregulated 
in several types of cancer [25–27], and corresponds well with known pathways to 
be deregulated in cancer. However, when the levels of a certain phosphatase are 
downregulated, as is the case in our LMWPTP knockdown cells, one would expect 
to find an increased phosphorylation of its substrates. This suggests that PKB and 
EGFR are not direct substrates of LMWPTP, but rather indirect targets. It is like-
ly that an intermediate phosphatase or kinase is the direct substrate of LMWPTP, 
and that the phosphorylation levels of PKB and EGFR are reduced through these 
intermediate LMWPTP substrates. Similarly, we observed a clear reduction in phos-
phorylation levels of ERK upon PTP1B knockdown. However, this phosphatase was 
Figure 4. Schematic representation of the four steps of cell migration. 1. Polymerization of actin 
filaments at the leading edge is translated into protrusive force. 2. Membrane protrusion facilitates 
the binding of transmembrane cell surface receptors to the substratum components. New adhesions 
are rapidly linked to the network of actin filaments. 3. The combined activity of retrograde actin 
movement and contractile forces produced by stress fibers generate tension to pull the cell body 
forward. 4. The forces produced by the contractile network combined with actin filament and focal 
adhesion disassembly, helps to retract the trailing cell edge. Used with permission from MBInfo: 
www.mechanobio.info; Mechanobiology Institute, National University of Singapore
215
Summary and discussion
previously shown to dephosphorylate the Src kinase at its inhibitory Y527 position, 
thereby activating this oncogenic kinase. As such, Src could act as an intermediate 
activator of ERK phosphorylation in the PTP1B cascade. Future research should be 
aimed at identifying more direct substrates of these interesting oncogenic phospha-
tases. Furthermore, while LMWPTP was upregulated in both prostate and colorec-
tal cancer, we observed discrepancies in the signaling routes that were activated 
upon LMWPTP modulation between these tumor types. This means that substrates 
can even differ between several tissue types, or at least that the specificity towards 
these substrates differ. This directly raises the question whether LMWPTP also acts 
as an oncogene in other forms of cancer – and if so – which substrates are affected 
in these tumor types. 
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Future perspectives
We have identified several phosphatases acting as oncogenes in colorectal and 
prostate cancer, based on human expression data and in vitro experiments. Howev-
er, the ultimate goal of future research will be to understand the functions of each 
of the phosphatases in vivo. Generation of more conditional and/or tissue-specif-
ic knockout animal models will therefore be necessary, especially using the Cre/
Lox-system to analyze intestine specific effects [28]. Once available, they can be 
crossed with existing tumor models like the APC-mutants for colorectal cancer, to 
gain more insights into their role in the pathogenesis of cancer. Since we found 
the most prominent effects for these phosphatases on cell migration rather than 
proliferation, animal models for metastasis might be of more interest than models 
for tumor initiation. The same hold true for the newly developed phosphatase tar-
geting drugs. Huge discrepancies can occur in sensitivity to chemical manipulation 
between in vitro and in vivo experiments. In order to find the clinically relevant 
drugs, animal models are the first step in this translation. 
Nevertheless, with the realization that expression of certain phosphatases is cor-
related to patient outcome, a clinical application as biomarker for phosphatases 
emerges. We already addressed the possibility for the use of the studied phospha-
tases as biomarker, however, this is based on relatively small cohorts. In order to 
find correct cut-off values, sensitivity and specificity, and true correlations to clinical 
parameters, our findings need to be repeated in larger and independent tissue co-
horts, preferably collected in a prospective manner. Also, the immunohistochemical 
analysis in our studies was performed on tissue micro arrays constructed from re-
sected cancer material. For biomarker studies it would be more valuable to perform 
the staining on biopsies, since the most important application of a biomarker will 
be to help decide whether a patient is – or is not – in need of invasive surgical treat-
ment. Future biomarker studies should therefore focus on the prospective collec-
tion of biopsies in which the immunohistochemical marker can be analyzed. Besides 
the use as biomarker for surgical decision making, these stainings could also be of 
value to decide whether the use of additional chemotherapy might be beneficial, 
especially since we observed that both LMWPTP and SHIP2 interfere with chemore-
sistance to the widely used chemotherapeutic agent 5-fluorouracil. 
The ultimate challenge for the coming years, will be to further extent the knowledge 
regarding phosphatase regulation and function in vivo, which will identify the most 
promising targets for therapeutic intervention. Next, by combining the knowledge 
on the crystal structures of these enzymes, the appropriate animal models, and 
large drug screens, phosphatase targeting drugs should become become available 
to prevent or cure diseases in the future.
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Nederlandse samenvatting
Kanker is een algemene term voor een groep aandoeningen die wordt gekenmerkt 
door cellen die zich abnormaal en ongecontroleerd gaan delen (proliferatie), waar-
na deze woekerende klomp cellen, de tumor, uitlopers kan vormen die het omrin-
gende weefsel binnen dringen (infiltratie). Soms kunnen cellen van de tumor zich 
afsplitsen en zich verplaatsen naar andere delen van het lichaam om hier nieuwe 
tumoren te vormen, we noemen dit metastasering of uitzaaiing. Normaliter bevat-
ten cellen regulerende mechanismen die er voor zorgen dat een cel op het juiste 
moment gaat delen, maar bij kankercellen zijn deze mechanismen vaak verstoord. 
Veel van de processen die bijdragen tot tumorvorming staan onder nauwgezette 
controle van eiwitten, die aan- en uitgezet kunnen worden middels fosforylering. 
Fosforylering houdt in dat een fosfaat-groep aan een eiwit wordt gekoppeld, wat 
meestal leidt tot de activering van dit eiwit. Het toevoegen van deze fosfaat-groep-
en wordt geregeld door een specifieke groep eiwitten, de ‘kinase enzymen’. Het 
tegenovergestelde proces, het verwijderen van de fosfaat-groep, ook wel defos-
forylering genoemd, wordt gedaan door de ‘fosfatase enzymen’. Aangezien er in 
kankercellen vaak een overtollige fosforylering van eiwitten wordt gevonden, is er 
in de onderzoekswereld veel aandacht geweest voor de rol die kinasen spelen in 
kanker. Dit heeft geleid tot de ontwikkeling van nieuwe medicijnen die de activiteit 
van verschillende kinasen kunnen verminderen, en sommige hiervan hebben zeer 
veelbelovende resultaten laten zien in de kliniek. De rol van de even belangrijke fos-
fatasen in het kankerproces is daarentegen erg onderbelicht gebleven. Het doel van 
dit proefschrift was dan ook om de rol en de mogelijke klinische toepassingen van 
fosfatasen in kanker in kaart te brengen. Onze bevindingen zullen worden samen-
gevat en besproken in dit hoofdstuk.
Fosfaat-groepen worden niet willekeurig aan een eiwit vast gemaakt, maar slechts 
op enkele anker-plaatsen die in deze eiwitten voorkomen, de aminozuren serine, 
threonine of tyrosine. Een cel bevat meer dan 100 eiwit fosfatasen, waarbij de be-
langrijkste onderverdeling te maken is in serine/threonine-specifieke fosfatasen 
en tyrosine-specifieke fosfatasen. In hoofdstuk 2 hebben we een uitgebreid over-
zicht gemaakt van de werking van met name de tyrosine fosfatasen in darmkanker, 
met de nadruk op de gevolgen van een veranderde expressie van deze eiwitten om 
kankercellen, en de mogelijkheid om deze eiwitten te gebruiken als aangrijpingspunt 
voor behandeling. Fosfatasen werden lange tijd beschouwd als ‘tumor suppressor 
eiwitten’, eiwitten die de groei van kankercellen remmen. Dit idee kwam voort uit 
de gedachte dat defosforylering door fosfatasen vooral zou leiden tot het remmen 
van signalering die verantwoordelijk is voor de ontwikkeling van kanker. Het ver-
lies van deze eiwitten zou derhalve leiden tot verhoogde celdeling. Er is inderdaad 
voor een aantal fosfatasen aangetoond dat ze op deze manier kunnen fungeren in 
kanker. Echter, wat duidelijk wordt in hoofdstuk 2, is dat sommige fosfatasen niet 
uitsluitend als remmers van signalering werken, maar ook een activerende rol kun-
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nen spelen in processen die bijdragen aan kankerontwikkeling, en dat de rol van 
fosfatasen niet in alle type tumoren hetzelfde is. Hierdoor is het belangrijk dat hun 
rol in de ontwikkeling van kanker opnieuw wordt bekeken.
Eén van de fosfatasen waarvan in hoofdstuk 2 bleek dat zij een tumor-versterkende 
(oncogene) rol zou kunnen spelen is ‘low molecular weight protein tyrosine phosha-
tase’ (LMWPTP). In de hoofdstukken 3 en 4 hebben we de rol van dit enzym nader 
onderzocht in prostaat- en darmkanker. We toonden aan dat LMWPTP aanwezig is 
in normale prostaat cellen, maar dat de hoeveelheid LMWPTP significant verhoogd 
is in prostaatkanker. Daarnaast zagen we dat een verhoogde hoeveelheid LMWPTP 
in prostaatkanker correleert met een slechtere uitkomst voor patiënten, zoals een 
eerdere terugkeer van de tumor. Dit suggereert dat LMWPTP inderdaad fungeert als 
een oncogen in prostaatkanker. Daarnaast laten we zien dat de expressie (de hoev-
eelheid van het eiwit) van LMWPTP gebruikt zou kunnen worden als voorspellende 
marker in deze ziekte. De expressie van LMWPTP correleerde niet met een marker 
voor de hoeveelheid celdeling, wat er op zou kunnen wijzen dat de signalering die 
wordt geactiveerd door dit enzym geen grote invloed heeft op de celdelingscapac-
iteit, maar op andere tumor kenmerken. Dit vermoeden werd bevestigd door onze 
in vitro studies, waaruit bleek dat wanneer wij de hoeveelheid LMWPTP eiwit in 
prostaat kanker cellen verlaagden, deze cellen minder goed konden migreren, ter-
wijl de celdeling niet beïnvloed werd.
Vergelijkbare resultaten werden verkregen in hoofdstuk 4, waar we de rol van 
LMWPTP in darmkanker onderzochten. In tegenstelling tot normale prostaatcel-
len, komt LMWPTP in normale darm epitheelcellen nauwelijks voor. De expressie 
van LMWPTP in afwijkende cellen was echter verhoogd, en nam nog verder toe 
in echte kanker cellen, wat opnieuw suggereert dat LMWPTP een rol speelt in het 
proces van kankerontwikkeling in de darm. Vervolgens hebben we het effect van 
LMWPTP op darmkankercellen onderzocht in het laboratorium. Zoals we eerder al 
zagen in prostaatkankercellen, resulteert ook het verminderen van de expressie van 
LMWPTP in darmkankercellen in een verlaagde cel migratie en invasie, twee belan-
grijke kenmerken voor het uitzaaiingsproces. Er werd geen direct effect gevonden 
op de celdeling, hoewel we wel aanwijzingen verkregen dat LMWPTP van invloed is 
op signaleringsroutes die belangrijk zijn voor de overleving van cellen. Het vermin-
deren van de hoeveelheid LMWPTP maakte de darmkanker cellen dan ook gevoe-
liger maakt voor chemotherapie. Bovendien gingen darmkanker cellen dood wan-
neer we ze behandelden met een chemische remmer van LMWPTP. Deze resultaten 
laten samen zien dat LMWPTP als oncogen fungeert in zowel prostaat- en darm-
kanker, waar het met name het vermogen van de cellen om te migreren bevordert, 
en dus metastasering kan bespoedigen.
Een ander fosfatase waarvoor een rol in kanker is beschreven is ‘protein tyrosine 
phosphatase 1B’ (PTP1B). Al eerder is aangetoond dat PTP1B als tumor suppressor 
kan fungeren in lymfklierkanker en leverkanker, terwijl het bij borstkanker en pros-
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taatkanker juist een tumor bevorderende rol speelt. Ook in darmkanker zou PTP1B 
tumorgroei kunnen bespoedigen, maar de precieze toedracht was tot op heden 
onduidelijk. Daarom hebben we in hoofdstuk 5 de rol van de PTP1B in darmkank-
er nader onderzocht. We toonden aan dat PTP1B verhoogd tot expressie komt in 
darmkanker, wat gepaard gaat met een significant slechtere overleving van darm-
kanker patiënten. PTP1B expressie zou zelfs als voorspellende marker voor ziekte 
uitkomst gebruikt kunnen worden. Van groter belang is echter dat we konden lat-
en zien dat niet alleen de expressie, maar ook de enzymatische activiteit van PT-
P1B sterk is toegenomen in de darmtumoren. Uit in vitro proeven bleek dat PTP1B 
expressie resulteert in een meer kwaadaardige tumor, via bevordering van zowel 
celdeling als celmigratie van darmcellen. Verlaging van PTP1B eiwit niveaus redu-
ceerde β-catenin signalering, een van de belangrijkste regulatoren in de ontwikke-
ling van darmkanker (verder besproken in hoofdstuk 8). Deze bevindingen samen 
suggereren dat een gerichte behandeling tegen de activiteit van PTP1B een veelbe-
lovende behandelingsoptie voor dit type kanker zou kunnen zijn, en een belangrijke 
stap voorwaarts in de strijd tegen darmkanker.
Het proces van fosforylatie en defosforylatie vindt niet alleen plaats op eiwitten, 
maar ook fosfaat-groepen kunnen ook aan vetachtige stoffen worden gekoppeld. 
Een voorbeeld hiervan is het bekende oncogen ‘PI3-kinase’, dat een fosfaatgroep 
overbrengt op het zogenaamde PI(4,5)P
2
 inositol lipide, een lipide met twee fos-
faatgroepen (aangeduid met ‘P’) dat verankerd is aan de binnenkant van de 
celmembraan. Het ontstane product, PI(3,4,5)P
3
 (het heeft een extra fosfaatgroep 
verkregen), zorgt vervolgens voor de activering van de ‘PKB’ signaleringscascade, 
een belangrijke route voor de overleving en deling van cellen. Defosforylering van 
PI(3,4,5)P
3
 tot PI(4,5)P
2
 wordt bewerkstelligd door een van de meest bekende tu-
mor suppressor eiwitten; PTEN. De fosfatase ‘SHIP2’ heeft een functie die vergeli-
jkbaar is met die van PTEN. Het herkent ook het gefosforyleerde lipide PI(3,4,5)
P
3
, maar haalt hier een andere fosfaatgroep vanaf, waarmee het product PI(3,4)P
2
 
ontstaat. Recentelijk is aangetoond dat in tegenstelling tot PI(4,5)P
2
, PI(3,4)P
2
 ook in 
staat is het PKB overlevings-signaal aan de cel door te geven. Hierdoor is het goed 
mogelijk dat in tegenstelling tot PTEN, SHIP2 misschien wel als oncogen werkt in 
kanker. In hoofdstuk 6 hebben we daarom de rol van SHIP2 fosfatase in darmkanker 
onderzocht. We hebben gevonden dat zowel de expressie als de activiteit van SHIP2 
verhoogd zijn in kanker. Daarnaast zagen we dat een verhoogde SHIP2 expressie 
gecorreleerd is met een slechtere uitkomst voor patiënten. SHIP2 verbeterde cel 
migratie en invasie in vitro, en verminderde de celadhesie van darmkanker cellen. 
Wanneer tumor cellen behandeld werden met een remmer van het SHIP2 enzym 
resulteerde dit in een dosis-afhankelijke sterfte van darmkanker cellen. Daarnaast 
zorgde deze remmer ervoor dat de cellen vatbaarder werden voor chemothera-
pie. Uit deze resultaten bleek derhalve dat SHIP2 inderdaad werkt als oncogen in 
darmkanker, waarmee we een nieuw therapeutisch doelwit voor deze ziekte heb-
ben geïdentificeerd.
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Nadat we hadden ontdekt dat fosfatasen potentieel gebruikt zouden kunnen worden 
als aangrijpingspunten voor behandeling, zijn we in hoofdstuk 7 gaan kijken naar de 
realistische mogelijkheden om dit te doen. Jarenlang zijn onderzoekers, maar ook 
de farmaceutische industrie, niet geïnteresseerd geweest in de ontwikkeling van 
medicijnen tegen fosfatasen, omdat dit als ‘onmogelijk’ of ‘te moeilijk’ werd geacht. 
Fosfatasen hebben namelijk onderling grote overeenkomsten, waardoor het spec-
ifiek benaderen van 1 fosfatase erg lastig zou zijn. Echter, op basis van gegevens 
die gepresenteerd werden op het ‘Europhosphatase 2015’ congres, is duidelijk ge-
worden dat de algemene mening hierover veranderd is. Er is steeds meer bekend 
over de structuur en het werkingsmechanisme van deze eiwitten, waardoor speci-
fiek gerichte behandelingen niet langer onmogelijk zijn. Het lijkt aannemelijk dat de 
fosfatasen die werken als tumor suppressor minder geschikt zijn als behandeldoel-
wit, aangezien remmen van de activiteit deze eiwitten juist tot verdere activering 
van kanker signalen zou leiden. Er is echter gebleken dat het mogelijk is om de tumor 
onderdrukkende fosfatasen te reactiveren in tumor cellen, wat een mogelijke nieu-
we strategie kan zijn voor de behandeling van kanker. Bovendien hebben wij in de 
vorige hoofstukken een aantal fosfatasen geïdentificeerd die als oncogenen werken 
in plaats van tumor suppressor genen. Net als de voorgaande jaren gedaan is voor 
de oncogene kinasen, is er nu veel aandacht voor het ontwikkelen van inhibitoren 
van dergelijke oncogene fosfatasen. Dit heeft inmiddels geleidt tot de ontwikkeling 
van activiteits-remmers van PTP1B, die veelbelovende resultaten hebben laten zien 
in het laboratorium en daarom binnenkort getest zullen gaan worden op patiënten. 
Vergelijkbare inhibitoren worden nu ook ontwikkeld tegen oncogene fosfatasen als 
SHP2 en LMWPTP. Hopelijk kunnen deze nieuwe ontwikkelingen in de nabije toe-
komst bijdragen aan de behandeling van kankerpatiënten. 
Tot slot hebben wij in in hoofdstuk 8 de zogenaamde Wnt/β-catenine signaalroute 
onderzocht. De overgrote meerderheid van darmkankers hebben een afwijking in 
deze signaalroute, als gevolg van een mutatie in het β-catenine gen zelf of het aan-
verwante gen APC. Dergelijke mutaties leiden tot een verhoogde β-catenine sig-
nalering, resulterend in een ongeremde celdeling. Het type APC mutatie kan ver-
schillen tussen tumoren, en elke mutatie zorgt voor een eigen mate van β-catenine 
signalering. Ieder celtype lijkt een ander niveau van β-catenine signalering nodig te 
hebben om uit te groeien tot een tumor. Dit principe is omschreven als het “just-
right” model, maar hoewel dit concept algemeen geaccepteerd is, ontbrak het di-
recte bewijs hiervoornog. In hoofdstuk 8 hebben wij geprobeerd om dit directe 
bewijs te leveren, door het β-catenine signaleringsniveau te verlagen in een muis 
model. Het gevolg hiervan was dat het type tumoren wat deze muizen ontwikkelen 
verschoof van darmtumoren naar borsttumoren, waarmee wij het directe bewijs 
hebben geleverd dat het niveau van β-catenine signalering een bepalende factor is 
in de ontwikkeling van kankers van verschillende origine.
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In het kort zouden we kunnen zeggen dat wij, met het werk gepresenteerd in dit 
proefschrift, laten zien dat fosfatasen een stuk belangrijker zijn voor de maligniteit 
van tumoren dan men voorheen aan nam. Wij presenteren drie fosfatasen, LM-
WPTP, SHIP2 en PTP1B, die allen verhoogd zijn in kankercellen, en daar bijdragen 
aan cel overleving, resistentie en metastaserings-processen. Hoewel wij ons nu 
hebben beperkt tot prostaat en darm-tumoren is het heel wel mogelijk dat fosfa-
tasen ook in andere tumor-typen een oncogene rol vervullen. Het remmen van deze 
fosfatasen is dan ook mogelijk een goede strategie in de bestrijding van verschillen-
de tumoren. Verder onderzoek zal moeten aantonen in hoeverre andere fosfatasen 
tumorgroei bevorderen en in welke typen kanker. Wij hopen dan ook dat ons werk 
internationaal onderzoekers zal aansporen fosfatasen nader te bestuderen, en dat 
dit onderzoek een stap is in de richting van nieuwe medicamenteuze oplossingen 
voor deze, nog altijd dodelijke, ziekte. 
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Dankwoord 
Ondanks dat mijn naam op de voorkant van dit proefschrift staat, had dit boek niet 
tot stand kunnen komen zonder de enorme support die ik van allerlei kanten heb 
mogen ontvangen, op wat voor manier dan ook. 
Ik kan niet anders dan te beginnen met het bedanken van mijn co-promoter en 
directe begeleider Gwenny. Ik denk dat ik me geen betere begeleider heb kunnen 
wensen dan jij! Vanaf het eerste moment dat we zijn gaan samenwerken denk ik dat 
we een zelfde kijk hadden op onze de invulling van mijn begeleiding. Dit begon al bij 
jouw “ik ben niet zo van de wekelijkse meeting, maar loop gewoon binnen als je iets 
wilt bespreken” opmerking. Dit klonk mij als muziek in de oren! Hierdoor kon ik lek-
ker vrij te werk kon gaan met mijn (of nog vaker jouw..) ideeën, terwijl ik wist dat je 
altijd met tips of suggesties voor me klaar stond als ik ze nodig had. Ik heb daardoor 
echt superveel van je kunnen leren, al is het me helaas niet gelukt om ook maar in de 
buurt te komen bij jouw talent voor schrijven. Elk stuk dat ik je opstuur, krijg ik binnen 
no-time weer terug. Waarna het was getransformeerd tot een fantastisch verhaal, 
met de mooiste zinnen! Ook naast het werk kunnen we het goed met elkaar vinden 
wat onze samenwerking denk ik nog meer verbeterd heeft. Je bent net als ik altijd in 
voor een lekker biertje met de BOTM, of een wijntje op een van onze feestjes! Hopeli-
jk kunnen we dat ondanks dat ik Rotterdam ga verlaten nog steeds blijven doen! 
Behalve onze samenwerking, was het ook heerlijk dat je zo’n geweldig team vormt 
met mijn andere begeleider, promotor Prof. Dr. Maikel Peppelenbosch. 
Beste Maikel, je bent echt een professor zoals een professor moet zijn. Je zit vol 
met spectaculaire ideeën die je op de mooiste manieren kunt formuleren, en voor 
elk probleem of onverwachtse uitkomst weet jij weer een alternatieve pathway 
tevoorschijn te toveren waar de mogelijke oplossing in verscholen zit. Ik heb daar 
heel veel respect voor en heb daar ook enorm van genoten en veel van geleerd. 
Op het begin is het lastig om je echt te leren kennen, maar gaandeweg mijn pro-
motie merkte ik dat ook bij jou de deur altijd voor iedereen open staat. Hier heb 
ik ook gretig gebruikt van gemaakt toen ik bezig was met mijn sollicitaties voor de 
MDL-opleiding. Je hebt me in die tijd ook altijd van waardevolle adviezen voorzien, 
ook hier ben ik je erg dankbaar voor!
Professor Ferreira, dear Carmen, I would like to thank you for all the help and valu-
able comments on the manuscripts we worked on together. I’m really pleased and 
honored that you were also willing to take place in the reading committee of my 
thesis!
Professor den Hertog, ik had uw naam door Maikel al vaak horen vallen, maar had 
u tot de Europhosphatase meeting nog niet ontmoet. Door deze meeting was uw 
naam de eerste die bij mij op kwam als potentieel lid van de leescommissie. Ik wil 
u dan ook hartelijk danken dat u bereid was op dit aanbod in te gaan. Erg leuk om 
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mijn data voor te leggen aan iemand met zo veel ervaring in het phosphatase-veld! 
Professor Metselaar, u heeft me al eens de Mark Blankensteijn-prijs uitgereikt voor 
een van de hoofdstukken uit dit proefschrift, en nu bent u ook akkoord gegaan om 
als lid van de leescomissie de rest van de hoofdstukken kritisch bestuderen, mijn 
dank daarvoor!
Beste Professor Fodde, Professor Verhoef en Professor Medema, hartelijk dank 
voor het plaatsnemen in mijn grote commissie, ik zie uit mijn werk met jullie te 
bediscussiëren. 
Ron, eigenlijk is mijn hele labonderzoek bij jou begonnen. Je hebt me de kans ge-
geven om mee te werken aan de studie van Elvira, waar ik de eerste kneepjes van 
het lab-werk heb mogen leren. Ook tijdens mijn promotie kon ik altijd langslopen 
voor advies, bedankt voor alles!
Janneke, als niet IBD-onderzoeker heb ik me altijd thuis gevoeld op de IBD-meet-
ings. Met veel interesse wilde je al mijn praatjes over signaling-pathways aanhoren, 
waarna je me meestal voorhield wat dit nou precies voor de patiënten (cases…) 
te betekenen had. Precies de opmerking die ik af en toe nodig had als ik in mijn 
enthousiasme voor het labwerk verdwaalde, en de klinische relevantie een klein 
beetje uit het oog was verloren. 
Mijn team aan paranimphen (je hebt er eentje extra nodig als de allochtoon wel-
licht het land uitgezet wordt..) Wesley, Rik en Evelyn! We zijn met z’n allen zo goed 
als tegelijk begonnen aan onze promoties, en daardoor kregen we gelijk een band. 
Dit is ook uitgegroeid van collega’s naar goede vrienden. Doordat jullie er waren (en 
een aantal anderen, maar daar kom ik later op terug), ben ik nooit met een naar 
gevoel naar mijn werk gekomen. De eindeloze bakjes koffie als er leuks - of minder 
leuks - te melden was. Het put-putten op onze kamer, de feestjes, Cadzand, borrels, 
verjaardagen, het was allemaal leuker doordat we zo’n geweldig groepje hadden. Ik 
ben dan ook vereerd dat jullie mijn team aan paranimphen willen vormen!! 
Wesley, m’n maatje vanaf dag 1, omdat we allebei als arts begonnen aan een la-
bonderzoek. Hierdoor hebben we elkaar veel kunnen helpen en liepen we tegen de 
zelfde problemen aan. We hebben je gelukkig snel kunnen overhalen om naar onze 
“Man Cave” te komen in de L-vleugel, en daarna heb je deze plaats nooit meer af 
hoeven staan. Ik heb ook genoten van onze congressen samen. Eerst samen naar 
Orlando, waar ik zelfs nog even met jou en Cin mee kon naar Universal Studios, 
daarna nog naar Chicago, waar we denk ik een fantastische tijd hebben gehad! Ook 
buiten het werk het vaak dingen samen gedaan, waardoor je echt een waardevolle 
vriend bent geworden. Ik hoop dan ook echt met heel mijn hart dat je in de toe-
komst naast me staat als MDL-arts, want er is niemand die ik het meer gun dan jij!
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Rik, bij jou is het eigenlijk hetzelfde verhaal als mede ‘Man Cave bewoner’, we 
werden al snel een hecht groepje met zn 3en. Eigenlijk is het jammer dat je niet 
ook op de MD-kant werkt, dan had jij ons alle mooie plekjes in jouw eigen “Merica” 
kunnen laten zien als daar weer een congres was. Ik vind het ook cool om te zien 
dat je gaandeweg je PhD weer een beetje ‘vernederlandst’ bent, want van mij mag 
je nog heel lang in dit landje blijven! Al is een vakantie adresje aan de Amerikaanse 
West Coast ook niet gek J! Heel veel succes met het afronden van je PhD, ik kan 
niet wachten op het filmpje bij jouw promotie!
Evelyn, mijn back-up paranimph, al klinkt dat eigenlijk te oneerbiedig. Het komt 
uiteindelijk heel goed uit dat Rik nog een onzekere factor is, want zo kan ik jou 
ook bij de promotie betrekken! Ook jij bent vanaf het begin van mijn promotie een 
goede vriendin geworden. Jouw enthousiasme werkt aanstekelijk op iedereen, je 
bent altijd vrolijk en positief. Ik weet ook zeker dat die dingen jouw ver gaan bren-
gen, en wens je dan ook heel veel succes in je zoektocht naar een nieuwe baan! 
Mocht het nou zo snel niet lukken, je kunt altijd nog als clown aan de slag ;-)
Zoals denk ik wel duidelijk is geworden uit de vorige stukjes, heb ik een fantastische 
tijd gehad op het laboratorium van de MDL. Dit is grotendeels te danken aan alle 
leuke collega’s waarmee ik heb mogen samenwerken. De lunches, koffiepauzes, 
uitstapjes, feestjes, BOTM-borrels, en meer van dat soort dingen hebben er voor 
gezorgd dat ik met veel plezier naar het werk kwam! Heel erg veel bedankt daar-
voor!!
Michelle, als 2 nieuwelingen op de diagnostiek analisten-kamer beginnen was ge-
nieten! Je bent een echte levensgenieter, met kleine kanttekening dat je dat soms 
vergeet als je een beetje gestresst bent… Je hebt altijd mooie verhalen over de leuk-
ste feestjes, tofste festivals, en mooiste vakantieplekjes! Ik vind het ook supertof 
dat je nu naar London gaat, iets wat je volgens mij altijd al wilde, heel veel succes 
daar! En aangezien London kennelijk het nieuwe Cadzand is houd ik me aanbevolen 
J.
Eelke, jij bent echt een van de meest enthousiaste mensen die ik ken. Jouw inter-
esse voor andere mensen is ongelooflijk. Je weet alles van iedereen, en staat altijd 
voor wie dan ook klaar! Het was gezellig dat je na je uitstapje naar Dublin naar de 
6de verdieping bent gekomen. Altijd leuk om nieuwe muziekjes te luisteren! Heel 
veel succes met het afronden van je promotie, en ik denk dat je een top-chirurg zult 
worden!
Vincent, je bent onze BOTM later komen versterken, maar je paste er perfect tus-
sen! Je bent een super gedreven persoon, waardoor je soms dingen misschien iets 
TE veel gaat overdenken, maar jouw altijd kritische blik gaat geweldig onderzoek 
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opleveren. Daarnaast ben je ook nog eens een fantastisch persoon, en die combi-
natie gaat je ver brengen. Veel succes met de rest van je onderzoek, en misschien is 
het tijd dat je een keer een feestje gaat organiseren ofzo??
Martijn, nog een extra versterking voor de BOTM, en wat voor één! Als ik dacht 
dat wij al veel biertjes geproefd hadden, kwam jij met de mededeling dat je zelfs 
op ‘biervakantie’ naar België gaat om de beste biertjes uit te proberen! Die biertjes 
moeten uiteraard wel gecombineerd worden met een goede BBQ, en daar hebben 
wij in Cadzand van mogen meegenieten! Je bent een topcollega, met een fantas-
tisch onderzoek! Veel succes met alle muisjes!
Emmeloes, je bent denk ik de meest ‘dedicated’ werker die ik heb meegemaakt 
tijdens mijn promotie. Dat is ook wel te zien aan je proefschrift met daarin alleen 
maar gepubliceerde papers, terwijl je in de tussentijd ook nog even 2 kinderen hebt 
gekregen. Je mag daar heel erg trots op zijn. Daarnaast ben je ook nog eens een 
super leuke collega, altijd in voor praatje, of andere gezelligheid. Al moest dat wel 
tussen de stapels boterhammen door ;-). Heel veel succes met je nieuwe carrière 
als fertiliteitsarts!
Renée, de eerste jaren op de L-vleugel was je voor mijn gevoel vooral bij de chiru-
rgen te vinden, maar toen je bij ons op de 6e kwam heb ik je echt leren kennen. Je 
bent een gezelligheids-mens en een harde werker. Op een of andere manier vond 
jij tussen het praatjes geven op congressen (met bijbehorende prijzen in de wacht 
slepen), toch nog tijd om alle borrels bij te wonen! Succes met het afmaken van je 
promotie en geneeskunde!
Xiaolei, the Chinese member of our Man Cave. You’ve been a great colleague and 
good friend from the beginning of our PhD. You also wanted to participate in all the 
things we did outside of work, and even introduced all of us to the Chinese cuisine 
at San San! You’ve learned me the real Chinese food, I taught you how to drink beer 
J. Good luck with your surgical training in Shanghai, I hope to meet you there some 
day!
Wouter, eigenlijk ook zo goed als tegelijk begonnen aan onze promotie, maar jij 
moest door jouw klinische promotie al een jaartje eerder klaar zijn. We hebben 
mooie tijden gehad op alle congressen, waar jij aan de lopende band praatjes mocht 
geven! Je bent een geweldig persoon en een zeer gewaardeerde collega! Daarom 
ben ik ook blij dat we binnenkort opnieuw collega’s zullen zijn als ik ook in Leiden 
aan de opleiding MDL ga beginnen!
Leonie, ja hoe kan ik jouw nou bedanken. Je hebt zo ongelooflijk veel voor mij 
gedaan (op een klein akkefietje na ;-)). Eigenlijk kunnen we het vanaf dag 1 al goed 
met elkaar vinden, en dat is alleen maar beter geworden. We hebben een hoop 
gelachen, en de laatste tijd begint mijn week elke maandag met een lach als je mij 
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weer een mooi plaatje of anekdote hebt gemaild. Feitelijk ben jij de baas van onze 
afdeling, want als iemand Maikel in zn zak heeft dan ben jij het wel. We moeten snel 
weer een wijntje drinken! 
Marcella, voor het eerst dat ik echt iemand moest (mocht) begeleiden. Ik vond het 
superleuk om te doen, en dat had veel te maken met jouw instelling. Je was altijd 
enthousiast en wilde graag leren. Hierdoor heb je in korte tijd ook mooie resultaten 
kunnen boeken, die deels zelfs in mijn proefschrift staan. Nogmaals dank hiervoor! 
Heel veel succes met het afronden van je master Oncology, en hopelijk kan je daar-
na doorstromen naar een mooie PhD-plek!
Werner, mol-lab mentor nummer 1, hoe zou mijn promotietraject zijn verlopen als 
ik niet eerst een half jaar een soort ‘Helvensteijn-Masterclass” had gehad. Ik kon 
nog geen pipet vasthouden, en toch vond je het leuk om alles aan me uit te leggen! 
Ik kan je daar niet vaak genoeg voor bedanken! Jasper, mol-lab mentor nummer 2, 
ook jij stond altijd voor me klaar als ik vragen had over wat voor techniek dan ook. 
Je hebt onze Man-cave als eerste verlaten, om over te stappen naar de “dark side” 
zoals je dat zelf noemde. Ik denk dat je nog altijd een goede keus hebt gemaakt. 
Onze trip in Kiruna was “EPIC”!! Ik hoop je nog vaak tegen op een congres, of als 
voor een kopje koffie als je in de buurt bent. Rajesh, my Indian friend, thanks again 
for asking me to be your paranimph! We had good times together in the lab, I wish 
you all the best in the rest of your carreer. Elvira, ook bij jou mocht ik paranimph 
zijn! Zal nooit vergeten dat jij in Kiruna was als “donor”, terwijl jij als enige liever niet 
geprikt wilde worden J! Wendy, je hebt me tijdens mijn stage echt op weg gehol-
pen en me laten geloven dat het een goede optie zou zijn om te gaan promoveren, 
bedankt hiervoor! Suus, bedankt voor je heerlijke “chicken in de hood”. Ik hoop je 
snel weer tegen te komen in Leiden (of Den Haag)! Anthonie, ik hoop dat wij als 
“jonge generatie” een beetje in de buurt zijn gekomen van de “oude garde”, want 
als er iemand investeert in de sfeer van het lab ben jij het wel! Je hebt me ook tal-
loze keren dezelfde dingen op de FACS uitgelegd als ik dat voor het eerst sinds tijden 
weer een keer moest doen, heel erg bedankt daarvoor! Estella, dear dear Estella, 
you are such a sweet person. Thanks for the great time we had together, and we 
should do the hot-potting again! Nadine, we hoeven straks allebei niet meer met 
de trein, maar dat was wel altijd op en top gezellig! Veel succes in Leiden, en ik zie 
je wel op de markt!! Buddy, we hebben wat afgelachen, altijd gezellig met jou. Ook 
altijd leuk om op woensdagochtend even de Champions League wedstrijden van 
dinsdag na te bespreken. High-Five! Jan, lab-oudste, de man die eigenlijk gewoon 
alles runt. Jouw gedrevenheid is ongekend, daarom is er geen persoon binnen het 
Erasmus MC die niet weet wie jij bent! Abdullah, you’re such a smart person, but 
you get amazed by the smallest things in life. Thanks for all your advice during my 
research, you can be proud of yourself what you have achieved so short after ob-
taining your PhD, but probably for you that was “very easy, no problem”. Wenshi, 
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I think you had to get used to us when you first came in, but now it seems like you 
enjoy all the activities we do in the lab! You are a great person! Paula, supertof dat 
je foto’s voor me wilt maken! Ik beloof je nogmaals dat ik ze minimaal 1x zal beki-
jken ;-). Patrick, stille genieter, altijd in voor een beetje gezelligheid. Ook al sta je 
niet op de voorgrond, ik kan helemaal stuk gaan om jouw droge humor! Auke, wat 
hebben we gelachen in Kiruna, zie jou nog staan toen ze kwamen vertellen dat de 
lancering misschien niet door zou gaan omdat de raket 36.9 graden celcius was! Su-
per leuk dat je daarna bij ons bent komen werken, en bedankt voor je feedback op 
mijn projecten! Rogier, fantastische collega, ik vond je echt een aanwinst voor onze 
afdeling, daarom ook extra jammer dat je al weer weg bent. Henk, de nuchterheid 
zelve, bedankt voor alle gezelligheid en uiteraard je mooie doosje voor de escape 
room! Aniek, ook bij jou ben ik talloze keren binnen gelopen voor hulp, en wat het 
ook was je wilde me altijd helpen! Heel veel succes en plezier met de kleine! Kim, 
vind het altijd mooi om discussies met je aan te gaan, we hebben er volgens mij een 
heleboel gevoerd J! Goed dat je weer terug bent op het lab na een paar maanden 
afwezigheid! Gertine, jij gaat denk ik een nog belangrijkere schakel in jullie groep 
worden dan je al bent, veel succes met het afronden van je opleiding! Petra, je bent 
een ongelooflijk warm persoon met brede interesses. Ik vind het supergaaf dat je 
terwijl je bij ons werkte een opleiding kunstgeschiedenis hebt afgerond! Je volkslied 
blijft legendarisch! Shanta, bedankt voor je hulp bij de immunohistochemie! Ester, 
ik vind het bewonderenswaardig hoe positief je bent gebleven tijdens je project. 
Het zit niet mee, maar je blijft er vol voor gaan, mooie instelling! Greta, je blijft maar 
doorgaan ons lab te helpen, ondanks dat je al met pensioen bent! Je bent een top-
per! Martine, het was gelijk gezellig toen ik bij jullie op de diagnostiek kamer mocht 
beginnen, of als ik weer aan het western blotten was op het oude lab! Frances, stille 
maar harde werker die alles volgens mij haarfijn door heeft, bedankt dat je altijd 
bereid was mee te helpen als ik weer eens serum moest opslaan. Pauline, good 
luck with finishing your PhD! Raymond, denk dat jij mij een hoop geld hebt opge-
leverd als ik weer eens een declaratieformulier verkeerd had ingevuld J. Jesse, de 
laatste tijd weer terug op onze kamer, ik hoop voor je dat het lukt om je onderzoek 
te kunnen vervolgen in een PhD-traject! Pieter(tje), Vincent heeft maar geluk met 
een student zoals jij! Je bent een topgozer, en een waardevolle aanvulling van onze 
kamer en hele afdeling! Ik heb het gevoel dat ik je nog wel tegen ga komen als toe-
komstig collega! Andre, Andrea, Sonja, Hanneke, Hugo, Marcel, Jaap, Monique en 
Luc, allen bedankt voor de gezelligheid en waardevolle vragen en suggesties tijdens 
seminars! To all my Chinese colleagues, Wanlu, Cindy, Effie, YingYing, Amy, Lei, 
Wen, Wenhui, Kan, Penyu, Shan, thanks for the great Chinese New Years parties, 
and all the great food I could try! Good luck to all of you with finishing your PhDs. 
And Yuebang, Bottoms up at my party? 
Daarnaast wil ik nog al mijn collega’s van de IBD-groep door de jaren heen bedan-
ken! Sergey, veel succes met je nieuwe baan bij Cruzel! Hester, succes met de rest 
van je onderzoek, hoop dat het lukt om je lab-onderzoek een beetje op de rails 
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te houden zonder Sergey. Veerle, succes met het afronden van je co-schappen en 
PhD! Alison, hopelijk kan ik het goede voorbeeld geven voor een paar dagen later! 
Shannon en Joany, superduo, heel veel succes met jullie onderzoeken en bedankt 
voor het lachen! Mitchel, topper, bedankt dat je me in leven hebt gehouden op de 
ski-piste en succes in Deventer!
Dank ook aan Esmee, Jihan, Raoul, WP, en alle andere toppers van de DAK! We 
zitten misschien een ver weg gestopt met ons laboratorium, maar we hebben moo-
ie tijden gehad tijdens meetings, borrels, ski-reis, en congressen. Hoop jullie in de 
toekomst allemaal nog vaak tegen te komen!
Ook buiten de afdeling MDL heb ik met veel mensen samen mogen werken die ik 
allemaal graag wil bedanken.
Dear Asha, thanks again for all your help with the migration experiments, you’ve re-
ally helped me a lot and improved all of my papers significantly! Even though I know 
how busy you were! Marije, bedankt voor je hulp met de prostaatkanker TMA, en 
succes met je opleiding tot patholoog! Beste Guido, het was fantastisch om samen 
te werken op ons prostaatkanker stuk, dankzij jouw enthousiasme werd het manu-
script constant verbetert! Ditzelfde geldt overigens voor Arno, ook heel erg bedankt 
hiervoor! Iedereen uit het LUMC, voor mijn eerste stuk Liudmila en Prof Hardwick, 
en later Marloes en Dr. Kuppen, heel erg bedankt dat jullie open stonden voor de 
samenwerkingen, dit heeft mijn projecten een stuk verder gebracht!
Uiteraard komt een proefschrift niet alleen tot stand met hulp van alle mensen op 
het werk.
Ik wil dan ook alle gasten van Vtown enorm bedanken. Jullie hebben me misschien 
niet geholpen met het vasthouden van een pipet, of met het doen van mijn analy-
ses, maar wel om mijn gedachten te verzetten in het weekend. Ik blijf me verbazen, 
en besef tegelijkertijd wat een geluk ik heb, over onze immense en hechte vrien-
dengroep. Hoeveel mensen zullen er kunnen zeggen dat ze met 25 mensen van de 
middelbare school nog elk jaar Sinterklaas vieren?! We hebben net de 10e editie 
gehad, maar als het aan mij ligt gaan we dat nog eindeloos volhouden! 
Hans en Angelique, bedank voor alle steun en interesse in mijn onderzoek de afge-
lopen paar jaar. Daarnaast bedankt dat jullie altijd voor ons klaar staan, in wat voor 
situatie dan ook! Heel veel succes met het Thomashuis, het kan niet anders dan een 
groot succes worden!
Mijn lieve grote zus Femke, dat ik mijn promotietraject goed ben doorgekomen is 
eigenlijk allemaal bij jou begonnen. Zonder dat pap en mam het wisten had jij me 
bij jou op je kamertje al leren lezen, dat is ongetwijfeld de reden waarom ik me nu 
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door alle ingewikkelde literatuur kon slaan ;-)! We hebben nu natuurlijk allebei onze 
drukke levens, maar eigenlijk is het jammer dat we elkaar zo weinig zien. Wat dat 
betreft was een baan in het VUmc ook niet gek geweest J. Dan was het makkelijker 
geweest om bij jou, Dennis en Tibo langs te komen! Jullie hebben het wel perfect 
voor elkaar, en ik bewonder jullie reislustigheid. Hoe klein Tibo ook is, hij heeft al 
meer van de wereld gezien dan menig persoon! Heel veel plezier en succes in de 
toekomst met zn 3en!
Dan mijn lieve grote broer Menno, jij hebt dit hele proces al meegemaakt. Daar-
om kon ik je altijd als vraagbaak gebruiken, of zelfs advies vragen over mijn manu-
scripten. Jij en Jolanda mogen echt enorm trots op jullie zelf zijn. Ik denk dat Finn, 
en vooral ook Isis, zich geen betere ouders dan jullie kunnen wensen. Jullie staan 
soms niet voor de makkelijkste situaties, maar slaan jullie overal doorheen! Jullie 
zijn toppers!!
Lieve Mam, jij hebt me altijd gesteund in alle keuzes die ik heb gemaakt, en altijd 
geholpen als ik ergens vast liep. Ik heb veel van je geleerd, en heb daarom ook altijd 
jouw motto “je kan niet meer doen dan je best” in mijn achterhoofd. Hierdoor zal 
ik altijd de volle 200% geven, maar kan ik ook tevreden terugkijken op mijn eigen 
werk. Daarnaast ben ik erg trots op wat jij allemaal voor jezelf hebt bereikt en hoop 
dat jij dat ook bent, ik denk dat er weinig mensen zijn die dat kunnen nadoen. 
Pap, ik hoop dat ik je trots heb gemaakt, Dr. Hoekstra nummer 3. Jij bent misschien 
wel de belangrijkste reden dat ik dit wilde bereiken. 
Lieve, lieve, lieve Linda, we zijn eigenlijk net zo lang samen als dat ik op dit lab werk. 
Maar gelukkig blijf ik ook nadat ik hier weg ga nog bij jou! Het is heerlijk om hard 
door te werken, als ik weet dat ik daarna weer bij jou thuis kan komen. Je had soms 
geen idee wat ik nou precies aan het doen was op dat lab, maar je wilde er wel al-
tijd alles van weten. Het is eigenlijk in zo’n dankwoord niet te omschrijven hoe blij 
ik met jou ben, en wat je allemaal voor me gedaan hebt, maar je staat altijd voor 
me klaar! Ik vind het echt super gaaf dat jij de voorkant van mijn proefschrift hebt 
gemaakt, om zo ook deel uit te maken van dit boekje! Ik vind dat het er fantastisch 
uit ziet! Bedankt voor alles lief, ik ben gek op je! 
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